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The high prevalence of obesity is a major public health concern 
worldwide. Conventional strategies have failed to provide solid solutions, 
greater than 90% of individuals who lost weight by diet and exercise 
eventually regained the weight (Arner and Spalding, 2010a). As such, 
biological factors including genetic contributions have become the research 
focus on pathogenesis of obesity and the target of effective disease control. 
Central to energy homeostasis is the mechanism by which animals 
regulate and/or response to fluctuation in energy intake and output. Adipose 
tissues participate in metabolic regulation by serving as an energy store and 
by secreting adipokines such as leptin and adiponectin. Leptin functions as 
the afferent signal to the central nervous system in a negative feedback loop 
that maintains homeostatic control of adipose tissue mass. Leptin gene 
expression is highly correlated with cellular lipid content in adipocytes but 
the transcriptional mechanisms controlling leptin expression in vivo are 
poorly understood. Leptin-BAC Luciferase transgenic mice combining with 
other computational and molecular techniques were used to identify 
transcription regulatory elements including a CCAAT-binding protein 
Nuclear Factor Y (NF-Y). The function of NF-Y in adipocyte was studied in 
vitro with 3T3-L1 cells and in vivo with adipocyte-specific knockout of NF-Y. 
The results showed that NF-Y binding site is essential for transcriptional 
regulation of leptin and NF-Y is also an adipogenic factor important for 
adipocyte development in vivo (Chapter 3 and Chapter 4). 
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Finally, since obesity is defined as excess accumulation of adipose 
tissue, understanding developmental control of adipose tissue size and body 
adiposity will aid the study on disease progress of obesity. We employed a 
blastocyst complementation method where wild-type ES-cell is injected into 
AZIP lipodystrophic blastocyst. The result suggested that while leptin 
production adipocyte-autonomous, adipose tissue expandability and glucose 
metabolism is controlled by other factors inv olving other cell types in 
adipose tissues and/or other organs (Chapter 5). In sum, the thesis identifies 
adipocyte specific quantitative and qualitative control of leptin transcription, 
at the same time presents the complexity of metabolic regulation in vivo.   
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CHAPTER 1: INTRODUCTION 
1.1 Obesity as a Health Concern 
In 2011-2012, the prevalence of obesity in the United States was 
16.9% in youth and 34.9% in adults (Ogden et al., 2014). Obesity is a major 
cause of morbidity and mortality in the United States. Studies show that the 
risk of death rises with increasing weight. Even moderate weight excess (10 
to 20 pounds for a person of average height) increases the risk of death (Calle 
et al., 1999; Patel et al., 2014). It is estimated that the annual number of 
deaths attributable to obesity is about 280,000 in the United States with 
more than 80% of deaths in people with BMIs (body mass index, see below) 
of at least 30 kg/m2 (Allison et al., 1999a). Aside from mortality rate, obesity 
substantially increases morbidity and impairs quality of life, and that clinical 
studies consistently show that weight loss improves health and happiness 
among obese people (Allison and Pi-Sunyer, 1995). In the midst of the energy 
crisis in the 70s, Hannon and Lohman expressed the cost of obesity in terms 
of the total fossil energy equivalent of the food calories saved by reducing the 
present degree of obesity to optimum body weight (2.3 billion pounds for the 
adult population in the US) (Hannon and Lohman, 1978). Later studies have 
shown that approximately 4% of direct healthcare costs are attributed to 
obesity itself (Allison et al., 1999b). Across all payers, per capita medical 
spending for the obese was $1,429 higher per year, or roughly 42 percent 
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higher, than for someone of normal weight, summating to a total of $147 
billion dollars in 2008 (Finkelstein et al., 2009). 
1.2 Definition of Obesity 
Obesity is defined as excessive adiposity (body fat). The historical 
method for estimating adiposity was by calculating a person's buoyancy, 
which was done by measuring his or her body weight under water (Ward et 
al., 1978). However, this method is cumbersome, so a surrogate measure 
known as the body mass index (BMI) is now routinely used. BMI (weight in 
kilograms per square of height in meters) is a convenient measure and useful 
for assessing the weight status of a population over time (Romero-Corral et 
al., 2008). The common classification system determines whether you are 
underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight 
(25-29.9 kg/m2), or obese (>30 kg/m2). There are three degrees of obesity: 
class 1 (30.0–34.9 kg/m2), class 2 (35.0–39.9 kg/m2) and class 3 (≥40 kg/m2) 
(WHO, 2015). 
However, BMI is often unreliable to assess an individual’s weight class 
because it does not account for body proportion, nor does it account for the 
wide variation in the nature of obesity between different individuals and 
populations (Kopelman, 2000). Particularly, BMI does not distinguish 
between fat and muscle mass or adipose tissue distribution (so called ‘pear-
shaped’ versus ‘apple-shaped’), both of which result in profound differences 
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in body metabolism. Other direct methods that measure adiposity include 
air-displacement plethysmography (commercial name BOD POD) and dual-
energy x-ray absorptiometry (DEXA) (Fields et al., 2002). The waist-to-hip 
circumference ratio distinguishes between central obesity and other types of 
obesity, and it has been suggested that waist circumference should be 
measured along with BMI to adequately classify obesity-related health risk 
(Cervellati et al., 2014; Wakabayashi, 2013). 
1.3 Obesity as Risk Factor 
Despite some shortcomings, there is a close relationship between BMI 
and the incidence of several conditions caused by excess body fat. This 
relationship is approximately linear for a range of BMIs less than 30 (kg/m2), 
but all risks are greatly increased for those subjects with a BMI above 30 for 
both genders (Willett et al., 1999). Obesity increases the risk of several 
debilitating diseases, including type 2 diabetes mellitus, cardiovascular 
disease, and some cancers. The condition most strongly influenced by body 
weight is type 2 diabetes, where men with BMIs of 30 (kg/m2) or higher had 
a sevenfold higher risk of developing type 2 diabetes, and women with BMIs 
of 30 or higher had a 12-fold higher risk compared with their normal-weight 
counterparts (Guh et al., 2009). Numerous studies have demonstrated a 
direct association between excess body weight and coronary artery disease 
and ischemic stroke, though the contribution is multifactorial (Whitlock et al., 
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2009). Obesity is associated with cancers of the esophagus, pancreas, colon 
and rectum, breast, endometrium, and kidney (Keum et al., 2015). Also, 
studies have shown correlation between obesity and depression, though it is 
likely that reciprocal interactions exist between the two conditions (Faith et 
al., 2011). To date, the integrated effect of obesity across physical, 
psychological, and social functioning as scored by a concept known as health-
related quality of life (HRQoL) in adults and youths is an active field of 
research being pursued (Jia and Lubetkin, 2005; Swallen et al., 2005). Obesity 
can influence various aspects of reproduction, especially in women. Both 
infertility rates and pregnancy risks increase with BMI, including both 
natural and assisted pregnancies (Brewer and Balen, 2010). Encouragingly, 
however, numerous studies have shown that weight loss, even 5 to 10 
percent of weight, offers meaningful health benefits to the obese person 
(Ben-Menachem, 2007). 
1.4 The Obesogenic Environment 
While the aforementioned studies were performed in the US, obesity 
is no longer a problem for developed countries alone. The largest expansion 
of obesity since the 1980s has occurred in developing countries in Latin 
America, Oceania, North Africa, and Asia (Finucane et al., 2011). This global 
upsurge of obesity is associated with the increased availability of food, 
especially energy-dense items with fat and sugar, as well as sedentary 
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lifestyle from industrialization and urbanization, best described as 
the  “obesogenic environment” (Kirk et al., 2010). Global changes in diet and 
physical inactivity have been fueled by changes in agricultural practices, food 
processing, marketing, transportation, and other aspects of urban planning. 
It is worth noting that obesity often co-exists with malnutrition in low-
income urban areas, presenting a complex socioeconomic problem for 
policymakers (Oliver and Hayes, 2005; Pearce et al., 2007; Robert and 
Reither, 2004). However, since not everyone who has unlimited access to 
food develops obesity, lifestyle and environment may be necessary but 
insufficient to cause obesity. 
One of the confounding phenomena is that people are well aware of 
and are sincerely concerned about being obese, owing to exposure of media 
and health campaigns (Kassirer and Angell, 1998). However, the battle 
against obesity is largely failing. At any given time of the year, an astonishing 
15 to 35 percent of Americans are trying to lose weight (Horm and Anderson, 
1993). Despite all the investment of a staggering amount of time, money, and 
effort, greater than 90% of individuals who lost weight by diet and exercise 
eventually regained the weight (Arner and Spalding, 2010a). Moreover, 
recent studies have suggested that individuals possess less control over their 
own weight than they themselves believed, and that biological factors and 
the modern environment are the main causes of obesity (King, 2011). Thus, 
understanding the physiology of obesity is critical to effective obesity control. 
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Individual differences in a common environment are reflective of 
genetic contribution (FIGURE 1.1), as is established through family studies, 
investigations of parent-offspring relationships, and the study of twins and 
adopted children (Maes et al., 1997; Stunkard et al., 1990). These studies 
estimated the heritability of obesity is 40-70%, which is slightly less 
heritable than height (Farooqi and O'Rahilly, 2006). Just as nutritional 
improvement has increased the mean of adult height in many populations, 
environmentally-driven changes in body weight occur against a background 
of susceptibility to weight gain that is determined by genetic factors (Barsh 
et al., 2000; Bouchard et al., 1990; Comuzzie et al., 1996; Price and Gottesman, 
1991). For instance, different inbred strains of mice respond differently to a 
high-fat diet (HFD) with varying caloric intake and weight gain (West et al., 
1992). Moreover, in the presence of gene-environment interactions, the 
effects of high genetic susceptibility are amplified by a high-risk environment 
(Barsh et al., 2000). Several known mutations that lead to obesity in mice 
have been cloned, and some homologous mutations have been identified as 
rare causes of human obesity (see below). These genes and their products 
provide the molecular basis for obesity and thus promising therapeutic 
targets of a complex and highly heterogeneous disease. However, these are 
rare and severe conditions that do not account for common forms of body 
weight variation and obesity. Overall, the etiology of modern obesity arises 
from interactions of multiple genes, environmental factors, and behavior, 
which makes the search for obesity genes especially challenging. Recent 
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human genome-wide studies estimate that common genetic variation 
accounts for approximately 20% of BMI variation (Locke et al., 2015). 
The rapid growth in the obese population in a short period of time 
excludes the possibility of significant change in the population’s genetic 
makeup. Therefore it is conceivable that obesity genes have long existed in 
the human genomes, which now become expressed as an obese phenotype 
FIGURE 1.1 Potential effect of genes and environment on adiposity 
assessed by body mass index. The modern “obesogenic” environment 
on the right side is characterized by the increase availability of high-
calorie density food and decreased need for physical activity. The 
variability in BMI will depend on the genetic susceptibility to weight gain 
of individuals. Note that due to gene-environment interaction, the 
distribution of BMI will have a higher mean and higher standard deviation 
under the high-risk obesogenic environment. Figure adopted from Energy 
metabolism, fuel selection and body weight regulation (Galgani and 
Ravussin, 2008). 
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under modern environmental conditions. Several explanations for the 
existence of obesity genes have been proposed. If genetic predisposition to 
energy efficiency conferred a fitness advantage, the genes that enhanced 
energy storage (as body fat) and avoided energy expenditure would likely be 
favored by selection. Individuals with alleles of these “thrifty genes” (Neel, 
1962) that favored efficient fat deposition would then survive subsequent 
famines, whereas those individuals with alleles that were inefficient would 
not survive. This view is supported by observations of animals that deposit a 
large amount of fat prior to hibernation and migration, presumably in 
prediction of reduced food availability (Klaassen and Biebach, 1994; Kunz et 
al., 1998; Martin, 2008; Moore and Kerlinger, 1987). In the modern 
environment, where food is abundant, the consequence is that people who 
carry the “thrifty” alleles more efficiently store energy by depositing 
enormous amounts of fat in preparation for a famine that never comes. The 
rise in obesity among different animal species living with or around humans 
in industrial societies may indicate that the “thrifty” alleles are a common 
survival strategy among many animal species (Klimentidis et al., 2011). It is 
worth noting that because food supplies were probably always low in 
preindustrial eras, the levels of obesity, even in those carrying the “thrifty” 
alleles, were probably quite modest, and individuals never became obese 
enough to experience the detrimental impacts of obesity on health. Others 
have proposed alternative scenarios where obesity genes arise as a side-
product of other selection forces and genetic drift (the “drifty gene” 
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hypothesis) from a neutral evolutionary process (Himmshagen, 1979; 
Rothwell and Stock, 1979; Speakman, 2008, 2013). 
1.5 Historical Perspectives on Energy Homeostasis 
At the beginning of the 20th century, the patriarchs of physiology, 
Claude Bernard and Walter Cannon, developed the concept that the internal 
environment of an organism remains constant, despite frequent fluctuations 
in the surrounding variables. Organisms respond to perturbations from the 
external environment with counteracting forces, a process that Cannon called 
“homeostasis” (Woods and Ramsay, 2007). Subsequently, animal studies by 
Gasiner and Mayer demonstrated that body weight remained remarkably 
constant over long periods of time, despite environmental perturbations 
including diet and physical exercise (Blundell and Bellisle, 2013). It was 
thought that the animals adjusted the amount of food intake in order to 
maintain constant body weight. Several theories were proposed to explain 
the physiological connection between regulation of body weight and feeding 
behavioral control. It was proposed that the beginning and terminating of 
feeding is controlled by some satiety factor, but was felt dissatisfactory in 
explaining long term body weight homeostasis. 
Around the same time, studies of the brain identified two discrete 
neurological pathways in which the hypothalamus controls feeding behavior 
in rats. Electrolytic lesions in the ventromedial hypothalamus (VMH) 
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resulted in hyperphagia and profound body weight gains due to excessive fat 
deposition (Hervey, 1959). Lesions in the ventrolateral hypothalamus (VLH) 
resulted in hypophagia and weight loss (Bernardis and Bellinger, 1993). 
Further studies showed that the “satiety center” and “feeding center” in the 
hypothalamus not only control food intake, but also regulate body weight 
and energy expenditure to maintain a body weight “set-point” (Keesey and 
Hirvonen, 1997).  Gordan Kennedy was the first to suggest that fat might 
produce a signal that was sensed by the brain, where it was compared with a 
target level of body adiposity; any discrepancy between the target and signal 
would subsequently trigger changes in intake or expenditure that would 
regulate the levels of body fat to bring its signal back in line with the target 
(Kennedy, 1953). This “lipostatic” model was based on a simple negative-
feedback system, yet the signal produced by adipose tissue remained elusive. 
1.6 Discovery of Leptin 
The existence of an appetite suppressing hormone was demonstrated 
by the results of a set of parabiosis experiments (FIGURE 1.2; a technique 
that allows continuous, low-volume blood exchange between two live 
animals) between genetically obese (ob) and diabetic (db) mice (Coleman, 
1973; Coleman and Hummel, 1969). 
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It was known that the ob and db loci are fully-penetrant autosomal 
recessive mutations that produce seemingly identical phenotypes such as 
obesity, hyperphagia, hyperglycemia, and hyperinsulinemia. Since these two 
genes are located on separate chromosomes (ob on chromosome 6 and db on 
chromosome 4), the implication was that the observed phenotype was 
secondary to some yet unidentified single primary defect. Parabiosis of db 
and normal mice resulted in hypoglycemia and death from starvation in the 
normal mouse, but no apparent change in its db partner. In contrast, 
parabiosis of ob and normal mice produced drastic a weight loss in the ob 
mouse. From these results, Coleman postulated that the db mutant produces 
but does not respond to a satiety factor that is missing in the ob mutant 
(Coleman, 1973). Supporting this viewpoint, parabiosis of normal rats with 
FIGURE 1.2 Schematic of effects 
on obese phenotypes of 
parabiosis of ob, db and wild-type 
mice. From these studies Coleman 
inferred that it ob might encode a 
secreted molecule, for which db was 
the receptor. Figure adopted from 
Molecular physiology of weight 
regulation in mice and humans 
(Leibel, 2008). 
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rats harboring VMH lesions or genetically obese Zucker rats (the rat version 
of db), resulted in the normal partner becoming emaciated and showing no 
interest in food (Harris et al., 1987; Hervey, 1959). 
The cloning and characterization of the ob gene in mice showed that it 
encodes leptin (leptos from Greek: thin), a 167-amino-acid protein secreted 
from adipose tissue (Zhang et al., 1994). In one of the mouse models, 
C57BL/6J ob/ob1J, a nonsense mutation in leptin results in the synthesis of a 
truncated and nonfunctional protein. In this mutant, the level of leptin mRNA 
is elevated, suggesting that expression of the gene is under feedback control 
(Maffei et al., 1995a). Subsequent studies showed that plasma levels of leptin 
are highly correlated with adipose tissue mass with increased plasma levels 
in obese humans and several obese mouse models and decreased levels 
following weight loss (Maffei et al., 1995b). Administration of leptin by 
intraperitoneal injection or constant subcutaneous infusion results in a dose-
dependent decrease in body weight that is restricted to adipose tissue with 
sparing of lean body mass in both wild-type and ob/ob mice, but not db/db 
mice (Campfield et al., 1995; Halaas et al., 1997; Halaas et al., 1995; 
Pelleymounter et al., 1995). These results indicate that leptin is an afferent 
signal in a negative feedback loop that regulates adipose tissue mass. 
Discovery of leptin provided the molecular basis for Kennedy and Keesey’s 
adipostatic set-point model of body weight regulation. 
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1.7 The Central Nervous System in Regulation of Food Intake 
Leptin's primary site of action is in the central nervous system 
(FIGURE 1.3), in particular, the hypothalamus, where a dense population of 
neurons expressing leptin receptor (encoded by Lep-R) reside (Mercer et al., 
1996; Vaisse et al., 1996). Using purified leptin protein, expression cloning 
from a phage library of the choroid plexus isolated Lep-R that binds to leptin 
(Tartaglia et al., 1995). The Lep-R candidate was confirmed by mapping to a 
db mutant, which contains a premature stop codon resulting in abnormal 
splicing (Chen et al., 1996; Chua et al., 1996; Lee et al., 1996). Positional 
cloning of Lep-R showed that this gene encodes five alternative spliced forms, 
but only one variant, Lep-Rb, is essential for leptin’s weight-reducing effect 
and the function of other forms are quite modest compared to Lep-Rb (Li et 
al., 2013). Taken together with the fact that db mice and mice with 
hypothalamic lesions are leptin resistant (Halaas et al., 1995; Maffei et al., 
1995a), these findings support the conclusion that the hypothalamus is an 
important site of leptin action. 
Several hypothalamic nuclei, including the arcuate nucleus, VMH, LH, 
DMH, and PVN express neuropeptides and neurotransmitters that regulate 
food intake and energy balance. Neuropeptide Y (NPY) and its receptors 
respond to the absence of leptin, whereas melanocyte-stimulating hormone 
(MSH) and its receptors, melanocortin-4 receptor (MC-4R) and agouti-
related receptor (AgRP), respond to increased leptin levels (Fei et al., 1997; 
Friedman, 1997; Mercer et al., 1996). Upon binding to leptin, the leptin 
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receptor activates the downstream pathways JAK/STAT3 and PI3-kinase, 
both of which are required for proper control of energy metabolism (Bates et 
al., 2003; Gao et al., 2004; Hill et al., 2008; Niswender et al., 2001). Chronic 
and acute dosing of leptin via intracerebroventricular (ICV) injection reduce 
food intake and induce other metabolic effects at doses significantly lower 
than peripheral administration (Halaas et al., 1997; Kamohara et al., 1997). 
Such leptin-induced anorexia is transient and is attenuated once the adipose 
FIGURE 1.3 Summary of leptin signaling pathway. Leptin is the afferent 
signal in a negative feedback loop that maintains constancy of adipose 
tissue mass. Leptin is secreted from adipocytes (bottom left) at levels 
correlated with body adiposity. Increased plasma leptin results in 
negative energy balance, whereas decreased levels lead to positive energy 
balance. Leptin acts mainly on the hypothalamus (top), via which leptin 
acts to decrease food intake and modulate glucose and fat metabolism 
(right). Figure adopted from Leptin and the regulation of body weight in 
mammals (Friedman and Halaas, 1998). 
15 
tissue is depleted, suggesting the presence of yet undiscovered afferent 
signals (Halaas et al., 1997; Montez et al., 2005). 
1.8  Metabolic and Physiological Effects of Leptin 
Animals treated with leptin voluntarily decrease their food intake and 
induce weight loss that selectively depletes body adipose stores (Halaas et al., 
1997). Although decreased food intake is a prominent effect of leptin 
treatment, the decrease in food intake alone cannot account for the metabolic 
changes observed. First, pair-fed ob/ob mice that are food restricted to the 
level of intake of leptin-treated ob/ob mice lose significantly less weight than 
the leptin-treated mice (Levin et al., 1996). Second, while leptin-induced 
weight loss is restricted to fat mass, starvation causes a loss of both lean 
body mass and fat mass at a ratio that maintains body adiposity (Halaas et al., 
1997; Pelleymounter et al., 1995). Third, leptin treatment does not lead to 
the compensatory drop in energy expenditure generally evident with 
decreased food intake (Halaas et al., 1997). Consistently, leptin-treated ob/ob 
mice showed a reduced respiratory quotient, indicating a preference for fat 
oxidation over carbohydrate oxidation (Hwa et al., 1997). Overall, both leptin 
replacement in genetically leptin-deficient animals and pharmacologically-
elevated leptin in wild-type animals within the physiological range have 
profound consequences on energy utilization independent of food intake and 
change in body weight. 
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Leptin directly regulates glucose metabolism. This is evident by the 
antidiabetic effect observed when ob/ob mice are treated with a low dose of 
leptin that does not decrease body weight (Pelleymounter et al., 1995). 
Treatment of lean animals with leptin leads to a reduction in serum glucose 
level without changing insulin levels and increases glucose usage during 
euglycemic clamp experiments (Sivitz et al., 1997). In type I diabetes mellitus 
(T1DM, also known as insulin-dependent diabetes), since insulin is required 
for the synthesis and storage of triglycerides in adipose tissue, weight gain 
cannot occur in untreated T1DM, and the associated loss of body fat is 
accompanied by markedly reduced plasma leptin levels. Leptin replacement 
prevents the development of insulin resistance, characteristic of T1DM in 
both humans and rodents (Defronzo et al., 1982; Ykijarvinen and Koivisto, 
1986). Also, the phenotype was associated with normalization of hepatic 
glucose metabolism and elevated plasma levels of glucagon and 
corticosterone (German et al., 2010; Yu et al., 2008). Such effects are likely 
mediated through the CNS, linking the known leptin signaling pathway to 
control of glucose metabolism and insulin sensitivity. For instance, rescuing 
Lep-R expression in the arcuate nucleus and pro-opiomelanocortin (POMC) 
neurons of Lep-R deficient mice normalizes their glucose and insulin levels, 
improves their hepatic insulin sensitivity, and reduces gluconeogenesis 
(Berglund et al., 2012; Coppari et al., 2005; German et al., 2009; Huo et al., 
2009). 
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Despite having enormous fat deposits, ob/ob mice show many of the 
abnormalities seen in starved animals, including decrease body temperature, 
hyperphagia, decrease energy expenditure and physical activity, 
compromised immune function, and infertility (Coleman, 1978). Low plasma 
leptin in ob/ob mice leads to a state of “perceived starvation,” which activates 
various response programs resulting in obesity under the presence of food 
(Friedman and Halaas, 1998). The striking similarity in metabolic 
implications between genetic leptin deficiency and lipodystrophy (loss of 
adipose tissue), despite being the complete opposites on body adiposity level, 
suggests that leptin is the key factor in mediating physiological consequences 
of energy imbalance (Haque et al., 2002). This is supported by the 
observation that leptin supplement attenuates the physiological responses to 
food restriction in mice, including changes in gonadal, adrenal, and thyroid 
axes in male mice, starvation-induced delay in ovulation in female mice, 
suppression of T-cell proliferation, and increase in circulating fatty acids and 
ketone bodies (Ahima et al., 1996; Lord et al., 1998; Shimabukuro et al., 
1997). These findings suggested that circulating leptin is a key signal to the 
brain regarding energy stores, and a fall in leptin results in the endocrine, 
behavioral, and autonomic responses characteristic of starvation. The nature 
of the efferent signals from the CNS that regulate metabolism in response to 
leptin are not well characterized, although some evidence suggests that the 
sympathetic nervous system may play a role (Dunbar et al., 1997; Elmquist et 
al., 1999; Haynes et al., 1997). 
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1.9  Leptin and Pathogenesis of Obesity 
The role of leptin in the pathogenesis of obesity can be inferred by 
measurements of plasma leptin in obese animals (Considine et al., 1996; 
Maffei et al., 1995b). An increase in leptin suggests that obesity is the result 
of resistance to leptin, while a low or normal level of leptin in context of 
obesity suggests an underproduction of leptin. These are analogous to insulin 
production in type II (insulin resistant) and type I (insulin deficient) diabetes. 
The molecular basis of known mouse models with monogenic obesity 
showing Mendelian inheritance have all been uncovered. The corresponding 
human disorder arising from homologous or similar genetic defects have 
been identified using a candidate gene approach. These genetic mutations 
include leptin (Montague et al., 1997a; Strobel et al., 1998), lep-R (Clement et 
al., 1998), and prohormone convertase 1 (Jackson et al., 1997), corresponding 
to the naturally occurring mouse mutants ob/ob, db/db, and fat. In addition, 
patients with mutations in POMC resulting in impaired melanocortin 
signaling are also obese (Krude et al., 1998). These mutations are rare and all 
result in severe obesity in childhood without pleiotropic developmental 
syndromes. Other human obesity mutations recognized by Mendelian 
inheritance have been determined for Prader-Willi, Cohen, Alstrom, and 
Bardet-Biedl syndromes, all of which obesity is one of its pleiotropic features. 
Using quantitative trait locus (QTL) analysis, no causative genes have been 
identified for these pleiotropic syndromes (Barsh et al., 2000; Gunay-Aygun 
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et al., 1997). Consistent with findings in monogenic forms of obesity, human 
genome wide studies have shown that genetic susceptibility to common 
obesity is mostly associated with the function of the central nervous system 
(Locke et al., 2015). 
It is striking how monogenic forms of obesity are all caused by either 
a defect in leptin itself or leptin downstream pathways. Yet, these defects do 
not account for common obesity associated with industrialized lifestyles, of 
which the molecular basis remains largely unknown. Obese humans and diet-
induced obese (DIO) rodents are hyperleptinemic yet do not showed 
decreased food intake or increased energy expenditure, suggesting that the 
pathogenesis of common obesity is leptin resistance (Considine et al., 1996; 
Van Heek et al., 1997). As such, therapeutic utility of leptin as an anti-obesity 
drug is limited to the rare cases of leptin deficiency and not the greater obese 
population (Heymsfield et al., 1999; Paz-Filho et al., 2011). 
Animal studies suggest that leptin resistance can be caused by 
reduced leptin access to its target and/or altered leptin signaling. Zealand 
obese (NZO) mice, a model with polygenic late-onset obesity, are resistant to 
peripherally administered leptin but responsive to centrally administrated 
leptin, suggesting leptin resistance is a result of impaired leptin transport 
into CNS (Halaas et al., 1997; Igel et al., 1997). Hyperleptinemic obese models 
AY and db/db mice have loss-of-function mutations in MC4R and lep-R 
respectively, both of which block leptin signaling in the CNS (Halaas et al., 
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1997; Ste Marie et al., 2000). Mutations can lead to altered processing of 
neuropeptides, or downstream intracellular signaling in the hypothalamic 
nuclei can also cause obesity with high leptin levels (Jackson et al., 1997; 
Naggert et al., 1995; Prada et al., 2013; Rovere et al., 1996). Study in DIO mice 
demonstrated that leptin resistance evolves over the course of diet treatment, 
and that both decreased access of leptin to the hypothalamus as well as 
defective STAT3 activation by the leptin receptor are involved (El-Haschimi 
et al., 2000). Furthermore, it has been shown that hyperleptinemia is 
required for development of leptin resistance (Knight et al., 2010). On the 
cellular level, chronic overstimulation of the leptin receptor and activation of 
negative feedback pathways block further leptin signaling through SOCS-3, a 
protein that directly inhibits leptin signaling (Bjorbaek et al., 1998; Bjorbak 
et al., 2000). Moreover, expression of a constitutively active form of STAT3, a 
key mediator of leptin signaling, is sufficient to induce central leptin 
resistance (Ernst et al., 2009). This mechanism is analogous to blunted 
insulin signaling under chronic insulin treatment mediated by IRS-1 (White, 
2006). 
In human studies, several groups have reported MC4R mutations 
(Hinney et al., 1999; Vaisse et al., 1998; Yeo et al., 1998), which remain the 
most common obesity syndrome found in 3-5% of people with BMI above 40 
(Barsh et al., 2000). The studies on MC4R demonstrated an overlapping 
continuum between monogenic and polygenic obesity, as it has been found 
the case in three other genes, PCSK1, POMC and BDNF (Choquet and Meyre, 
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2011). Various inheritance patterns have been reported for MC4R mutations 
(Farooqi and O'Rahilly, 2006), indicating that expressivity and penetrance of 
the phenotype can be modulated by other genetic and environmental factors. 
Together, these suggest that development of leptin resistance is likely 
multifactorial, especially within the context of environment-induced obesity. 
In humans, although the notion of leptin resistance is only inferred from 
elevated leptin in obese individuals, it has been shown that susceptibility to 
leptin resistance or leptin production and/or leptin signaling 
disproportionate to energy status underlies common obesity. For instance, 
lower leptin concentrations than would be expected from BMI is linked to a 
predisposition to weight gain (Ravussin et al., 1997; Scholz et al., 1996). 
1.10 Alternative to “Set-Point” Model 
While the leptin signaling pathway provides that strongest argument 
for a feedback system that maintains energy homeostasis based on energy 
storage (adipose tissue), development of leptin resistance in common obesity 
and increased prevalence of obesity over the past decades suggest certain 
shortcomings of our understanding. In other words, if, as Kennedy and 
Keesey (Keesey and Hirvonen, 1997; Kennedy, 1953), had put forth, each 
body possesses an energy status “set-point” in terms of adiposity, each 
individual ought to maintain his or her body weight through a negative 
feedback mechanism that offsets short-term energy fluctuation. However, 
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anthropological studies disprove such a system by demonstrating that 
modern obesity is dependent on socioeconomic status of an individual 
(Dykes et al., 2004; Poskitt, 2009) and is often associated with certain major 
life events such as attending college, marrying, and immigration to Western 
countries (Cluskey and Grobe, 2009; Oza-Frank and Cunningham, 2010; 
Sobal et al., 2009). In Western countries, most people gain weight throughout 
their life, suggesting at least age-dependent effect for an individual’s energy 
“set-point” (Kuczmarski et al., 1994). 
As such, a “settling-point” model was proposed from a mathematical 
model for weight regulation (Payne and Dugdale, 1977), where any 
imbalance between energy intake and energy requirement results in a 
change in body weight. Such change, in turn, alters the maintenance energy 
requirement so as to counter the original imbalance and the system would 
hence be stabilized. Since there is no actual set-point or feedback signal in 
the “settling point” model, altered energy status occurs whenever a regulated 
variable is adjusted to balance change in an unregulated variable. This model 
provides cogent explanations for the “obesogenic” environment where food 
intake can be increased by external cues such as large portion size, exposure 
to high density foods, frequency of dining out, as well as eating with others 
(O'Keefe and Abuannadi, 2010; Rolls et al., 2007; Thornton et al., 2011). The 
extent to which energy intake and expenditure are regulated appears to be 
determined largely by genetic factors (Vogels and Westerterp-Plantenga, 
2005; WesterterpPlantenga et al., 1996). In mice with fixed levels of plasma 
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leptin, nonetheless, gained weight in response to a HFD at a rate that was 
indistinguishable from wild-type animals on the same diet, and the two 
groups reached an identical body weight plateau (Knight et al., 2010; Tanaka 
et al., 2005). If proportional increase in leptin with weigh gain is necessary 
for establishing energy balance, these animal models with artificial leptin 
deficiency would be predicted to gain weight more quickly than wild-type 
controls. The fact that this was not observed indicates that a leptin-
independent mechanism specifies the body weight set point in animals fed a 
high-fat diet. Likewise, leptin infusion fails to prevent weight gain in wild-
type animals undergoing HFD treatment (Surwit et al., 2000). In aggregate, 
these results are consistent with settling-point model. How energy regulation 
is achieved through balancing various long and short term variables remains 
an important question. 
Despite its shortcomings in explaining development of obesity under 
over-nutrition, the “set point” model provides a better picture for energy 
regulation during starvation and deprivation. In the classical Minnesota 
Experiment, food-restricted individuals over-eat to replenish the body mass 
(both fat and lean) to pre-restricted level (Dulloo et al., 1996; Speakman et al., 
2011), suggesting an active regulatory mechanism in response to being 
underweight. Even after energy homeostasis, which is substantially 
perturbed in anorexia nervosa, recovered patients often return to premorbid 
body weight (Coners et al., 1999; Hebebrand et al., 1997). On the other hand, 
in both normal and overweight humans, diet-induced weight loss is resisted 
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by reduced energy expenditure (Dulloo and Jacquet, 1998; Luke and 
Schoeller, 1992). Perhaps most strikingly, body fat removed by surgery is 
restored within one year post-operation (Hernandez et al., 2011). In sum, 
body weight and body adiposity are defended in the face of energy 
deprivation, since loss of energy storage and intake due to starvation present 
an immediate risk to survival. Consistently, hypothalamic targets of leptin, 
including NPY, POMC, and CART neurons, are more responsive to leptin 
during fasting than in the overfed or obese state (Ahima et al., 1999). Low 
leptin levels induced by fasting and reduction in energy stores mediate 
various physiological consequences of energy deprivation (Ahima et al., 1996; 
Keim et al., 1998). As such, falls in body adiposity and leptin levels serve as 
signals of negative balance from the “set-point,” which activates adaptive 
response to starvation and defense against further deviation. 
1.11 Regulation of Leptin Gene in Adipose Tissue 
Acting as a surrogate for fat mass, plasma leptin levels are highly 
correlated with adipose tissue mass in animals and humans over a very large 
dynamic range (Frederich et al., 1995; Maffei et al., 1995b). Changes in 
plasma leptin levels are associated with changes in leptin mRNA per 
adipocyte and the levels of leptin mRNA per cell are highly correlated with 
intracellular lipid content (Couillard et al., 2000; Maffei et al., 1995a). This 
suggests that regulation of leptin is primarily achieved at the transcriptional 
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level with only a few in vitro studies demonstrating increased leptin 
secretion with insulin treatment (Barr et al., 1996; Bradley and Cheatham, 
1999; Lonnqvist et al., 1997; Moreno-Aliaga et al., 2000). Small amounts of 
leptin expression have been reported in brain, pituitary, stomach, mammary 
epithelial cells, liver, chondrocytes and muscle, but the physiological 
importance of this low level expression, if any, is unclear (Birsoy et al., 2008b; 
Rosenbaum et al., 2002). Both quantitative (fat mass dependent) and 
qualitative (tissue-specific) regulation of leptin gene expression is important 
for its physiological role in metabolic regulation, yet little is known since the 
cloning of leptin in 1994. 
Leptin production is regulated by various metabolic stimuli including 
positive regulator glucocorticoids (Devos et al., 1995; Slieker et al., 1996) and 
proinflammatory cytokines TNF and IL-1 (Grunfeld et al., 1996; Sarraf et al., 
1997), and negative regulators include beta adrenergic agonists and cAMP 
(Mantzoros et al., 1996; Slieker et al., 1996). Insulin has also been found to be 
capable of modulating leptin expression (Wabitsch et al., 1996), particularly 
as a suppressor during starvation where a rapid fall in leptin is 
disproportional to the fall in adipocyte energy stores (Ahima et al., 1996; 
Boden et al., 1996). Despite these external influences, it is likely that cell-
autonomous factors are the major links between adipocyte size and leptin 
gene expression. Recent studies have shown that individual adipocytes 
maintain idiosyncratic levels of fat accumulation and nutrient uptake during 
de-differentiation and re-differentiation (Katz et al., 2014; Varlamov et al., 
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2015). Which intracellular metabolites, signaling molecules, or transcription 
factors provide the necessary link is still unclear. 
Further studies have been impeded by lack of a tissue culture model 
for adipocytes, as leptin expression levels in preadipocyte cell lines are 1–2% 
of that seen in adipose cells in situ (Macdougald et al., 1995). Interestingly, 
cultured adipocytes transplanted subcutaneously can grow into fat pads, 
which showed a 10-fold increase in leptin expression to a level 10–15% of 
that seen in adipocytes in situ (Green and Kehinde, 1979; Mandrup et al., 
1997). These results suggest the existence of a key, unidentified, in 
vivo regulatory factor, and it mandates studies of leptin expression 
performed in vivo. 
The proximal promoter of leptin, a 762bp region upstream to the 
transcriptional start site (TSS) has been characterized by DNA sequence 
analysis in both humans and mice (de la Brousse et al., 1996; Gong et al., 
1996). This region contains several transcription factor binding sites of 
factors known for adipocyte functions such as the C/EBP family, Sp-1, CREB, 
and SREBP-1c (He et al., 1995; Hwang et al., 1996; Mason et al., 1998). 
The  promoter of leptin is positively regulated through by C/EBPα (He et al., 
1995; Miller et al., 1996), and suppressed by PPARg through functional 
antagonistic interaction between C/EBPa and PPARg (DeVos et al., 1996; 
Hollenberg et al., 1997). However, a transgene driven by the 762bp proximal 
promoter showed a lower expression than the normal physiological level and 
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did not confer adipose tissue specific expression (Chen et al., 1999; Hwang et 
al., 1996). This suggested that while the proximal promoter contains 
sequences sufficient to drive leptin transcription using ubiquitous machinery, 
additional mechanisms involving distal cis-elements and novel trans-factors 
are required to confer tissue specific regulation. Suppression of leptin 
transcription in other tissues remains to be explored. 
In adipocytes, leptin expression is proportional to cell size, which in 
turn is dependent on the amount of triglyceride stores. Several possibilities 
on cell-autonomous regulation of leptin expression have been proposed. It is 
known that membrane cholesterol concentration is inversely proportional to 
adipocyte size and that cholesterol regulates glucose metabolism in 
adipocytes via gene expression modulation (Le Lay et al., 2001). However, 
manipulation of cholesterol concentration in 3T3-L1 cells, despite alteration 
of many metabolic genes, does not change leptin expression (Le Lay et al., 
2001), and that membrane cholesterol composition may simply be the 
adaptive response to change in cell size and mechanical strain in the cell 
membrane (Khatibzadeh et al., 2012). Mechanical force itself has been 
implicated in regulating adipogenesis (David et al., 2007; Sen et al., 2008; 
Tanabe et al., 2004). Notably, the extracellular matrix (ECM), serving as a 
scaffold of adipose tissue, is also capable of regulating physiological and 
pathological responses of fat mass expansion. Up-regulation of many ECM 
components results in reduced mechanical plasticity of fibrotic adipose 
tissue and presents a hallmark of metabolically dysfunctional adipose tissue 
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in a state of obesity (Khan et al., 2009; Sun et al., 2011). The direct 
relationship and the signal transduction pathway between mechanical 
strains exerted on expanding adipocytes and increased leptin expression is 
unknown. Alternatively, hypoxic conditions encountered by large adipocytes 
with limited oxygen diffusion can directly regulate leptin expression through 
hypoxic response transcription factor HIF1α (Sun et al., 2013). Hypoxic 
stress is also prominent at the tissue level in obesity as capillary density is 
lower in the adipose tissue of obese humans compared with lean subjects 
(Pasarica et al., 2009; Rajala and Scherer, 2003). The molecular mechanism 
coordinating and connecting these different cellular responses to leptin 
expression remains to be explored. Chapter 3 of this thesis presents the 
identification of a distal enhancer sequence of leptin gene, and the 
identification of its binding protein and subsequent functional analysis is 
detailed in Chapter 4. 
From the approach of genomic study, transcriptional regulation of 
leptin can be considered as specific molecular programs in white adipose 
tissue that coordinates as well as responds to physiological and metabolic 
changes in animals. As such, comprehensive molecular characterization and 
comparison of white adipose tissue from different states of ambient leptin 
can elucidate specific cellular programs affected by leptin. Previous study 
had utilized a microarray technique to characterize the molecular events in 
white adipose tissue associating with alteration in circulating leptin levels 
(Soukas et al., 2000). These results uncovered a large number of metabolic, 
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inflammatory, and structural genes dysregulated with chronic leptin 
deficiency (ob/ob) as well as the acute responses of fatty acid and 
triglyceride metabolic pathway following leptin change. Chapter 5 of this 
thesis presents an updated work of similar approach, which utilized next-
generation-sequencing that allows unbiased molecular characterization. 
Since plasma leptin level is determined by aggregated production 
from all adipocytes in an animal, it remains uncertain how leptin gene 
regulation within individual adipocytes rely metabolic signal at an 
organismal level. Indeed, with the production of various adipokines with 
hormonal functions, adipose tissues should be considered, as a whole, an 
endocrine organ in addition to its classical role as a storage organ (Ahima, 
2006). Indeed, as organ size control is central to mammalian development, 
each species also possesses predefined body adiposity. However, prominent 
heterogeneity in adipocytes from different depots and within each depot 
complicates studies of adipocyte biology (Guo et al., 2004; Montague et al., 
1997b; Montague et al., 1998). In addition, two distinct processes, 
hypertrophy and hyperplasia, that accompany adipose tissue expansion 
during normal development and obesity (Jo et al., 2009; Sun et al., 2011), 
contribute to the complexity of the issue. Therefore, understanding the 
process of adipogenesis from the perspective of organ size control in 
multicellular organisms is essential to elucidate regulation of the leptin gene. 
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1.12 Transcriptional Regulation of Adipogenesis 
The mechanisms controlling cellularity of adipocytes in vivo is best 
approached by studying adipose tissue development. Adipogenesis is 
described as a two-step process: generation of committed adipocyte 
precursors (or preadipocytes) from embryonic stem cells and terminal 
differentiation of preadipocytes into mature adipocytes (Billon et al., 2007). 
Differentiation of preadipocytes has been studied extensively in vitro, from 
which several adipogenic transcription factors, such as peroxisome-
proliferator activated receptors PPARγ and PPARβ and CCAAT-enhancer 
binding proteins C/EBPα, C/EBPβ, and C/EBPδ, were identified (Chawla et al., 
1994; Christy et al., 1991). 
Adipogenesis in vitro follows a highly ordered and well characterized 
sequence of events (Rosen et al., 2000). Initially, there is growth arrest of 
proliferating preadipocytes, usually achieved in cultured cell lines after 
contact inhibition. This growth arrest is induced by the addition of pro-
differentiation hormones into the cultured models and is followed by one or 
two additional rounds of cell division known as clonal expansion. This 
process is followed by expression of the key transcription factors PPARγ and 
C/EBPα and a second, permanent period of growth arrest. Over the course of 
terminal differentiation, the preadipocyte converts to a spherical shape, 
accumulates lipid droplets, and progressively acquires the morphological 
and biochemical characteristics of the mature white adipocyte. The 
appearance of PPARγ and C/EBPα activate and/or enhance expression of 
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most or all of the genes that characterize the adipocyte phenotype, including 
glycerophosphate dehydrogenase, fatty acid synthase, acetyl CoA carboxylase, 
malic enzyme, Glut4, insulin receptor, and aP2 or FABP4 (Spiegelman et al., 
1993). At the molecular level, differentiation can be considered as a shift in 
gene expression patterns from that of a proliferative, multipotent state to 
that which defines the phenotypic appearance of the differentiated stage. In 
this sense, changes in transcription factor expression and activity define the 
process of differentiation. 
It is now well-accepted that the transcriptional network of 
adipogenesis involves a sequential activation of C/EBP factors and PPARg 
(FIGURE 1.4). First, C/EBPb and C/EBPd mRNA and protein levels rise early 
and transiently (Cao et al., 1991; Yeh et al., 1995) and induce the expression 
of PPARg through direct transcriptional effects (Fajas et al., 1997; Wu et al., 
1996; Zhu et al., 1995). PPARg is responsible for inducing C/EBPa, which 
further reinforces PPARg expression during the differentiation cascade 
(Kubota et al., 1999; Rosen et al., 1999; Wu et al., 1999). This positive 
feedback feature ensures that the cascade, once initiated, will maintain the 
expression of these critical factors as well as the terminal differentiated state. 
How PPARg and C/EBPa orchestrate their transcriptional activities remains 
uncertain, although it is known that PPARg is sufficient to stimulate most, but 
not all, adipocyte markers (Wu et al., 1999) and that PPARg and C/EBPa act 
synergistically at many adipogenesis-linked loci (El-Jack et al., 1999; 
Lefterova et al., 2008). 
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1.13 Adipose Tissue Development in vivo 
Histological and microscopic observations performed on human and 
porcine embryos indicate that white adipose tissue forms early in life. 
Developmental history of adipose tissue starts with the sites of fat deposition 
in the embryo called the primitive organs of the white adipose tissue (Han et 
al., 2011; Wassermann, 2010). The primitive organs are characterized by a 
network of capillaries and cells with the appearance of fibroblasts except for 
the presence of small fat droplets in cytoplasmic vacuoles (Wassermann, 
2010). 
FIGURE 1.4 Transcriptional Regulation of Adipogenesis. The 
expression of Pparg is regulated by several pro-adipogenic (green) and 
anti-adipogenic (orange) factors. PPARg  itself is activated by an as-yet-
uncharacterized ligand. CCAAT-enhancer-binding protein a (C/EBPa) is 
regulated through a series of inhibitory protein–protein 
interactions. Figure adopted from Adipocyte differentiation from the inside 
out (Rosen and MacDougald, 2006). 
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In humans, lipid-filled adipocyte precursors are first visible around 
gestational week 14 in structures called fat lobules (Poissonnet et al., 1984). 
These primitive adipose tissue depots progressively increase in both size and 
number until gestational week 23, when fat lobule number begins to plateau. 
In the following weeks, fat lobule growth is almost exclusively accomplished 
through hypertrophy of existing adipocytes (Poissonnet et al., 1983; 
Poissonnet et al., 1984). In mice, the appearance of cells expressing 
adipogenic markers in subcutaneous compartments is observed relatively 
late in embryogenesis, with overt lipid filling of white adipocytes being 
initiated at birth (Birsoy et al., 2011). Visceral adipose depots form after 
birth during the first week of life (Han et al., 2011). Studies in rats show 
increases in both adipocyte number and size early in life, followed by a 
plateau in adipocyte number by 3 months of age, with WAT mass increasing 
thereafter resulting from increased adipocyte size (Greenwood and Hirsch, 
1974; Hirsch and Han, 1969). A recent study using inducible, irreversible 
labeling of mature adipocytes via the adiponectin promoter (termed 
AdipoChaser mice) supports these findings (Wang et al., 2013b). 
The developmental origin of adipose tissue in different depots has not 
been characterized, with the exception of depots in the head region, which 
have been shown to derive from the neural crest (Billon et al., 2007). It is 
generally considered that adipocytes are of mesenchymal origin based on the 
ability of mesenchymal cells and fibroblastic cell lines to form adipocytes in 
culture (Rosen and MacDougald, 2006; Taylor and Jones, 1979). Further, 
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recent studies using transgenic mouse reporter showed that mesenchymal 
cells expressing pref-1 form early precursors of adipocytes in vivo (Hudak et 
al., 2014). Other studies have suggested that white adipocytes are derived 
from endothelial (Tran et al., 2012) or hematopoietic lineage (Crossno et al., 
2006; Sera et al., 2009). However, conflicting results of these studies indicate 
that the appearance of endothelial lineage markers in mature adipocytes was 
due to proximity of adipocytes and vascular structures (Berry et al., 2014; 
Berry and Rodeheffer, 2013b), and that hematopoietic linage likely 
originated from contamination of macrophages (Berry and Rodeheffer, 
2013b; Koh et al., 2007; Tchoukalova et al., 2012). Lastly, based on the 
observation that differentiating preadipocytes reside within vascular 
compartments of adipose tissue, it was proposed that a subset of pericytes 
are adipocyte precursors (Cinti et al., 1984). Lineage tracing using pericyte 
marker PdgfRβ-cre:R26R-LacZ mice showed that all mature adipocytes stain 
positive for β-galactosidase, and PdgfRβ-expressing cells can form adipocytes 
when transplanted into mice (Tang et al., 2008). Developmental origin of 
adipocytes may reflect the interplay between vascular growth and 
adipogenesis in vivo (Fukumura et al., 2003; Rupnick et al., 2002). 
Several studies have isolated different cell subpopulations from total 
stroma vascular fraction (SVF) of adipose tissue in an effort to identify 
adipocyte precursors. Using flow cytometry and fluorescence-activated cell 
sorting (FACS), several recent studies were able to isolate populations of live 
adipocyte progenitors with adipogenic properties ex vivo in culture and 
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in vivo following transplantation (Lee et al., 2012; Rodeheffer et al., 2008; 
Tang et al., 2008). This leads to the identification of a population 
characterized by the cell surface marker profile 
CD45−;CD31−;Ter119−;CD29+;CD34+;Sca-1+;CD24+ (hereafter CD24+), 
which is highly adipogenic in culture and capable of considerable expansion 
prior to differentiation, leading to reconstitution of an entire functional 
adipose depot with correction of hyperglycemia and hyperinsulinemia when 
transplanted into lipodystrophic AZIP mice (Rodeheffer et al., 2008). Further 
analysis revealed that the CD24+ adipocyte progenitor loses CD24 
expression to commit into CD24− preadipocytes, which express early 
adipogenic factors PPARg and C/EBPa but not AdipoQ or Perilipin (FIGURE 
1.5). Interestingly, adipogenic capacity of CD24+ progenitors is dependent of 
FIGURE 1.5 Model of in vivo adipogenesis. A schematic representation 
of the adipocyte cellular lineage is shown. The defined lineage, cell 
surface, and transcriptional markers for each cell type are shown below 
each listed cell type. Figure adopted from Weighing in on Adipocyte 
Precursor (Berry et al., 2014). 
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adipose tissue microenvironment (Berry and Rodeheffer, 2013b), suggesting 
certain non-adipocyte autonomous factors contribution to regulation of 
adipogenesis in vivo. Chapter 6 of this thesis describes a novel blastocyst 
complementation technique to elucidate cell-autonomous versus non-cell-
autonomous mechanisms that participates in regulation of whole body 
metabolism and adiposity.  
1.14 Disease of Adipogenesis: Lipodystrophy 
While the disproportional gain of fat mass is described by obesity, 
disproportional loss of adipose tissue is termed lipodystrophy. 
Lipodystrophy is a heterogeneous acquired or inherited disorder 
characterized by the partial or general loss of adipose tissue (Prieur et al., 
2014). Based on linkage analysis of candidate gene screening, the molecular 
basis of lipodystrophy primarily involves genes that regulates adipocyte 
differentiation, nutrient uptake (particular fatty acid), and/or lipid droplet 
(its main component triacylglycerol) formation (Huang-Doran et al., 2010). 
The genetic forms of lipodystrophy are very rare, and a large number of 
patients carry no mutations in known genes. In contrast, the most common 
form of lipodystrophy is induced by protease inhibitors used to treat HIV, 
affecting up to 50 % of HIV patients (Asterholm et al., 2007). 
Loss of adiposity results in decreased adipokine secretion, 
particularly leptin, and excess lipid deposit in other tissues such as the liver 
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with the development of a severe metabolic syndrome, including insulin 
resistance, hyperglycemia, and dyslipidaemia in both humans and mouse 
models (Reue and Phan, 2006; Savage, 2009; Schott et al., 2004). Despite 
their opposite phenotypic appearance in adiposity, obesity and 
lipodystrophy syndrome share paradoxical similarity in these metabolic 
complications, suggesting common factors on the pathogenesis of these 
diseases (TABLE 1.1). In turn, the “lipid overflow” hypothesis proposes that, 
since the capacity of adipose tissue to accommodate excess energy in the 
form of triglyceride is finite, excessive lipid load, typically in obesity, leads to 
ectopic lipid accumulation and insulin resistance (Unger, 2003). Insulin 
resistance as a result of such “lipotoxicity” is most prominent in the liver, 
skeletal muscles, and pancreas (Huang-Doran et al., 2010). Lipodystrophy is 
an extreme example of reduced adipose tissue “capacity” and therefore is 
characterised by severe ectopic lipid accumulation and insulin resistance 
(Savage, 2009). Moreover, abnormal secretion of adipokines and hormones 
TABLE 1.1 Phenotypic Comparisons among Lipodystrophy, Obesity, and 
Leptin-Deficiency. 
Lipodystrophy Obesity Ob/Ob 
Fat mass ↓ ↑ ↑ 
Leptin ↓ ↑ ↓ 
Adiponectin ↓ ↓ ↓ 
Inflammatory cytokines ↑↓ ↑ ↑ 
Metabolic complications ↑ ↑ ↑ 
38 
from dysfunctional adipose tissue can lead to an altered energy balance and 
loss of dynamic metabolic regulation (Asterholm et al., 2007). Consistently, 
leptin replacement therapy improves both insulin sensitivity and lipid 
metabolism in patients and mouse models with generalized lipodystrophy 
(Colombo et al., 2002; Ebihara et al., 2007; Gavrilova et al., 2000; Javor et al., 
2005). 
Several mouse models of lipodystrophy have been constructed. These 
models not only contribute to understanding disease etiology, but also to 
providing different perspectives on the study of normal adipose tissue 
physiology. The induced lipodystrophy mouse model FAT-ATTAC  (Pajvani et 
al., 2005) make it possible to characterize the physiological functions of 
adipocytes and their secreted factors by acute fat loss without the 
confounding effects of long-term ectopic lipid accumulation in liver and 
muscles. Earlier constitutive loss of adipocytes during development, 
including PPARg2-knockout mice, flp mice with lipin mutation, and AZIP-F1 
(Barroso et al., 1999; Moitra et al., 1998; Peterfy et al., 2001; Zhang et al., 
2004), can be achieved by blocking adipogenesis. These animals seem to 
have much more profound consequences on systemic energy homeostasis 
compared to a late onset loss, suggesting the important role that adipose 
tissue plays during the early developmental stages. More refined time 
courses of fat loss during development are needed to understand the effects 
of adipose tissue on the developmental aspect of metabolic regulation. In 
addition, the ability to precisely block adipogenesis in utero or in the early 
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postnatal period will be useful in understanding adipogenesis in vivo. The 
blastocyst complementation technique described in Chapter 6 of this thesis 
presents a novel genetic approach to study adipogenesis in vivo. 
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CHAPTER 2: METHODS AND MATERIALS 
2.1 BAC Modificaiton 
Recombineering was performed as previously described (Gong et al., 
2003) on a leptin gene containing BAC (RP24-69D4) and with primer 
sequence included in supplementary to produce the -22kb to +18kb and -
22kb to +8.8kb leptin-luciferase reporter construct and the subsequent 
modified construct with 32 bp deletion. Sequences of cloning primers are 
included in TABLE 2.1. Genomic sequence and coordinates were based on 
NCBI37/mm9 mouse genome. Modified BAC were purified using CsCl 
gradient followed by restriction digestion using NotI (NEB) to remove the 
cloning backbone. Linearized BAC was separated by gel purification, followed 
by electro-elution and spot dialysis to remove debris and contaminants that 
might impede embryo manipulation.   
2.2 Animal Experiments 
Generation of transgenic mice: Leptin-luciferase reporter BACs were 
used to generate transgenic animals in either C57BL/6J or FVB N/J mice 
(Jackson Lab) using common pronuclear injection techniques (Birsoy et al., 
2008a; Nagy, 2003). 
Generation of chimeric mice: AZIP(FVB) chimeras were generated by 
injecting CAG-driven tubulin-YFP-ES-cells (B6-Tyrc; Gene Targeting Resource 
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TABLE 2.1 BAC Modification Primers. 




22kb GalK primer Rev 
5’TGTTTTTTGAAATGTATTTAAATATTTATTTATTTTATGT
ATATGAGTATCAGCACTGTCCTGCTCCTT 












18kb GalK primer Rev 
5’CGGTACCCAATCAATGGTCATGGCTTTCTACGATGTTTG
AGTGTCTACAGACATCTCTCAGCACTGTCCTGCTCCTT 












32bp GalK primer Rev 
5’TGGTGGCTTCCTGCTGTGGCCTCTTCTTCCCTCCCCTCCC
CAGCACAGCTTCTTGCTTTCAGCACTGTCCTGCTCCTT 








32bp deletion sequencing 
primer For 5’-AGTTGACCTGTGCTTCCATACCCT 
32bp deletion sequencing 
primer Rev 5’-TGTTCTCTTATATCCGCCCTGGGT 








Center at Rockefeller) into 3.5-day blastocysts from breeding of wild-type 
FVB females (Jackson) to AZIP(FVB) transgenic males (Moitra et al., 1998). 
Since both the blastocyst and the ES-cells have white coat color, AZIP(FVB) 
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chimeras are completely albino. Degree of chimerism was determined by the 
percent of YFP-genotype cells in blood DNA samples. AZIP(B6) chimeras 
were generated by injection B6-Tyrc ES-cells into 3.5-day blastocysts from 
breeding of wild-type C57BL/6J females to AZIP(B6) transgenic males. 
AZIP(B6) transgenic mice were generated by backcrossing AZIP(FVB) male 
to wild-type C57BL/6J females for more than 7 generations. Chimerism of 
AZIP(B6) chimeras were scored by coat color and averaged from two 
independent observers as well as quantifying the percentage of Tyrc allele 
versus Tyr wild-type allel using Taqman qPCR (Applied Biosystem). AZIP 
transgenic mice are genotyped according to previous protocol (Moitra et al., 
1998). Primer sequences are detailed in TABLE 2.2. 
TABLE 2.2 Genotype and ChIP primers 
CRE For 5'-CAC GAC CAA GTG ACA GCA AT 
CRE Rev 5'-AGA GAC GGA AAT CCA TCG CT 
gLUC For 5'-GTT GTT CCA TTC CAT CAC GG 
gLUC Rev 5'-TCC TCT GAC ACA TAA TTC GCC 
gAZIP For 5'-CTG TGC TGC AGA CCA CCA TGG 
gAZIP Rev 5'-CCG CGA GGT CGT CCA GCC TCA 
gNFYAf_For 5'-GTA AGT CAG GCT CCA GGG 
gNFYAf_Rev1 
5'-AGG CAA GGC AGA TTT AGG AAG 
GTC 
gNFYAf_Rev2 5'-GGG TTG TCA GGA TGT TCG CAG 
YFP_For 5'-GCG AGG GCG ATG CCA CCT AC 
YFP_Rev 5'-GCG AAG CAC TGC AGG GCG TA 
FABP4_For 5'-AAT GTC AGG CAT CTG GGA AC 
FABP4_Rev 5'-GAC AAA GGC AGA AAT GCA CA 
chip_leptin5e_For 5'-CGC AGA ATT GGC TGC AGC GT 
chip_leptin5e_Rev 5'-GGT GGC TTC CTG CTG TGG CC 
chip_ins_For 5'-GGA CCC ACA AGT GGA ACA AC 
chip_ins_Rev 5'-GTG CAG CAC TGA TCC ACA AT 
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Housing condition for AZIP mice: Due to cold sensitivity of neonates, 
breeding pairs consist of AZIP male and wild-type females are housed in non-
ventilated cages and in elevated temperature (27˚C-30˚C). AZIP-pups were 
weaned around 4 weeks old, upon which the animals are transferred to 
standard housing condition.  
In vivo Luciferase imaging: Measurement of luciferase reporter 
activity in Leptin-BAC transgenic mice was performed with Xenogen IVIS 
Lumina imaging system (Caliper), 10 mins after ip-injecting 150mg/kg of 
luciferin (PerkinElmer) in 150uL 1XDPBS prepared freshly. 
Generation and experiments of adipocyte-specific knockout NF-YA: 
Adiponectin-CRE mice were purchased and genotyped according to standard 
protocol (Jackson Lab). NFYA-fl/fl strain and its genotyping were described 
previously (Bhattacharya et al., 2003). NFYA-fl/fl mice were backcrossed to 
C57BL/6J background for at least 8 generations prior to all experiments. 
Leptin at 350ng/hour (Amgen) or PBS was delivered for 14 days by 
subcutaneously implanted pre-equlibrated osmotic pumps, model 2002 
(Alzet). Insulin (Alpco), serum Leptin (R&D Systems), and serum total 
Adiponectin (Alpco) were measured by ELISA according to the 
manufacturers' protocols using serum samples collected by retro-orbital 
bleeding using EDTA coated capillaries (Drummond). Blood glucose was 
measured by tail vein sampling using a Breeze2 glucometer (Bayer). High fat 
diet treatments used 58Y1 60 kcal% fat (TestDiet). Body adiposity was 
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measured by DEXA scan using Lunar PIXImus2 Densitometer and analyzed 
with manufacture software (GE Medical Systems). Glucose tolerance test 
(GTT) was performed by IP injecting 10% glucose aqueous solution 
calculated to 1mg/g of body weight following a 12 to 16 hour overnight fast. 
For triglyceride quantification in liver, fresh liver tissue with known weight 
(between 60 to 80mg) was homogenized using Polytron in 5%NP-40/water 
on ice, followed the assay protocol outlined in Triglyceride Quantification Kit 
(Abcam). 
Metabolic profiling: Energy expenditure and oxygen consumption 
were measured using Oxymax Comprehensive Lab Animals Monitoring 
System (Columbus Instrument). Core body temperature was measured using 
IPTT-300 transponder probes and DAS-8001Console reader (Bio Medics 
Data Systems). The probes were implanted into the peritoneal space. 
All animal surgeries were performed under Isothesia (Henry Schein) 
delivered via a flow regulator. All animal experiments were performed 
incompliance with regulation and approved by institutional board at The 
Rockefeller University.  
2.3 Biochemical Assays 
In vitro Luciferase assay: Various tissues (spleen, muscle, stomach, 
brain, heart, liver, kidney, intestine, inguinal adipose tissue, epididymal 
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adipose tissue) were dissected and collected from transgenic mice and flash-
frozen with liquid nitrogen. The tissues are homogenized in cell lysis buffer 
(Promega) with a polytron homogenizer. Luciferase activity in tissue lysate 
was measured using the Luciferase Assay kit (Promega) and normalized to 
protein content with a BCA kit (Pierce). 
Western Blot: White adipose tissue and liver tissue were collected and 
minced with razor blade and heated in 95C in loading buffer for 5min. 
Antibodies against NF-YA H209 (Santa Cruz) and b-Actin 13E5 HRP 
conjugated (Cell signaling) were used. 
2.4 Molecular Experiments 
EMSA and supershift assays: EMSA was performed by incubating 6 µg 
of adipose tissue nuclear extracts from 12-16 weeks old Lep ob/ob mice 
(Jackson Lab) in a 20 µl reaction volume with 10 mM HEPES pH 7.9, 4% 
glycerol, 80 mM KCl, 1 mM MgCl2, 2 µg poly (dI-dC), 3 µg BSA, with 20,000 
cpm of the 32P-labeled DNA probe for 20 min at room temperature. Samples 
were then loaded onto a 4-6% polyacrylamide gel, run at 150V for 4 hours, 
dried, detected overnight in a phosphor screen (GE healthcare) and read in 
an Amersham Biosciences Typhoon 9400 imager. For supershift assays 2 µg 
antibody was added after 20 min of incubation with the probe and incubated 
another 20 min before loaded onto the gel. Antibodies were NFY-A (H209), 
NFY-B (FL207), C/EBPα (14AA), C/EBPβ (Δ198) from Santa Cruz 
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Biotechnology, Inc. The sequence of the wild type 32 bp probe is 
TAGTGGGTTAGAGTCTAATTGGAGTAGAGCAG (individual sequences of 
mutated oligos are shown in TABLE 2.3). 
CHIP assay and luciferase reporter assay: Adipose tissues were 
harvested from 8 to 10 weeks old C57BL/6J male mice of either wild-type or 
Lep ob/ob genotype (Jackson Lab). Tissues were washed in cold 1XPBS and 
minced with razor blade on ice, followed by cross linking in 1% 
formaldehyde/PBS for 20min and quenching with glycine for 5min at room 
temperature. The tissues were washed with 1XPBS three times and flash-
freezed in liquid nitrogen. Frozen cross linked tissues were thawed in buffer 
A (20mM Tris, pH7.9, 25% glycerol, 0.1mM EDTA, 0.5% TX-100, 0.5% NP40, 
0.5mM PMSF) and homogenized with a douncer on ice. The lysate was span 
at 2000xg for 5min to collect the nuclei, which were suspended in CHIP 
buffer (50mM HEPES/KOH, pH7.5, 140mM NaCl, 0.1% Na-deoxycholate, 1% 
TX-100, 1mM EDTA, 0.1% SDS) with complete protease inhibitor cocktail 
(Roche). The nuclei were sonicated at 50% amplitude for 15min on ice. The 
1mL of supernatant was used to perform one IP reaction using ProteinG 
Dynal beads (Invitrogen), preincubated with 2ug antibody against NF-YA 
(H209; Santa Cruz) for 2 hrs. After overnight incubation at 4C on a rotator, 
the reaction was washed with high salt buffer (20mM Tris pH8.1, 500mM 
NaCl, 2mM EDTA, 1% TX-100, 0.1% SDS) three times and EB buffer once. 
Reverse cross link was performed using TE with 1% SDS at 65C for 15min on 
a thermomixer. Sample was treated with RNase and protrease K (Sigma), 
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TABLE 2.3 Gel shift and super shift assay oligonucleotides. 
32bp wt F TAGTGGGTTAGAGTCTAATTGGAGTAGAGCAG 
32bp wt R CTGCTCTACTCCAATTAGACTCTAACCCACTA 
32bp mut1F TAGTGGGTTAGAGTCcAATTGGAGTAGAG 
32bp mut2R CTGCTCTACTCCAATTgGACTCTAACCCA 
32bp mut2F TAGTGGGTTAGAGTCTcATTGGAGTAGAG 
32bp mut2R CTGCTCTACTCCAATgAGACTCTAACCCA 
32bp mut3F TAGTGGGTTAGAGTCTAcTTGGAGTAGAG 
32bp mut3R CTGCTCTACTCCAAgTAGACTCTAACCCA 
32bp mut4F TAGTGGGTTAGAGTCTAAcTGGAGTAGAG 
32bp mut4R CTGCTCTACTCCAgTTAGACTCTAACCCA 
32bp mut5F TAGTGGGTTAGAGTCTAATcGGAGTAGAG 
32bp mut5R CTGCTCTACTCCgATTAGACTCTAACCCA 
32bp mut6F TAGTGGGTTAGAGTCTAATTcGAGTAGAG 
32bp mut6R CTGCTCTACTCgAATTAGACTCTAACCCA 
32bp mut7F TAGTGGGTTAGAGTCTAATTGcAGTAGAG 
32bp mut7R CTGCTCTACTgCAATTAGACTCTAACCCA 
32bp mut8F TAGTGGGTTAGAGTCTAATTGGcGTAGAG 
32bp mut8R CTGCTCTACgCCAATTAGACTCTAACCCA 
32bp mut9F TAGTGGGTTAGAGTCTAATTGGAcTAGAG 
32bp mut9R CTGCTCTAgTCCAATTAGACTCTAACCCA 
32bp mut10F TAGTGGGTTAGAGTCTAATTGGAGcAGAG 
32bp mut10R CTGCTCTgCTCCAATTAGACTCTAACCCA 
purified with PCR purification kit (Qiagen), and analyzed with qPCR (see 
supplementary for primer sequences). For Luciferase reporter assay, 115bp 
leptin enhancer site (GAGAACACTTAACAGCAAAGGTTAATCTTTGAAGTCCCT 
AAAGATTTGAACTTTCCGCAGAATTGGCTGCAGCGTCTAGTGGGTTAGAGTCTA
ATTGGAGTAGAGCAGAAGCAAG) was PCR amplified using -22kb to +8.8kb 
leptin BAC as template and primers 5’-gcggcgcg CTCGAG AAC ACT TAA CAG 
CAA AGG TTA ATC and 5’-cgcccggc AGATCT CTT GCT TCT GCT CTA CTC CAA 
TTA GA. The PCR product was cloned into pGL4.15 (Promega) between XhoI 
and BglII sites. Expression plasmids of NF-YA, NF-YB, NF-YC, and CEBPa in 
pCMV-SPORT6 vector as well as vector plasmid were commercially available 
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(Open Biosystem). The constructs were transfected into 293T cells using 
Lipofectamine 2000 (Invitrogen). The assay was performed using Duo 
Luciferase Reporter Assay System (Promega).    
Gene expression analysis: To extract RNA from adipose tissues, 
approximately 70mg of adipose tissue was harvested and flash-frozen in 
liquid nitrogen. The frozen tissue was homogenized with a Polytron 
homogenizer for 30 sec in 700uL of Trizol Reagent (Invitrogen) on ice. After 
removing debris with centrifugation, the lysate was added to a column of 
Direct-zol RNA MiniPrep (Zymo) and processed according to the 
manufacture’s manual. cDNA was synthesized using qScript cDNA SuperMix 
(Quanta Bioscience). Quantitative PCR was done using Quantitect SYBR Green PCR 
Kit (Qiagen) and 7500 Fast Real-Time PCR (Applied Biosystem) with primers 
specific for each gene of interest (TABLE 2.4). 
2.5 Tissue Culture Experiments 
Gene knockdown and differentiation in 3T3-L1: Knockdown 
of NFYA in 3T3-L1 cells was achieved by lentiviral vector-mediated shRNA 
expression with MISSION shRNA plasmids 439 (CCGGAGCAAGTTACAGTCC 
CTGTTTCTCGAGAAACAGGGACTGTAACTTGCTTTTTTG) and 441 (CCGGCCA 
AACCAAGCTGACGAAGAACTCGAGTTCTTCGTCAGCTTGGTTTGGTTTTTG) 
(Sigma). Lentivirus was generated in 293T cells using 2nd generation 
packaging system (Addgene) and Lipofectamine 2000 (Invitrogen). Viral 
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TABLE 2.4 qPCR primers for gene expression analysis 
Gene Forward Reverse 
NFYA 5’-ATC AAC AGG CCA ACC CAT CA 5’-CTG GAT CTG TCC AGG AGG CA 
HPRT1 5’-TCA GTC AAC GGG GGA CAT 
AAA 
5’-GGG GCT GTA CTG CTT AAC 
CAG 
AdipoQ 5’-GCC GTG ATG GCA GAG ATG 
GCA C 
5’-GGA AGC CCC GTG GCC CTT 
CAG 
Leptin 5’-GCA AGA AGA AGA AGA TCC 
CAG G 
5’-CAG ATA GGA CCA AAG CCA 
CAG 
Adipsin 5’-CAT GCT CGG CCC TAC ATG G 5’-CAC AGA GTC GTC ATC CGT CAC 
Resistin 5’-AAG AAC CTT TCA TTT CCC CTC 
CT 
5’-GTC CAG CAA TTT AAG CCA 
ATG TT 
TNFa 5’-TCC CAG GTT CTC TTC AAG GGA 5’-GGT GAG GAG CAC GTA GTC GG 
FABP4 5’-AAG GTG AAG AGC ATC ATA 
ACC CT 
5’-TCA CGC CTT TCA TAA CAC ATT 
CC 
PPARg 5’-GCA TGG TGC CTT CGC TGA 5’-TGG CAT CTC TGT GTC AAC CAT 
G 
CEBPa 5’-CAA GAA CAG CAA CGA GTA 
CCG 
5’-GTC ACT GGT CAA CTC CAG CAC 
CEBPd 5’-CGA CTT CAG CGC CTA CAT TGA 5’-CTA GCG ACA GAC CCC ACA C 
CD36 5’-ATG GGC TGT GAT CGG AAC TG 5’-GTC TTC CCA ATA AGC ATG TCT 
CC 
Glut4 5’-GTG ACT GGA ACA CTG GTC 
CTA 
5’-CCA GCC ACG TTG CAT TGT AG 
Ehhadh 5’-ATG GCT GAG TAT CTG AGG 
CTG 
5’-GGT CCA AAC TAG CTT TCT GGA 
G 
Hadha 5’-ACT ACA TCA AAA TGG GCT 
CTC AG 
5’-AGC AGA AAT GGA ATG CGG 
ACC 
Ctsk 5’-GAA GAA GAC TCA CCA GAA 
GCA G 
5’-TCC AGG TTA TGG GCA GAG 
ATT 
PGC1a 5’-GAT GCG CTC TCG TTC AAG AT 5’-GGT GTC TGT AGT GGC TTG AT 
UCP1 5’-GCT TTG CCT CAC TCA GGA TT 5’-TAA GCC GGC TGA GAT CTT GT 
Pref1 5’-AGT GCG AAA CCT GGG TGT C 5’-GCC TCC TTG TTG AAA GTG GTC 
A 
Klf4 5’-ACA CCT GCG AAC TCA CAC AG 5’-ACT TCT GGC ACT GAA AGG GC 
supernatants were supplemented with 8 μg/ml polybrene and added to cells 
for infections for 36 hours. Cells were selected with 3 μg/ml puromycin 
(Sigma) for 48 hours, expanded and seeded for differentiation experiments. 
3T3-L1 cells were maintained in DMEM with 10% heat inactivated NCS 
(Invitrogen) in 5% CO2. Differentiation was performed as previously 
described (Zebisch et al., 2012). Oil red staining was performed as previously 
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described (Zebisch et al., 2012). Non-differentiated controls were maintained 
in DMEM with 10% FBS. RNA extraction was performed using RNeasy 
(Qiagen) following manufacturer’s instruction. 
2.6 Statistical Analysis 
Two-ended, unpaired Student T’s test was used. Error bars indicated 
standard error of mean. Unless specifically mentioned, * indicated p<0.05, ** 
indicated p<0.01, *** indicated p<0.001, and **** indicated p<0.0001. 
Outliers were detected by comparing to corresponding Thomspon Tau values. 
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CHAPTER 3: TRANSCRIPTIONAL REGULATION OF LEPTIN BY 
DISTAL ELEMENTS 
3.1 Introduction 
Leptin is an adipocyte hormone that functions as the afferent signal in 
a negative feedback loop that maintains homeostatic control of adipose 
tissue mass. When weight is lost, leptin level falls thus stimulating appetite 
and altering metabolism and neuroendocrine function leading to weight gain 
(Coll et al., 2007). Conversely, in leptin responsive individuals, weight gain 
results in an increase in leptin levels and a reduction of food intake and body 
weight (Friedman-Einat et al., 2003; Jequier, 2002). Leptin production by 
adipocytes is highly correlated to body adiposity (Frederich et al., 1995; 
Maffei et al., 1995b) and is capable of exerting profound effects on both 
energy intake and energy expenditure (FIGURE 3.1). A fuller understanding 
of the elements of this system could have important implications for the 
pathophysiology and treatment of obesity. 
Particularly, the changes in plasma leptin levels are associated with 
changes in leptin mRNA per adipocyte, and the levels of leptin mRNA per cell 
are highly correlated with intracellular lipid content (Couillard et al., 2000; 
Maffei et al., 1995b; Marikovsky et al., 2002; Motyl and Rosen, 2012). These 
observations have raised the possibility that the regulatory elements of the 
leptin gene consist of a putative lipid sensing mechanism that regulates leptin 
expression in response to changes in the amount of intracellular lipid and 
adipocyte size. However, the nature of such a mechanism is not known. To 
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elucidate this, we undertook a similar approach to that used to identify a 
cholesterol sensing pathway. In Brown and Goldstein’s seminal work on the 
regulation of cholesterol metabolism,  the identification of the sterol response 
element (SRE), a key cis-element, led to the identification of SREBP (SRE 
binding protein) and the cholesterol sensor SCAP (SREBP cleavage-activating 
protein) that controls a set of cleavages that leads to the transport of this 
transcription factor to the nucleus (Brown and Goldstein, 1999; Lee et al., 
1994; Nohturfft et al., 2000). As such, we focus our endeavor on dissecting 
the transcriptional regulation of the leptin gene, although there is no 
FIGURE 3.1 Plasma Leptin is Highly Correlated with body adiposity. 
In leptin responsive individuals, weight gain results in an increase in 
leptin levels and a reduction of food intake and body weight. By this 
mechanism, body weight is maintained within a relatively narrow range. 
Plasma leptin thus serves as a surrogate for fat mass. The changes in 
plasma leptin levels are associated with changes in leptin mRNA per 
adipocyte and the levels of leptin mRNA per cell are highly correlated with 
intracellular lipid content.  
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evidence to exclude other means of gene expression regulation such as post-
transcriptional modification.   
Analysis of quantitative expression of the leptin gene necessitates that 
studies be conducted in vivo because cultured adipocytes express orders of 
magnitude lower amounts of leptin mRNA compared to adipcoytes in vivo 
(Macdougald et al., 1995; Mandrup et al., 1997). A previous study from our 
laboratory showed that a leptin-luciferase BAC reporter construct extending 
from from -22kb to +150kb (RP2469D; mm9 chr6: 28987901-29158589) 
showed faithful qualitative and quantitative expression in vivo with 
increased reporter expression in ob/ob adipocytes and decreased expression 
in adipocytes after fasting (Birsoy et al., 2008b). This finding was consistent 
with data from another report showing that this BAC and a second clone 
extending from -160kb to +18kb (mm9 chr6:28854232-29028379) showed 
fat-specific reporter expression, although in the previous report, studies of 
reporter expression in ob/ob and fasted mice were not performed (Wrann et 
al., 2012). This part of the thesis presents the follow-up study on a series of 
modified leptin-luciferase BAC reporter mice to identify cis- and trans-
elements regulating leptin transcription. 
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3.2 Results and Discussion 
In aggregate of previous leptin-BAC reporter mice, it is inferred that 
DNA sequences between -22kb to +18kb (mm9 chr6:28987900- 29199010) 
are likely to be sufficient for leptin transcriptional regulation (FIGURE 3.2A). 
To test this directly, we generated a BAC-transgenic luciferase reporter 
mouse carrying a single 40kb leptin-luciferase BAC that extends from -22kb 
to +18kb, the region of overlap between the aforementioned BAC clones 
(FIGURE 3.2B). Using the same strategy as in a previous study (Birsoy et al., 
2008b), luciferase was cloned into the leptin start codon in the second exon 
of the leptin gene together with a polyadenylation signal (this construct is 
used to generate all subsequent constructs presented in this chapter) so that 
luciferase is expressed under the control of the leptin promoter. 
Two out of two founders expressed luciferase specifically in adipose 
tissue as shown using in vivo luciferase imaging and by analyzing luciferase 
activity from tissue lysates under chow-fed ad libitum (one representative 
animal shown as “fed” in FIGURE 3.2B). In addition, we did not find luciferase 
expression in the GI tract, muscle, brain or any other visceral organs in which 
low levels of leptin gene expression have previously been reported (Birsoy et 
al., 2008b; Rosenbaum et al., 2002). Quantitative regulation of luciferase 
expression was assayed by crossing the reporter mice to ob/ob animals, 
which increases endogenous leptin expression (Note, the ob mice that were 
used carry a mutation of the leptin coding sequence but still show marked 
induction of leptin gene expression), and by food restricting wild-type mice 
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for 48 hours to lower endogenous leptin expression (representative images 
are shown and labeled as “ob/ob” and “fasted” respectively in FIGURE 3.2B). 
Luciferase expression was increased 3.3 fold in eWAT, p=0.02, and 4.7-fold in 
iWAT, p=0.0083,  in ob/ob background  (n=4) and decreased 145.4-fold in 
eWAT, p=0.094, and 35.6-fold in iWAT, p=0.0054, after fasting(n=4); both 
results are compared to 7 animals from transgenic line -22kb to +18kb that 
FIGURE 3.2 Analysis of Leptin-Luciferase BAC-transgenic animals. (A). A 
luciferase construct including a poladenylation signal was cloned into the Leptin 
initiation codon of two nested leptin-BAC clones by homologous recombination 
in bacteria, -156kb to +18kb (RP2433803; chr6:28854232-29028379) and -22kb 
to +148kb (RP2469D4; chr6: 28987901-29158589) and both recapitulate leptin 
expression in vivo, suggesting that the essential regulatory element of leptin 
must be contained in the 40kb region -22kb to +18kb. (B). Transgenic founders 
carrying a single clone of -22kb to +18kb leptin-luciferase BAC, the region of 
overlap between the two BACS in (A), showed adipose tissue specific luciferase 
expression using in vivo imaging (one representative mouse out of 2 founder 
mice as “fed”). The level of luciferase with metabolic status where fasting 
reduced Luciferase expression by 145.4-folds in eWAT (p=0.09) and 35.6-folds 
(p=0.0054) in iWAT and crossing to ob/ob genotype increase expression by 3.3-
folds in eWAT (p=0.02) and 4.7-folds in iWAT (p=0.0083) (labeled as “fasted” 
and “ob/ob” respectively in B). The numbers of animals used are 4 for fasted, 7 
for fed, and 4 for ob/ob. Luciferase assays from tissue lysate confirm that 
luciferase expression is qualitatively and quantitatively regulated similarly to 
leptin.  
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are fed ab libitum. These data confirmed that all of the cis-elements required 
for qualitative and quantitative expression are within this 40 kb interval and 
provided a starting point for the identification of cis-elements and trans-
factors responsible for this regulation. 
We then generated a comprehensive set of 5’ and 3’ deletions, the data 
from which revealed that there were redundant cis-elements upstream and 
downstream of the leptin transcription start site. Thus in order to further 
study leptin gene regulation, we needed to subdivide the leptin gene into 
separate 5’ and 3’ reporter constructs. A manuscript on the complete series 
of leptin-luciferase BAC transgenic mice study is in preparation and partial 
data is available in previous thesis work (Birsoy, 2009). 
To further study the 5’ cis-element without the complication from 3’ 
element, we then generated a leptin-luciferase BAC that extends from -22kb 
to +8.8kb BAC clone (chr6:28987900- 29019010, ending at exon 2 of the 
leptin gene, thus excluding any element 3’ to leptin gene). All of the founders 
(5 out of 5) of this new -22kb and +8.8kb leptin-luciferase BAC were found to 
express luciferase specifically in vivo. Quantitative regulation of leptin 
expression was confirmed by crossing the transgenic animals to ob/ob where 
we found a 1.5-fold increase in luciferase in eWAT, p=0.46, and a 3-fold 
increase in iWAT, p=0.0013 (n=3 for ob/ob). Fasting resulted in a 17-fold 
decrease in eWAT, p=0.019, and 6.5-fold decrease in iWAT, p=0.0002, leptin 
expression (n=6 for starved), compared to 8 wild-type ab libitum fed animals 
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(FIGURE 3.3A). Individual founders showed similar expression pattern 
(FIGURE 3.3B). These data confirm that sequences between -22kb to +8.8kb 
can, or in another word the 5’ upstream of leptin is sufficient to, recapitulate 
qualitative and quantitative expression of the leptin gene in vivo. 
We next performed a homology search of sequences within this -
22kb and +8.8kb interval and identified an 115bp sequence (mm9 
chr6:28993746-28993860) that is highly conserved among all mammals 
including mice (FIGURE 3.4). We found that 84.4% of the 115bp sequence is 
identical between human (GRCh37/hg19 genome) and mouse (NCBI37/mm9 
genome) and there is 73.9% sequence identity between platypus (WUGSC 
5.0.1/ornAna1 genome) and mouse. Gel shift assays using a series of 5 
overlapping 32 bp oligonucleotides spanning this 115bp region assays were 
performed using nuclear extracts from adipose tissue of ob/ob mice and 
other tissues. One of these 32 bp oligonucleotides showed a clear gel shift 
activity using nuclear extract prepared from adipose tissue, as well as liver 
and spleen (FIGURE 3.5A; data for liver and spleen not shown). This 32 bp 
segment included a CCAAT-box on the minus-strand which is known to be a 
binding site for a number of transcription factors including the CEBP and the 
NF-Y transcription factors. Further, gel shift assays with mutant oligos 
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FIGURE 3.3 Analysis on -22kb to +8.8kb leptin-luciferase BAC-
transgenic animals. (A). A leptin-Luciferase BAC extending from -22kb to 
+8.8kb (5 founders) also recapitulates leptin expression in vivo, showing 
that the included sequences along are sufficient for leptin regulation. 
Schematic maps of the three reporter transgenes are shown over the 
respective animals with the yellow bands indicating luciferase, the black 
segments indicating exons of leptin, the white segments indicating introns 
of leptin, the blue segments indicating genomic sequence framing leptin, 
and the red band indicating an internal deletion. All heat maps are scaled 
to minimum 0 and maximum 2000 luminescence counts in the 
manufacturer’s program. (B). Individual founders of -22kb to +8.8kb, 5 
mice, all showed adipose tissue specific leptin expression. Each tissue of 
individual transgenic founders (5 mice) of -22kb to +8.8 kb construct is 
shown. Luciferase activities are normalized to total protein amount as 
measured by BCA assay. Schematic maps of the two reporter transgenes 
are shown over the respective panels. 
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showed that base changes within the CCAAT sequence abrogated this DNA-
protein interaction (FIGURE 3.5B). 
To assess whether it was NF-Y or another DNA binding protein that 
was responsible for the activity, the gel shift assays were repeated in the 
presence of anti-NFYA (H209, Santa Cruz) and anti-NFYB (FL207, Santa 
Cruz). These data revealed a clear super-shift in the presence of the antibody 
which is directed against two subunits of the factor, NF-YA and NF-YB 
(FIGURE 3.5C). In contrast, antibodies to two other CCAAT-box binding 
protein C/EBPA or C/EBPB (14AA and Δ198 respectively, Santa Cruz), both 
of which are known to play a role in adipocyte function, did not result in a 
super-shift. To confirm that NF-Y binds to the CCAAT sequence of the leptin 
gene in vivo, chromatin immunoprecipitation (ChIP) assays from adipose 
tissue nuclear extract were performed. The ChIP assay revealed a 2.7-fold 
enrichment (p=0.02) of the NF-Y binding sequences from ob/ob inguinal 
FIGURE 3.4 Conserved Non-Coding Region Upstream of leptin. The 
figure includes an 115bp region at -16.5kb of leptin (mm9 
chr6:28993746-28993860) that is highly conserved among all mammals 
including mice. We found that 84.4% of the 115bp sequence is identical 
between human (GRCh37/hg19 genome) and mouse (NCBI37/mm9 
genome). Genome information extracted from UCSC Genome Browser.    
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FIGURE 3.5 Identification of an NF-YA binding site between -16.401kb to -
16.370kb. A series of overlapping radioactive oligonucleotide probes were used 
to perform gel shift assay using adipose tissue nuclear extract from ob/ob mice in 
this region to identify enhancer site. Two of the five probes showed DNA-binding 
activity in (A) and the 5’5 site containing a 32bp sequence from -16.401kb to -
16.370kb (mm9 chr6: 28993820- 2899385) was further analyzed. (B). A series 
of oligos of the 32 bp sequence of 5’5 site with single mutations (from “wt” 
sequence to “mut” in figure) identified a core binding sequence of a DNA binding 
protein compatible with NF-Y binding. (C). Super-shift assays shown in were 
performed for possible CCAAT binding proteins NF-YA (H209), NF-YB (FL207), 
C/EBPa (14AA), or C/EBPb (Δ198) to gel shift reaction with wild-type 
oligonucleotide. A super-shift using the NF-YA (H209) and NF-YB (FL207) 
antibodies is indicated with an arrow. Antibodies against CEBPs did not cause a 
super-shift. (D). CHIP assay in mouse subcutaneous white adipose tissue using 
anti NF-YA shows binding at the identified 32bp enhancer sequence (labeled 5’e) 
in 10 week old ob/ob mice. Fold enrichment is normalized to insulin (labeled 
Ins), a locus that is not expressed in adipose tissue. (E). NF-YA mRNA levels as 
normalized against HPRT1 expression are indistinguishable in fast, fed, or ob/ob 
adipose tissue. (F).  An ex vivo luciferase assay was performed using a luciferase 
construct driven by an 115bp region encompassing the 32bp sequence co-
transfected with  NF-YABC subunits (lane NF-Yabc) showed a 60-fold increase in 
luciferase activity compared to vector-only control (VC), while co-expression of 
the reporter with CEBPA,  or NFYA alone did  not increase activity. 
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adipose tissue using the anti-NFYA antibody (H209, Santa Cruz) compared to 
DNA sequences from the insulin gene (FIGURE 3.5D). Insulin was used as the 
control region because the gene is not expressed in adipose tissues. We next 
assayed the levels of NF-Y mRNAs and did not find a change in mRNA levels 
among ob/ob, and wild-type mice fed ab libitum and fasted (FIGURE 3.5E). 
A functional analysis of the transcriptional activity NF-Y was 
demonstrated by co-transfecting plasmids expressing three subunits of NF-
YA, NF-YB, and NF-YC together with a luciferase reporter cloned downstream 
of the 115bp homologous sequence of leptin enhancer. We found a 60-fold 
increase in luciferase expression when the NF-Y plasmids were co-
transfected compared to vector control (FIGURE 3.5F). Consistent with the 
super-shift data, expressing C/EBPA failed to increase luciferase expression 
in the same assay, nor did NF-YA alone consistent with previous data 
showing that all three NF-Y subunits are required for its transcriptional 
activity. Together, these experiments showed that NF-Y binds to the CCAAT-
box 16.5kb upstream of the leptin TSS and can increase the level of 
expression of a reporter construct. The identified cis-element is a true 
enhancer that can activate transcription independent of their location, 
distance or orientation with respect to the promoters of genes (Ong and 
Corces, 2011). Note that since NF-Y was identified using a candidate 
approach, it is likely that other transcription factors also interact with this 
enhancer site. Other trans-elements can be identified using the same in vitro 
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luciferase assay combined with cDNA library of transcription factors, which 
is an approach under active pursue. 
Although the C/EBP family transcription factors are known for 
inducing preadipocyte differentiation and in modulating gene expression in 
the fully differentiated adipocyte (Darlington et al., 1998), it is not 
unexpected that we did not detect bindings of either C/EBPa or C/EBPb at 
the identified distal enhancer. As mentioned, leptin is expressed at much 
higher levels in vivo versus in vitro such as in differentiated 3T3-L1 or F442 
cells (Macdougald et al., 1995; Mandrup et al., 1997). Since these cultured 
models express C/EBP factors and their targets in abundance (Soukas et al., 
2001), it can be inferred that adipocyte specific expression of leptin is 
controlled by a different set of transcriptional mechanism from that dictating 
adipogenesis, at lease in vitro. Nonetheless, since expression of leptin serves 
as a hallmark of adipocyte maturation both in vivo and in vitro (Hwang et al., 
1997; Slieker et al., 1998), the in vivo adipogenesis events leading to leptin 
activation during development is worth of further investigation. 
To confirm a role for the 32 bp sequence that includes the NF-YA 
binding site in vivo we generated a -22 kb to +8.8 kb leptin-luciferase BAC 
reporter line in which there was an internal deletion of the 32 bp that 
included the NFY-A CCAAT-sequence. (GTCTAGTGGGTTAGAGTCTAATTGGA 
GTAGAG found between mm9 chr6: 28993820- 2899385; FIGURE 3.6A).  
This deletion completely abrogated reporter expression in all 11 transgenic 
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FIGURE 3.6 Deletion of a 32bp sequence abolish leptin expression in 
vivo. (A) A 32bp sequence internal deletion of the 32 bp NF-YA binding 
site (GTCTAGTGGGTTAGAGTCTAATTGGAGTAGAG; mm9 chr6: 28993820- 
28993851) in the -22kb to +8.8kb BAC (11 mice) abrogated Luciferase 
expression, confirming that these sequences are essential for leptin 
expression in vivo. (B). Luciferase activity of individual tissues from each 
founders of the -22kb to +8.8 kb leptin-luciferase gene with the 32 bp 
deletion are graphed, showing no adipose tissue specificity nor 
comparable expression level to wild-type construct. Luciferase activities 
are normalized to total protein amount as measured by BCA assay. 
Schematic maps of the two reporter transgenes are shown over the 
respective panels. 
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founders using in vivo Luciferase imagining as well in biochemical assays 
from tissue lysates as described above (FIGURE 3.6B). To confirm that the 
reverse CCAAT-box is essential for the transcriptional activity observed from 
the -22 kb to +8.8 kb leptin-luciferase BAC reporter line in vivo, we generated 
two additional transgenic lines: a 4bp mutation from 5’-ATTGG to 5’-Acgta 
(construct NFY-4bp; mm9 chr6: 28993840- 28993843) and a 1bp mutation 
to 5’-ATTcG (construct NFY-1bp; mm9 chr6:28993842). For NFY-4bp 5 out 
of 5 and for NFY-1bp 4 out of 5 transgenic founders lost leptin expression in 
vivo (FIGURE 3.7A and B). These data confirmed that the CCAAT-box element 
is essential for leptin and led us to test the function of NF-YA in adipocytes in 
vitro and in vivo (see Chapter 4). 
This finding is in contrast to data from a prior publication by Wrann et 
al suggesting that a DNA sequences between -5.2kb and the proximal 
promoter are responsible for leptin expression in vivo (Peterfy et al., 2001). 
In this prior report, the authors generated the same -22kb to +18kb Leptin 
BAC clone (except for using EGFP as oppose to Luciferase), that we used to 
recapitulate Leptin expression. They then used a -5.2kb to +18kb BAC clone 
and showed that these sequences can also recapitulate fat specific leptin 
expression though quantitative expression in ob/ob and fasted mice was not 
analyzed. The authors thus concluded that the regulatory element controlling 
fat specific leptin expression must reside within the 5.2kb 5’ region. However, 
we have found that there are redundant elements controlling leptin 
expression including either the 32 bp sequence on the 5’side at -16.5kb 
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presented here or a 3’ sequences at approximately +14kb (manuscript in 
preparation). Either of these 5’ or 3’ sequences is capable of independently 
conferring fat specific expression of the leptin gene (manuscript in 
preparation). For example, we find that a BAC clone that extends from -
16.4kb to +8.8 kb does not lead to fat specific expression of a luciferase 
reporter thus excluding sequences between -5.2 kb and +1bp as being 
capable of supporting leptin expression. Thus the reason the BAC extending 
from -5.2kb to +18kb shows fat specific expression is because of sequences at 
~ +14 kb, not sequences between -5.2 kb and the transcription start site. The 
FIGURE 3.7 Point mutations at NFY binding site ablate leptin 
transcription. Two transgenic lines were generated by point-
mutagenesis on -22kb to +8.8kb leptin-luciferase BAC (top diagram). The 
red bar corresponds to the sequences in each line and mutated base pairs 
are in low case red letters. (A). Four base pair mutation of reverse CCAAT-
box from ATTGG to Acgta abolishs leptin expression in 5 out of 5 founders. 
(B). Single base pair mutation from ATTGG to ATTcG abolishs leptin 
expression in 2 out of 2 founders. Biochemical assay from tissue lysate of 
individual founders are on the right.     
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findings explain our data showing that there is faithful qualitative and 
quantitative expression of a 5’ reporter extending from -22 kb to +8.8 kb, and 
that an internal deletion of a 32 bp sequence at -16.7 kb abrogates this 
expression despite the fact that more proximal promoter elements between -
5.2 kb to +1bp are intact. 
To investigate in vivo function NF-Y binding site, it will be necessary to 
generate knockout mouse model. With the recent advance in genome editing 
technique using CRISPR (Wang et al., 2013a), precise deletion or mutation of 
the sequence of interest can be achieved in one generation. Although the 
aforementioned redundancy of multiple cis-elements could mask the 
potential effect of knockout, such mouse model will also provide information 
on broader role of leptin regulation in vivo that was beyond the scope of 
luciferase reporting.   
Since NF-Y is ubiquitously present in many tissues, adipocyte specific 
and fat mass dependent expression of leptin cannot be explained by the 
regulatory function of NF-Y factor alone. Recent advances in understanding 
transcriptional mechanism suggested an important role of repressor in 
conferring spatial and temporal gene expression (Ong and Corces, 2011). 
Since leptin gene is not expressed until late gestation in mice in differentiated 
adipocytes, transcription of leptin must be repressed in the early 
developmental stages of adipocytes. Indeed, several studies have suggested 
that NF-Y is capable of activating as well as inhibitory regulation, either by 
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direct interaction with different DNA sequences or by recruiting different co-
factors (Peng and Jahroudi, 2002; Zhu et al., 2012). Genome wide study 
showed that NF-Y functions as “switch” between proliferation and 
differentiation in stem cell by re-directing the transcriptional profile in global 
level (Ceribelli et al., 2008; Donati et al., 2008). The precise molecular 
mechanism of leptin transcriptional regulation remains to be explored. 
Particularly, identification of other cis-elements and corresponding trans-
element will facilitate further investigation on interactions among these 
factors. One straightforward speculation is that other cis-elements are 
modulated by some yet unknown adipocyte specific factors, while NF-Y 
serves as co-factor in transcriptional activation. Unfortunately, there is a lack 
of unbiased method to identify trans-factor to a known sequence, and 
classical biochemical purification of transcription factor requires large 
amount of material that is impractical to obtain from animal tissue (Yang, 
1998). 
Recent studies highlight the importance of NF-Y on stem cell 
proliferation and maintenance, notably in mesenchymal linages including 
myoblast and hematopoetic stem cell (Bungartz et al., 2012; Farina et al., 
1999; Gurtner et al., 2008; Gurtner et al., 2003). Similar to our observation in 
3T3-L1 cells where NF-Y expression is reduced during adipogenesis, down-
regulation of NF-Y accompanies differentiation in both the hematopoetic and 
muscle lineage. NFY has also been shown to control tissue specific gene 
expression by interacting with other cell specific DNA binding proteins. For 
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instance, a study comparing fetal and adult erythrocytes shows that NF-Y 
differentially recruits activators or repressors to induce or inhibit the 
gamma-globin gene during development (Zhu et al., 2012). Biochemical 
studies also showed that NF-Y displays histone-like DNA binding activities, 
and can regulate transcription in a non-sequence specific manner (Nardini et 
al., 2013; Oldfield et al., 2014). Further studies of NF-Y and other factors will 
be required to dissect how NF-Y controls qualitative and quantitative leptin 
transcription. 
69 
CHAPTER 4: NF-Y KNOCKOUT AS A NOVEL LIPODYSTROPHY 
MODEL 
4.1 Introduction 
Identification of NF-Y as a trans-element regulating leptin gene 
expression, described in Chapter 3, prompted us to study its function in the 
3T3-L1 adipogenesis model and in a knockout mouse model. NF-Y (also 
known as CBP, CCAAT-box Binding Protein) is a transcription factor 
composed of three subunits, NF-YA, NF-YB, and NF-YC (also as CBP-B, CBP-A, 
CBP-C respectively). NF-Y recognizes the CCAAT sequence mostly through 
the conserved C-terminus of NF-YA, although all three subunits are required 
for DNA binding activity (Mantovani, 1999). A germ line knockout of NF-YA is 
embryonic lethal at E8.5, demonstrating that NF-Y is essential for early 
development (Bhattacharya et al., 2003). In addition, NF-Y is required for 
stem cell maintenance and for controlling cell type specificity during 
differentiation, particularly in mesenchymal lineages such as blood cells, 
myoblasts, and osteoblasts (Bungartz et al., 2012; Goeman et al., 2012; 
Gurtner et al., 2003; Zhu et al., 2005). NF-Y has been implicated in human 
diseases including myodystrophy, neurodegenerative diseases, cancer, and 
cardiovascular diseases (Ly et al., 2013; Tohnai et al., 2014; Yamanaka et al., 
2014). From in vitro studies, NF-Y binds to the promoters of genes 
controlling cholesterol and fatty acid synthesis as well as adiponectin 
although its function in adipogenesis and tissue specific gene regulation in 
vivo has not been evaluated (Park et al., 2004; Reed et al., 2008). 
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In Chapter 3, we showed that a 32bp sequence at -16.5kb of the leptin 
gene is essential for in vivo expression of leptin in luciferase reporter mice. A 
computational analysis identified a CCAAT-box sequence this 32 bp segment 
and NF-Y was identified as the binding protein using a candidate approach in 
super-shift assay. ChIP using an anti-NFY antibody confirmed that it binds to 
this site in vivo. A knockdown of NF-YA in vitro and a fat specific ablation of 
NF-YA in vivo both decreased adipogenesis and leptin gene expression, but 
the decrease in leptin expression appeared, in part, to be a result of a general 
effect on adipocyte development rather than an exclusive effect on the leptin 
gene. Thus animals with a knockout of NF-YA develop a moderately severe 
lipodystrophy with low leptin levels and a metabolic phenotype that is 
remediable with leptin therapy. Overall, these data identify a new etiology for 
lipodystrophy and further suggest that there could be a large number of 
other causes for this disorder. The data also provide a framework for future 
studies aimed at identifying the gene regulatory mechanisms that control 
leptin gene expression. 
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4.2 Results and Discussion 
Preadipocyte culture model 3T3-L1 has been widely used in studies of 
adipogenesis. Since 3T3-L1 cells can be induced to differentiate into lipid-
filled adipocytes in vitro in the presence of insulin, dexamethasone and IBMX 
(FIGURE 4.1A), this model allows precise control over the process of 
adipocyte differentiation (Zebisch et al., 2012). In wild-type 3T3-L1 cells, the 
mRNA levels of NF-YA were detected early in undifferentiated 3T3-L1 cells 
and decreased approximately 10-fold after induction of adipocyte 
differentiation by hormone treatment starting from day3 (FIGURE 4.1B). This 
pattern is similar to other preadipocyte genes such as KLF4 and Pref-1 
(FIGURE 4.1C). In contrary, adipogenic transcription factors PPARg and 
C/EBPa as well as mature adipocyte markers show increase expression 
following differentiation (FIGURE 4.1D and E).  
To assay a role for NF-Y in adipogenesis, we next introduced RNAi 
constructs, labeled 439 and 441, targeting NF-YA into 3T3L1 cells using 
lentivirus. We first confirmed that NF-YA down-regulation is an adipogenesis 
specific effect, because un-differentiated cells do not show lowered 
expression (FIGURE 4.2A). Construct 439 and construct 441 achieved 34% 
and 62% knockdown of NF-YA mRNA levels respectively (FIGURE 4.2B). 
Despite the incomplete knockdown, both constructs abrogated adipogenesis, 
with a markedly decreased number of oil-red stained cells after 
differentiation of cells (stained on day10, 7 days post induction) compared to 
wild type cells or cells expressing a non-hairpin control (SCRAM) construct. 
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These data show that adipogenesis is quite sensitive to even a modestly 
reduced expression level of NF-YA (FIGURE 4.2C top panel). Cells that were 
not induced to differentiate showed comparable viability versus SCRAM cells, 
FIGURE 4.1 Differentiation of 3T3-L1 cells. (A). Schematic summary of 
differentiation protocol of 3T3-L1 cells. The red bars indicates presence of 
hormonal induction. Top panel depicts oil red staining of cells in three 
different time points. (B). NF-Ya expression lowers during differentiation 
and remains low in mature adipocytes. (C). Two other preadipocyte 
factors Klf4 and Pref1 show similar expression profile as NF-Ya. (D) and 
(E). Adipogenic factors and mature adipocyte markers are induced by 
initiation of terminal differentiation and remain expressed in mature 
adipocytes. 
73 
showing that the defect did not affect pre-adipocyte viability and rather that 
NF-YA is essential for adipogenesis (FIGURE 4.2C bottom panel). Consistent 
with an effect of an NF-YA knockdown on adipogenesis, on day14, mRNA 
levels of adipocyte markers C/EBPa, FABP4, LPL, leptin, and adipoQ were 
reduced, further confirming that there is a defect in adipogenesis in the NF-
YA shRNA targeted cells (FIGURE 4.2D). 
Our results showed that NF-Y expression reduces with differentiation 
and that knockdown of NF-Y reduces adipocyte differentiation, both of which 
suggest that it plays a role either to prime pre-adipocytes prior to 
differentiation or functions early in the process before the point of adipocyte 
development when it is no longer expressed. Further studies will be needed 
to distinguish these possible mechanisms. Consistent with the former 
possibility, NF-Y has been shown to play a role in the proliferation and 
maintenance of stem cell precursors, although we failed to note any 
difference in the proliferation or viability of preadipocytes after an NF-Y 
knockdown (Benatti et al., 2008; Bhattacharya et al., 2003; Bungartz et al., 
2012). Moreover, since many adipocyte markers including leptin are only 
expressed in mature adipocytes that are terminally differentiated, the altered 
expression of a differentiated marker reflects defects during differentiation 
process to some extent. Consistently, expressions of many mature adipocyte 
genes are dependent on adipogenic factors PPARg and C/EBPa (Rosen et al., 
2000). While C/EBPa was shown to transcriptional activation of leptin via 
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FIGURE 4.2 NF-YA Expression and Function of NF-YA in 3T3-L1 adipocytes 
in vitro. (A). NF-YA mRNA is expressed at a high level in undifferentiated 3T3-L1 
and its level is decreased during day3 to day7 after differentiation using a 
standard cocktail of insulin, dexamethasone and IBM treatment after which NF-
YA remains expressed at a low level in differentiated 3T3 cells (black diamonds), 
as compared to non-differentiated controls (white diamonds). (B). Two lentiviral 
mediated shRNA targeting NF-YA, denoted 439 and 441, were introduced into 
undifferentiated 3T3-L1. After puromycin selection, normalized NF-YA mRNA 
levels were reduced by 34% and 62% in cells expressing 439 (white diamonds) 
and 441 (grey squares) respectively compared to SCRAM (black circles). After 
differentiation of 3T3-L1 cells, NF-YA levels become comparable in knock down 
and SCRAM cells. (C) Despite an incomplete knockdown, both lines show reduced 
adipogenesis after 7 days of differentiation with staining with oil-red for lipid 
droplets on day10. The bottom panel shows virus-treated, non-differentiated 
controls with comparable cell numbers in knocked down and non-hairpin 
control cells. SCRAM indicates scramble, non-hairpin control construct. (D). The 
mRNA levels of CEBPa, PPARg, LPL, leptin, and adipoQ in the shRNA knockdown 
3T3-L1 were measured and normalized to housekeeping HPRT1). The 
adipogenic transcription factors CEBPa and PPARg were lowered by 78%/47% 
and 45%/16% in the knockdown cells, LPL was lowered by 52%/36%, and 
adipokine genes leptin and adipoq were lowered by 59%/46% and 55%/32% 
respectively.  
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proximal promoter (He et al., 1995; Hwang et al., 1997; Miller et al., 1996), it 
the functions of other distal elements that interact with C/EBP factors 
remain unknown. Nonetheless, recent genome-wide study uncovered 
cooperative binding of PPARg and C/EBPa at many adipocyte genes, 
including non-coding regions of leptin, suggesting global transcriptional 
regulation in differentiated adipocytes (Lefterova et al., 2008). 
Since a total body knockout of NF-YA is lethal (Bhattacharya et al., 
2003), we generated an adipocyte-specific NF-Y knockout by crossing the 
adipocyte-specific Adiponectin-CRE mouse to conditional knockout NFYA-fl/fl 
mouse to study the function of NF-Y in adipocytes in animals (FIGURE 4.3A). 
(In the following sections, we refer to the Adiponectin-CRE; NFYA-fl/fl mice as 
NFY-KO and wildtype control NFYA-fl/fl as WT control). The knockout was 
confirmed by genotyping as well as by performing western blots to assay NF-
YA protein expression (FIGURE 4.3A). When fed a chow diet, the NFY-KO and 
WT had similar body weights beginning at weaning (3 weeks old) up until 28 
weeks old (FIGURE 4.3B). However, on chow diet the NFY-KO mice showed a 
significantly decreased adiposity as assessed using DEXA (p=0.002 at at 8 
weeks). Furthermore, while WT mice showed an age-dependent increase in 
body adiposity between 8 weeks to 28 weeks old, NFY-KO mice actually 
showed a progressive loss of body fat, with an adiposity of 9.7% at 28 weeks 
of age which is comparable to the fat content of lipodystrophic AZIP mice 
(FIGURE 4.3C). The result was confirmed by measuring the weight of 
individual epididymal, inguinal, and brown adipose tissues at different ages 
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FIGURE 4.3 Generation of an Adipose Tissue Specific NF-Y Knockout. 
NF-YA adipocyte specific knockout mice, NFY-KO, were generated by 
crossing Adiponectin-CRE to NFYA-flox/flox mice. CRE-negative NFYA-
flox/flox animals are used as WT control (A). Depletion of NF-YA protein 
is confirmed by western blot from adipose tissue. The NFY-KO mice 
(white diamonds) have lower body weight compared to the WT control 
(black diamonds) from weaning (3 weeks) to 6 weeks, but the difference 
becomes insignificant afterwards, n=9 (B). NFY-KO mice (white bars) 
show significantly reduced body adiposity (total fat mass divided by total 
body weight) by DEXA scan with an age dependent worsening with a % fat 
level consistent with lipodytrophy, n=9 (C). At 28 weeks, NFY-KO mice 
show 9.7% body adiposity, comparable to the previously published AZIP 
strain which shows generalized-lipodystrophic mouse model, at 10.7%  
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which revealed significantly decreased fat pad weights in NFY-KO mice 
(FIGURE 4.3D), while other visceral organs remain comparable sizes (Table 
5.1). A decreased body fat mass could be a result of extreme leanness or 
could be a sign of lipodystrophy, a condition in which a pathologic decrease 
in adipose tissue mass leads to a severer metabolic syndrome with decreased 
levels of serum leptin and adiponectin and diabetes, hyperlipidemia and liver 
steatosis. Constitutional leanness in contrast is associated with low levels of 
leptin and high levels of adiponectin without signs and symptoms of 
metabolic disease. Heterozygous knockout mice, though expressing lower 
level of NF-YA protein, showed no significant abnormality on body weight, 
body adiposity, plasma adipokines, insulin and glucose levels (data not 
shown), therefore it is not included in further investigation. It should be 
noted that the shRNA knockdown in 3T3-L1 resulted in less than 50% 
reduction in gene expression yet a rather dramatic impairment in 
adipogenesis. The phenotypic discrepancy between 3T3-L1 knockdown and 
NFY heterozygous knockout was likely due to the timing of gene ablation. In 
NFY-KO mice, NF-Y gene ablation was introduced following expression of 
adiponectin in mature adipocytes, while in 3T3-L1, the gene knockdown was 
performed prior to terminal differentiation. This result is consistent with the 
notion that NF-Y’s critical role in pre-adipocytes. In another word, using a 
CRE-line expressing in preadipocyte population (which is not yet available) 
will provide a comparable in vivo model to the 3T3-L1 experiment. 
FIGURE 4.3 (cont.) (grey bar, 7 age matched animals). (D) Gross tissue 
weight of EWAT, IWAT, and BAT of NFY-KO and WT animals of various 
ages are shown, n=9. Consistent with DEXA result, NFY-KO show 
significantly reduced amount of EWAT and IWAT, while other visceral 
organs remain comparable sizes (Table 4.1); BAT is less affected by NF-Y 
knockout. (E). NFY-KO show lowered levels of serum Leptin with age 
progressing lowering and (F) non-detectable (ND) level of serum 
adiponectin at all age groups measured, n=9. (G). Gene expression 
profiling in epididymal adipose tissues of 3-months old mice show 
significantly decreased levels of adipocyte marker genes (adipokines 
adipoQ, leptin, adipsin, resistin; adipogenic transcription factor FABP4, 
PPARg, CEBPs; adipocyte surface marker CD36, and lipid metabolism 
genes glut4, Ehhadh, Hadha, Ctsk) when expression level is normalized to 
HPRT1, n=2 for WT and n=4 for NFY-KO (G). Inflammatory factor TNFa 
shows increased expression.  
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Consistent with the possibility that a fat specific knockout of NF-YA 
can cause lipodystrophy, NFY-KO mice showed a 2-fold decrease of plasma 
leptin at 8 weeks and a 25-fold decrease in leptin level at 28 weeks with 
undetectable levels of serum adiponectin at all ages tested (FIGURE 4.3E and 
F). Epididymal adipose tissues were collected from 3 months old mice and 
mRNA levels of various adipocyte specific genes were measured using qPCR 
(Figure 4.3G). Consistent with ELISA results, the mRNA levels of adiponectin 
(AdipoQ) and leptin, as well as adipsin and resistin RNAs were significantly 
lowered in NFY-KO mice as were the RNAs for other adipose marker RNAs 
including FABP4, PPARg, C/EBPs, CD36, Enoyl-CoA dehydrogenase (Ehhadh), 
hydroxyl-CoA dehydrogenase (Hadha) and Glut4. These data showing a 
FIGURE 4.4 Histology of adipose tissue in NFY-KO animals. Prominent 
stromal structures in tissues from knockout animal is characteristic of 
lipodystrophy. Larger yet fewer adipocytes are present in knockout tissue, 
suggested possible compensatory growth of remaining cells. However, the 
mechanism of such growth is unknown. All slides were prepared from 5 
months old male mice.   
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general decrease in the expression of a battery of adipocyte specific genes 
are consistent with the adipogenesis defect observed in 3T3 cells after an NF-
Y knockdown. Histological study of the adipose tissue showed prominent 
stroma vascular structure characteristics of adipose tissue dysfunction 
(FIGURE 4.4). The enlarged adipocytes in NF-YA are likely mature cells that 
were not affected by the knockout and resulted in compensatory growth for 
loss of total cell number. As such, progressive lipodystrophic model like this 
one may be useful to study the dynamics between hypertrophy and 
hyperplasia processes. 
NF-Y, also known as CBP or CCAAT-binding protein, binds to the most 
prevalent enhancer sequences in the mammalian genome, CCAAT, and has 
been shown to be essential for a range of cellular functions including cell 
cycle, proliferation, and as mentioned stem cell maintenance (Bhattacharya 
et al., 2003; Bungartz et al., 2012; Dolfini et al., 2012a; Dolfini et al., 2012b; 
Mantovani, 1999; Zhu et al., 2005). A whole-body knockout a NF-Y is 
embryonic lethal due to a failure of cell proliferation during in utero 
development, and that other pluripotent stem cells such as mesenchymal 
stem cells and hematopoietic stem cells requires NF-Y to maintain their 
population (Bhattacharya et al., 2003; Bungartz et al., 2012; Dolfini et al., 
2012a; Tohnai et al., 2014). In adipocytes, prior studies have only showed 
that NF-Y can regulate adipocyte specific genes such as adiponectin and fatty 
acid synthetic pathway in vitro (Park et al., 2004; Reed et al., 2008), 
suggesting a role in mature adipocytes. Our results suggest that NF-Y also 
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plays a role in pre-adipocyte (and/or an adipocyte stem cell) maintenance 
and/or commitment to adipogeneis, leading to the development of an age-
progressive fat loss by and lowering of serum leptin in NFY-KO mice. 
The NFY-KO animals also showed an age dependent hyperglycemia 
and hyperinsulinmia. At 28 weeks old, NFY-KO mice showed 1.5-fold higher 
blood glucose (p=0.001) and 10-fold higher insulin levels (p=0.01) compared 
to WT (FIGURE 4.5A). Glucose tolerance tests (GTT) were next performed 
showing that the NFY-KO had higher blood glucose levels at all of the time 
points during the 120 minute assay (Figure 4.5B). The NFY-KO mice also 
showed reduced glucose clearance with an area under curve (AUC) of blood 
glucose 1.3-fold greater than WT control group (p=0.007; FIGURE 4.5C). 
During GTT, the NFY-KO mice showed an ~ 4-fold higher insulin level at 30 
minutes after glucose injection (p=0.03), suggesting insulin resistance 
contributed to the reduced glucose clearance (FIGURE 4.5D). Finally, the 
NFY-KO mice had hepatic steatosis with a 2-fold higher of triglyceride 
content in liver (p=0.009, FIGURE 4.5E).  
Leptin replacement has been shown to markedly improve the 
metabolic abnormalities of lipodystrophy in animals and humans and a leptin 
response can be considered a sine que non for this condition. To test the 
effect of leptin, we treated NFY-KO animals with 350ng/hour of recombinant 
leptin via osmotic pumps for 14 days (red graph in FIGURE 4.6). Control NF-Y 
KO mice received PBS (black graph in FIGURE 4.6). Leptin treatment of 20 
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week old NFY-KO mice normalized blood glucose at day 10 and day 14 
(p=0.006 and p=0.05 respectively) compared to control mice (FIGURE 4.6A). 
Leptin treatment lowered insulin level to wild-type levels (wide-type data 
not shown) (p<0.01 after day 4, FIGURE 4.6B). Leptin treatment also 
corrected the glucose tolerance during a GTT with a marked lowering of 
blood glucose (p=0.006) and the AUC (P=0.04) (FIGURE 4.6C and D). After 14 
days of treatment, the liver triglyceride content of NFY-KO was lowered by 
50% (p=0.002; FIGURE 4.6E) and the total wet weight of liver was lowered 
by 40% (p=0.001; FIGURE 4.6F). Cessation of leptin treatment led to a 
worsening of glucose tolerance and heaptic steatosis (data not shown). 
We next analyzed the effect of a high fat diet on these animals by 
feeding NFY-KO and WT mice a 60% fat diet (HFD) starting at 4 weeks old. 
On this diet NFY-KO mice failed to gain body weight with a statistically 
different body weight compared to WT mice beginning at 7 weeks of age 
(p<0.01 and p<10-5 after 11 weeks, Figure 4.7A). Similarly, DEXA 
measurements for body adiposity after 6 month of HFD showed that while 
WT showed a marked increase of adiposity of 40%, NFY-KO had an adiposity 
of 9% which is the same adiposity that is seen when these mice are on a 
chow diet (p<10-16; FIGURE 4.7B). Consistent with their low adiposity, serum 
leptin remained low, between 2 to 10 ng/ml, in NFY-KO mice (FIGURE 4.7C). 
The hyperglecemia and hyperinsulinemia were similar in HFD and CHOW fed 
NFY-KO mice, suggesting that a lack of adipose tissue caused the metabolic 
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complications and that the diet per se did not contribute to the phenotype of 
the knockout mice (FIGURE 4.7D). 
FIGURE 4.5 Mice with an Adipose Tissue Specific NF-Y Knockout 
Develop Lipodystrophy. (A). NFY-KO mice develop hyperglycemia (red 
graph) and hyperinsulinemia (blue graph) that progresses with age, n=9. 
At 5 month old, NFY-KO mice show significantly higher increase of blood 
glucose level. (B) The knockout caused an abnormal glucose tolerance test 
(GTT) compromised glucose clearance with (C) a significantly increased 
area under curve (AUC) after IP injection of 1mg glucose/g body weight 
given at time 0, n=16. (D). At 30min after GTT, NFY-KO animals show 3.5-
fold higher insulin level compared to WT, n=7 (E). The knockout mice had 
hepatic steatosis with a 2-fold increased triglyceride levels in liver tissue 
of NFY-KO, n=9. NFY-KO is indicated by white and WT is indicated by 
black in each result.  
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FIGURE 4.6 Leptin treatment ameliorates lipodystrophy phenotypes 
in 5-month-old NFY-KO mice. (A). 14 days of 350ng/hour of Leptin 
treatment via osmotic pump (red graph from day0 to day14 in figure; 
black graph indicates PBS treated NFY-KO animals) normalizes insulin 
level and (B) blood glucose in NFY-KO mice. The difference in insulin 
levels become significant after the initial response to surgery (after day 4) 
and the blood glucose difference becomes significant after day10 of leptin 
treatment. (C) .The GTT is normalized by Leptin at day14, with smaller 
AUC (D). Liver tissues harvested from animals sacrificed on day14 showed 
reduced liver triglyceride content (D left) as well as smaller overall liver 
weight (D right) after Leptin treatment. The numbers of animals shown 
are 10 for Leptin treatment and 7 for PBS control and age-matched 5 
months old. 
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To understand the mechanism of HFD-resistance in NFY-KO mice, we 
measured the energy expenditure of NF-Y KO compared to WT mice using 
calorimetry. Under chow diet, the NFY-KO animals showed decrease 
respiratory exchange ratio (RER), suggesting that these animals utilize 
primarily fat energy source as well as maintain a lower basal metabolism 
(FIGURE 4.8A). Consistently, the NFY-KO animals have lowered core body 
temperature (34.3˚C compared to 34.8 ˚C in WT control animals, p=0.02; 
FIGURE 4.8B). However, these differences were not due decreased food 
intake (data not shown). These result suggested that defect in adipose tissue 
is the primary cause of low adiposity as oppose to increase energy 
expenditure or physical activity. 
In addition to reducing leptin expression, a knockdown of NF-Y in 
vitro and a fat specific knockout in vivo also led to a general effect on 
adipocyte development. This raises the possibility that NF-Y might play a 
general role early in adipocyte development and functions later in 
development to regulate the leptin gene. Indeed, the data are consistent with 
the possibility that, together with other factors, NF-Y directly contributes to 
the regulation of leptin gene expression and that the identification of factors 
interacting with NF-Y could help elucidate the mechanisms controlling leptin 
expression. A recent study showed that NF-Y knockout in neural cells 
resulted in progressive neural degenerative disease via accumulation of 
dysfunctional ER membrane (Luo et al., 2008; Yamanaka et al., 2014). Recent 
studies reveal that ER stress occurs in adipocytes in obesity and diabetes
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FIGURE 4.7 NFY-KO mice are resistant to HFD. (A) The average body 
weight of NFY-KO and WT animals treated with HFD (60% fat) starting 
from 4 weeks old to 28 weeks old is shown, n=9. NFY-KO mice remain a 
lower body weight compared to WT and the difference is significant after 
6 weeks old. (B). After 6 months of HFD, the 28 weeks old NFY-KO mice 
show significantly lowered body adiposity compared to matched WT 
control mice, n=9. (C). NFY-KO mice did not show an increase in serum 
Leptin levels compared to WT animals on the high fat diet (D) Blood 
glucose and insulin levels of various age groups are shown, n=9. At 28 
weeks old hyperinsulinemia and hyperglycemia are present in both NFY-
KO and WT mice. 
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(Gregor and Hotamisligil, 2007; Ozcan et al., 2004); this would be a possible 
mechanism by which NF-Y regulates leptin expression under different 
metabolic states of adipose tissue. However, NF-Y’s general effect on adipose 
cell development with lower levels of expression of adipocyte specific genes 
appears to mask a specific effect on the leptin gene. 
FIGURE 4.8 Calorimetric measurements of NFY-KO mice under chow 
diet.  (A)Oxymax data of NFY-KO and WT animals under chow diet, n=4. 
NFY-KO animals show significantly lowered RER (respiratory exchange 
ratio) during dark cycle, indicating that these animals utilize fat energy. 
(B) During both dark and light cycles, the core temperature of NF-Y-KO 
mice are lowered for about 0.5 ˚C, p=0.02 for both condition, n=8. 
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One caveat of the in vivo studies is that the adiponetin-CRE line that 
was used is not expressed until somewhat later in fat cell development 
(Eguchi et al., 2011; Lee et al., 2013; Wang et al., 2010), and thus cannot be 
used to assess the role of NF-Y at early developmental stages (Jones et al., 
2005). It is thus interesting that a knockout of a gene in adipocyte precursors  
under the control of a promoter that is only expressed at later developmental 
times (the adiponectin promoter) can have a dramatic effect on adipocyte 
mass with an age- dependent worsening of lipodystrophy between 4 and 28 
weeks. One possible explanation is that an NF-Y knockout also has an effect 
on mature adipocytes that leads to reduced replenishment of adipocytes as 
they turnover (Arner and Spalding, 2010a). This would explain the 
worsening of the lipodystrophy with age compared to the normal trend of 
mice to gain fat mass as they get older. It has been previously suggested 
using a model of inducible lipodystrophy mouse models that total pool of 
adipocytes is finite (Pajvani et al., 2005; Wojtanik et al., 2009).  As such, if 
there were a defect in adipogenesis and/or a faster turnover of the knockout 
adipocytes in NFY-KO mice, the adipose tissues would be depleted over time 
manifesting in a progressive lipodystrophy similar to that which we 
observed. It should also be noted that when adiponectin-CRE mice are used to 
generate PPARg and Raptor adipocyte specific knockout mice, the knockout 
animals are lean, resistant to a high fat diet, but metabolically healthy and do 
not show signs of lipodystrophy (Jones et al., 2005; Polak et al., 2008). The 
phenotypic difference between these mouse models and ours suggests that 
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NFY could play a prominent role to specifically control leptin expression, in 
addition to its more general role in fat cell development. NFY could also play 
a functional role in preadipocytes, thus a knockout could exacerbate 
depletion of adipocytes by disruption of the generation and/or maintenance 
of a preadipocyte pool. This possibility is supported by our observations in 
3T3-L1 preadipocytes, as well as other studies where NF-YA was shown to be 
crucial for cell proliferation and stem cell maintenance (Bhattacharya et al., 
2003; Bungartz et al., 2012; Dolfini et al., 2012a). 
Thus one possible mechanism for the lipodystrophy in NF-Y KO mice 
could be that there is a population of adipocyte precursors that expresses 
adiponectin, and that NF-Y ablation in this population compromises the 
ability of animals to replace adipocytes over time. Indeed, recent studies 
report expression of late adipogenic genes including FABP4 and adiponectin 
in a population of preadipocytes in the stromal vascular fraction where 
adipocyte precursors reside (Berry and Rodeheffer, 2013b; Shan et al., 2013) . 
In addition, adiponectin expression can be detected during early 
development at E14 (Birsoy et al., 2011; Wang et al., 2013b). The possibility 
that lipodystrophy is a result of gene ablation in preadipocytes is also 
supported by a previous published lipodystrophy mouse model in FPLD 
(Dunnigan’s familial partial lipodystrophy). The FPLD mouse was generated 
by expressing a dominant negative form of LMNA, the major component of 
nuclear lamina, using the aP2 promoter (Wojtanik et al., 2009). The FPLD 
mice showed progressive fat loss and metabolic complication manifesting 
89 
lipodystrophy in human patient with the same genotype. Further, primary 
culture isolated from FPLD mice showed impaired adipogenesis in vitro. The 
FPLD mice and NFY-KO mice are phenotypically similar mouse models in 
that both are expressed later in development but also develop a more 
profound defect in adipogenesis than would be expected from an effect only 
on mature adipocytes. 
The importance of the early stages of adipogenesis is also highlighted 
by data from  a patient with congenital generalized lipodystrophy who had a 
de novo, homozygous point mutation in the promoter of c-fos (Knebel et al., 
2013). In 3T3-L1 cells, c-fos expression peaks at early times during hormone 
induction, which then modulates expression of other downstream 
proadipogenic factors during differentiation (Distel et al., 1987; Rangwala 
and Lazar, 2000). Genome wide in silico analysis showed co-localization of 
FOS and NF-Y, but whether this interaction has biological relevance in 
adipose tissue will require further investigation (Fleming et al., 2013). The 
importance of early transcriptional events is also supported by our findings 
for NF-Y which is also expressed only early in adipogenesis and can cause 
lipodystrophy in homozygous knockout mice. It is also possible that other 
mutations in NF-Y can act in a dominant negative manner as it has been 
shown that a dominant negative form NF-Y suppresses c-jun activity, a 
transcription factor that is also important for early adipogenesis (Nabokina 
et al., 2013; Rangwala and Lazar, 2000; Tiwari et al., 2012). 
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Several possible mechanisms for the pathologic loss of adipose tissue 
and lipodystrophy have been identified in both human and mouse models 
though none have appeared to have a specific role on leptin production. For 
instance, lipodystrohpy can be caused by an autosomal recessive mutation in 
AGPAT2, an acyltransferase highly expressed in adipose tissues and 
important for triglyceride synthesis, which leads to an imbalance in fat 
storage and lipolysis (Luckman et al., 1999; Rosenblum et al., 1996; 
Rosenblum et al., 1998). A dominant mutation of PPARg can cause human 
lipodystrophy, as the mutant PPARg showed reduced transcriptional activity 
with a reduced rate of adipogenesis (Rosenbaum et al., 1996; Zhang et al., 
2014). The fld mice (fatty liver dystrophy), a spontaneous form of 
lipodystrophy in mice, results from a point mutation in lipin-1(Peterfy et al., 
2001). Lipin-1 is a phosphatase that plays a role in triglyceride metabolism 
and transcriptional co-activation of PPARg during adipogenesis (Reue and 
Dwyer, 2009). Both dominant and recessive mutation of LMNA (the 
aforementioned FPLD mouse) causes lipodystrophy potentially due to its 
involvement in nuclear lamina that regulates nuclear trafficking and 
transcriptional activity (Schmidt et al., 2001; Wojtanik et al., 2009). Further 
studies will be needed to determine whether NF-YA interacts with any of 
these or other factors that play a role in adipocyte development and/or that 
can contribute to the development of lipodystrophy. It should be noted that 
the lipodystrophy can also be acquired resulting from what appears to be an 
immune mechanism or more recently in HIV patients on triple therapy that 
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includes protease inhibitors (Schott et al., 2004). Lipodystrohy can be the 
result of defective adipogeneis and/or an increase rate of loss of of mature 
adipocytes which then secondarily lead to a reduced leptin level. This 
condition is distinct from leanness, in which adipose tissue mass is reduced 
in the absence of metabolic disorders. Lipodystrophy is caused by a relative 
deficiency of leptin. Thus while fat cell transplants from wild type to 
lipodystrophic mice can correct this condition, transplants of leptin deficient 
adipose tissue cannot (Tran and Kahn, 2010). The fat loss in the NF-Y KO 
mice while significant is not as severe as it is in other etiologic forms (such as 
AZIP model) raising the possibility that the NF-Y KO could have a 
disproportionate effect to decrease leptin production.  
In summary of Chapter 3 and Chapter 4, In addition to establishing a 
role for NF-Y in adipocyte development in vivo and as a potential cause of 
lipodystrophy, these data also provide a framework for dissecting the 
regulation of the leptin gene. In unpublished studies we have identified other 
factors that interact with the leptin gene raising the possibility that leptin is 
regulated by a transcription complex of which NF-Y is a component, 
potentially through both sequence specific and non-specific mechanisms. The 
elucidation of the underlying transcriptional mechanisms by which NF-Y 
controls leptin gene expression could thus lead to the identification of a lipid 
sensing mechanism in fat cells that modulates adipocyte function and leptin 
production in response to changes in adipocyte lipid content. 
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TABLE 4.1 Weight of different organs of NFY-KO and WT control at various ages. 
Testicles Kidneys Liver Spleen 
KO WT KO WT KO WT KO WT 
3 mon 214±12 211±36 419±26 406±31 1408±94 1282±116 110±22 86±7 
5 mon 239±10* 213±8 439±8 422±5 1972±100** 1441±30 121±17 116±12 
7 mon 212±25 234±15 572±66* 422±24 1970±510 1573±106 208±63 94±3 
Pancreas Lung Heart 
KO WT KO WT KO WT 
3 mon 250±41 193±8 193±8* 167±8 215±27 242±26 
5 mon 398±92* 185±12 222±21 171±17 260±6** 186±7 
7 mon 508±140 251±23 367±85* 176±9 251±19* 185±23 
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CHAPTER 5: ES-CELL COMPLEMENTATION 
5.1 Introduction 
Based on the lipostatic viewpoint of energy homeostasis, adiposity 
level serves as a gauge for body energy availability. By modulating leptin 
production, adipose tissue signals the central nervous system to adjust food 
intake and energy expenditure, which are physiological and behavioral 
responses aiming to maintain adiposity homeostasis. As such, adipose tissue 
size control is central to energy homeostasis in animals. The collection of 
studies on adipose tissue development in humans and rodents suggests a 
framework of coordinated hypertrophy (increase in cell size) and 
hyperplasia (increase in cell number) in determining body adiposity. Under 
healthy conditions, total adipocyte number in an animal remains close to 
constant after the adolescence period (Greenwood et al., 1979; Greenwood 
and Hirsch, 1974; Knittle and Hirsch, 1968) and the average size of 
adipocytes also stabilizes in early adulthood (Hemmeryckx et al., 2010; Stiles 
et al., 1975). This leads to the hypothesis that the plateau in adipocyte 
number in adult animals is determined and controlled by their 
developmental program. Restoration of adipose tissue following lipectomy 
(surgical removal of adipose tissue) in rodents and humans further suggests 
that total adiposity is regulated (Espejel et al., 2010; Hernandez et al., 2011; 
Huang-Doran et al., 2010; Reyne et al., 1983). Experiments that studied 
adipose tissue cellularity in juvenile rats demonstrated compensatory 
growth to generate the same total number of adipocytes as control animals, 
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which was not observed when the same manipulation was performed on 
adult rats (Faust et al., 1977a, b). Nutritional manipulation by altering litter 
size during early development leads to a decrease in adipocyte numbers 
(Knittle and Hirsch, 1968), yet starvation and refeeding of non-obese adults 
do not affect the total adipocyte number (Hirsch and Han, 1969; Yang et al., 
1990). Additionally, it was recently shown that mature adipocytes turn over 
at a constant, albeit slow, rate in both adult humans and mice (Spalding et al., 
2008; Wang et al., 2013b). In sum, these results suggest developmental 
programming in determining adipocyte cell number, which is maintained 
through a fine balance of adipogenesis and adipocyte death. The mechanism 
involved in regulation of adipocyte cell number and coordination of 
adipocyte hypertrophy together in determining total adiposity is largely 
unknown. 
The plasticity of adipose tissue is most prominent in the case of 
obesity. Several studies have investigated the relative contribution of 
hypertrophy and hyperplasia to achieve massive adipose tissue accumulation 
in obesity, with varying results. The presented data consistently showed 
significant contribution of hyperplasia in early-onset obesity, prior to the 
developmental establishment of adipocyte number (Lemonnier, 1972; Salans 
et al., 1973), however, it remains in debate whether hyperplasia also 
contributes to late-onset obesity. Nonetheless, given the upper limit on 
adipocyte size (Leonhardt et al., 1972), which would limit adipose tissue 
expansion by hypertrophy alone, it is assumed that hyperplasia must 
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accompany hypertrophy at least in cases of extreme obesity. Mathematic 
modeling on total fat mass versus mean adipocyte volume supports this 
conclusion (Jo et al., 2009; Spalding et al., 2008). Additionally, the extent of 
hyperplasia contribution to adipose gain appears to be dependent on many 
factors including sex, genetic background, genetic versus dietary causes of 
obesity, as well as timing of the assay and the specific adipose depot of 
question.  A recent study using AdipoChaser mice demonstrated that the 
appearance of new adipocytes in visceral adipose tissue under HFD much 
precedes that in the subcutaneous compartment (Lee et al., 2012; Wang et al., 
2013b), while another study showed that HFD induced a higher adipogenic 
capacity in subcutaneous rather than visceral adipose tissue (Joe et al., 2009). 
Expansion of adipose tissue in response to HFD is critical to the metabolic 
health of animals. Under positive energy balance, adipose tissue not only 
stores energy for future use but also ensures that the storage is in a safe form. 
However, since the capacity of adipose stores is finite, sustained energy 
balance results in failure of adipose tissue to accommodate surplus energy as 
fat and results in lipotoxicity in other peripheral tissues. Such an 
“expandability” model (Virtue and Vidal-Puig, 2008) is supported by studies 
of human and mouse models on the opposite ends of the obese spectrum. 
Both lipodystrophy (with a very limited adipose capacity) and morbid 
obesity (with a very large capacity yet deficit compared with chronic energy 
surplus) represent conditions of stressed and unhealthy adipose tissue, thus 
various metabolic conditions ensue. Thus, it is possible to ameliorate insulin 
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resistance in the face of obesity by increased capacity of adipose tissue, 
which has been demonstrated by crossing adiponectin-overexpression mice 
to ob/ob (Kim et al., 2007). 
The mechanism by which obesity affects adipogenesis in vivo is also 
not clear, although the observation of similar turnover rates of adipocytes in 
obese and non-obese adults suggested that the state of obesity alters the 
adipocyte number set point (Spalding et al., 2008). Several HFD feeding 
studies have demonstrated that the appearance of new adipocytes coincides 
with existing adipocytes reaching their maximal size (Faust et al., 1978; Joe et 
al., 2009; Wang et al., 2013b). Although it has been shown that paracrine 
activity of mature adipocytes can affect adipogenesis (Janke et al., 2002; 
Marques et al., 1998), the details of these processes are not well understood. 
Adipose tissue, as a whole, is an essential regulatory component in energy 
homeostasis acting as both an energy reservoir and an endocrine organ. 
Moreover, it appears that adipocyte cellularity is predictive of whole-body 
metabolic health in obesity, in which hypertrophy is an independent risk 
factor for insulin resistance and T2DM regardless of BMI (Arner et al., 2010; 
Lonn et al., 2010; Weyer et al., 2000). Altogether, studying the mechanisms 
controlling adipocyte hypertrophy and hyperplasia is instrumental to our 
approach in viewing adipose tissue as a metabolism organ as well as 
understanding pathogenesis of obesity and metabolic diseases. 
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This chapter describes a series of experiments employing a novel 
blastocyst complementation assay to elucidate the molecular mechanisms 
that control adipose tissue deposition in mice in vivo. Specifically, wild-type 
embryonic stem cells (ES cells) are injected into the blastocysts of AZIP 
lipodystrophic mice (FIGURE 5.1). When pluripotent wild-type ES cells are 
injected into AZIP blastocysts, the resulting chimeras (AZIP-chimera) are 
expected to have restored adipose tissue and rescued AZIP phenotypes. As 
the AZIP blastocyst is defective in adipogenesis, such a developmental defect 
is complemented by the progeny of pluripotent ES-cells. By necessity, the 
adipocytes in AZIP-chimera are exclusively derived from injected ES cells. 
Since the ES cells are incorporated into the embryo and will contribute to all 
lineages including adipocyte precursors, this method allows us to observe 
the earliest developmental processes of adipogenesis in vivo. To date, there is 
no other tool capable of specific manipulation of early adipogenesis in vivo, 
since the nature of these stages is largely unknown. 
Similar blastocyst complementation assays have provided unique 
tools to test the ability of a mutant to form the cell type or organ in question. 
These are effective in vivo systems not only to study the developmental 
processes but also to study the effect of a genetic defect on adult tissues. 
Some examples include studies on lymphocytes (Chen et al., 1993), ocular 
lens (Liegeois et al., 1996), liver (Espejel et al., 2010), pancreas (Jonsson et al., 
1994), muscle (Cote et al., 1999), and CNS (Low et al., 2009). Analysis of cell 
lineage in chimeric tissues allows the distinction of cell-autonomous and 
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non-cell-autonomous effects of the mutant. A prominent example is the study 
on developmental determinant of pancreas and liver sizes (Stanger et al., 
2007). In such case, wild-type ES cells were injected into blastocysts of 
apancreatic Pdx1-deficient mice. The resulting chimeras are restored with a 
pancreas. However, the size of the restored pancreas is limited by the 
number of injected progenitor cells. In contrary, liver size is not limited by 
the number of progenitor cells and other intrinsic factors dictate its final size 
(Stanger et al., 2007). In a preliminary study, we determined the relationship 
FIGURE 5.1 Generation of AZIP-chimera by ES-cell complementation 
into AZIP blastocysts. AZIP transgenic animals possess lipodystrophic 
phenotype with complete lack of white adipose tissue (see right side 
photo). Multipotent wild-type ES-cells are injected into AZIP blastocysts, 
which will complement the lipodystrophic phenotype and restore adipose 
tissue exclusively derived from ES-cells. Photograph of animals adapted 
from Life without white fat: a transgenic mouse (Moitra et al., 1998). 
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between the number of progenitor cells and whole body adipose content and 
showed that adult adiposity under normal conditions is independent of 
progenitor number. This is consistent with various prior studies using 
individual animals that adiposity is maintained by some intrinsic 
mechanisms during external perturbations. Notably, HFD can be viewed as 
an external challenge under which adipose tissue responds with 
hypertrophic and hyperplastic expansion. Using AZIP-chimeric mice with 
varying chimerism, this part of the thesis discusses how predisposition of 
limited progenitor affects adipose tissue expansion during HFD exposure.  
Previous examples of a loss-of-function study of PPARg in 
adipogenesis utilized a similar approach. Homozygous knockouts of PPARg 
do not survive past embryonic day 10 due to a defect in placental 
development (Barak et al., 1999; Kubota et al., 1999). To circumvent this 
problem, one approach was to create an aggregation of chimeras derived 
from wild-type ES cells and homozygous PPARg knockout ES cells (Rosen et 
al., 1999). The result demonstrated that PPARg is required for adipogenesis 
in vivo by showing exclusion of knockout cells from adipose tissue, but not 
several other tissues. The alternative approach was to create chimeric 
embryos using wild-type tetraploid cells, which allow rescue of the placental 
defect, and PPARg knockout ES cells, which are the sole contributor to the 
embryo proper (Barak et al., 1999). Unfortunately, this resulted in only one 
live birth with a brown adipose tissue defect and died shortly after birth. In 
the second part of our study, we demonstrate the utilization of our ES-
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complementation model in the study of adipogenesis in vivo by first 
performing the proof-of-principle experiment with PPARg knockout cells. 
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5.2 Results and Discussion 
AZIP (FVB) chimeras were generated by injecting B6-Tyrc-YFP mouse 
ES-cells into 3.5-day blastocysts from breeding of wild-type FVB females to 
AZIP(FVB) transgenic males. Since both the blastocyst and the ES-cells (both 
harboring homozygous Tyrc alleles) have white coat color, AZIP(FVB) 
chimeras are completely albino. Within the AZIP positive group, 11 males 
carried YFP genotype, which indicated these are AZIP(FVB) chimeric mice 
with composed of both AZIP-positive cells and YFP-positive cells. 
Alternatively, the B6-ES cell derived cells can be distinguished from FVB-
blastocyst derived cells at agouti locus, where FVB strain carries the alleles 
for agouti A/A and B6 strain carries nonagouti a/a. However, we did not 
employ this genotyping strategy, nor did we compare measurements for 
chimerism using different loci. In practice, degree of chimerism of these 
AZIP-chimeric mice was determined by the percent of YFP-genotype cells 
comparing to a genomic locus common to both strains, fabp4, in DNA sample 
extracted from whole blood samples. This approach was rationed that, since 
adipose tissue are always 100% ES-cell contributed (see below) and that 
different developmental lineages may demonstrate variability in ES-
contribution (Kusakabe et al., 1988), a tissue type that is closely related to 
adipose tissue should be used as a surrogate for chimerism in preadipocyte 
population. In addition, this surrogate tissue is best collected via simple, non-
invasive biopsy. Since adipocytes are generally considered mesenchymal 
linage along with muscles, endothelial cells, osteoblasts, and blood cells, we 
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hypothesized that DNA extracted from whole blood could represent the 
genotype composition of DNA from adipose-lineage tissues. This hypothesis 
was tested by comparing DNA samples of wild-type chimeric animals (i.e. 
chimeric mice produced by combing wild-type ES cell and wild-type 
blastocyst), which are chimeric for every tissue including adipose tissue and 
blood (FIGURE 5.2). Our hypothesis is confirmed, because the percentage of 
YFP-cells in adipose tissue in wild-type chimeras highly correlated 
(R2=0.6968) to the percentage measured in whole blood samples. Using this 
method, we measured the degree of chimerism of 11 AZIP(FVB) chimeric 
male mice, and summarized the result in TABLE 5.1. Sectioning of the 
y = 0.0624x + 0.0017 






















Normalized YFP in blood 
FIGURE 5.2 Correlation between degrees of chimerism measured in 
genomic DNA of subcutaneous adipose tissue versus whole blood of 
WT-chimera. Chimerism is defined as amount of YFP genes (carried by 
ES-cells) out of amount of FABP4 gene (carried by both ES-cell and 
blastocyst).    
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adipose tissue collected from one of the chimeras showed 100% YFP mature 
adipocytes (FIGURE 5.3).  
Lack of adipose tissue in AZIP transgenic mice results in severe 
metabolic complications, including hyperglycemia, hyperinsulinemia, 
hyperlipidemia, and liver steatosis (Moitra et al., 1998). Moreover, it has 
been shown that surgical transplantation of adipose tissue (Colombo et al., 
2002; Gavrilova et al., 2000; Tran and Kahn, 2010) and isolated adipocyte 
FIGURE 5.3 Immunohistology of adipose tissue from one AZIP-
chimeric animal. The tissue is fixed in 4% PFA and paraffin embedded 
before sectioning. FABP4 staining indicates white adipocytes, which 
colocalized with YFP staining for ES cells.  
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progenitor cells (Rodeheffer et al., 2008) rescue these metabolic phenotypes, 
primarily by restoration of adipokine secretion (Colombo et al., 2002). In the 
AZIP-chimeric animals, adipose tissue was restored by providing ES-cells 
capable of adipogenesis in vivo. As such, the lipodystrophic defects caused by 
AZIP-transgene can be complemented and the metabolic phenotypes can be 
rescued if the ES-cells developed into functional adipocytes in the chimeric 
mice. At 8 weeks of age, all 11 out of 12 AZIP(FVB) chimeric mice showed 
normalized blood glucose from 580±12 mg/dL in AZIP(FVB) transgenic 
animals that are not complemented (n=10; labeled “uncomp.”) to 166±6 
mg/dL in complemented chimeric animals (n=11), p=3x10E-7 (FIGURE 5.4A). 
Age matched wild-type chimeric mice have blood glucose 167±7 mg/dL 
(n=9), which showed no significant difference with the complemented group. 
One additional chimeric mouse with 2% chimerism was hyperglycemic and 
leptin deficient, suggesting that the ES-cell did not complement adipocyte 
development in this animal. Compared to hyperinsulinemia AZIP(FVB) mice, 
which have plasma insulin of 9.3±0.4 ng/mL (n=5), AZIP(FVB) –chimera have 
significantly lowered insulin level of 3.5±0.9 ng/mL (n=11; p=2x10E-4). 
Wild-type chimeric mice have 0.8±0.2 ng/mL plasma insulin (n=7), which is 
slightly lower than AZIP-chimeric group with p=0.05 (FIGURE 5.4B). 
Euglycemia accompanied by potential hyperinsulinemia in complemented 
animals suggested partial insulin resistance and only partial rescue of AZIP 
phenotypes by wild-type ES cells. Body adiposity as measured by DEXA and 
serum leptin levels do not correlate with degree of chimerism, ranging from 
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1% to 97% in both AZIP- and WT-chimeras (FIGURE 5.5A and B). Moreover, 
body adiposity measurements correlate with leptin levels in both groups of 
chimeras, where the degrees of correlation are identical between the groups 
(FIGURE 5.5C). The three groups of animals showed no difference in total 
body weight from 4 to 13 weeks old (FIGURE 5.5D). This suggested that body 
adiposity and leptin level are controlled by adipocyte autonomous factors 
FIGURE 5.4 Metabolic phenotypes of AZIP(FVB)-transgenic animals.  
Hyperinsulinemia and hyperglycemia are rescued by YFP-labled ES-cell 
complementation in AZIP(FVB)-chimeras. All animals depicted are live 
born from blastocyst injection and categorized into three groups: 
AZIP(uncomp.) as AZIP animals without ES-cell contribution, AZIP-
chimera as animals carrying both AZIP-cells and YFP-cells, and WT-
chimera as animals carrying wild-type FVB cells and ES cells. (A). Blood 
glucose in AZIP-chimera is significantly lowered from 580 mg/dL in 
AZIP(uncomp.) to 166 mg/dL (p=3x10E-7). WT-chimeras have similar 
blood glucose level of 167 mg/dL. (B). Insulin in AZIP-chimeras is lowered 
from 9.3 ng/mL in AZIP(uncomp.) to 3.5 ng/mL (p=2x10E-4), yet this 
level is slightly elevated compared to 0.8 ng/mL in WT-chimera (p=0.05). 
n=10 for AZIP(uncomp.), n=11 for AZIP-chimera, and n=9 for WT-
chimera.  
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and that limitation on progenitor number per se does not affect adiposity 
under normal condition. 
Similar insulin resistance phenotype was observed in AZIP-animals 
underwent either transplantation of wild-type adipose tissue or leptin 
replacement (Colombo et al., 2002). On the other hand, ob/ob mice treated 
with leptin showed complete normalization on insulin level. Together these 
FIGURE 5.5 Relationships between degrees of chimerism, body 
adiposity, and serum Leptin levels in AZIP(FVB)-chimeric animals. 
Wild-type chimeric animals, which are chimeras that do not carry AZIP 
transgenes and therefore are chimeric at every tissues, are plotted in 
white diamonds, while AZIP-chimera are depicted in black diamonds. 
Degree of chimerism does not affect serum Leptin levels (A) nor body 
adiposity (B). Leptin level is correlated with body adiposity in chimeric 
animals (C), as would be expected in normal animals. (D). Both groups of 
chimeric animals showed no difference in body weight compared to 
AZIP(uncomp.) mice (green squares) generated from microinjection.    
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results demonstrated that while lack of adipocytes and leptin are the primary 
defect to insulin resistance, additional factors of adipose tissue that are 
missing in AZIP and/or other tissues remain important in glucose 
metabolism. In AZIP-chimeric mice, the only cell type completely derived 
from ES cells is mature adipocytes. As such, it is concluded that cell-
autonomous factors of mature adipocytes cannot fully rescue the metabolic 
defects caused by AZIP transgene. Non-cell-autonomous factors such as 
AZIP-associated defect in the stroma vascular fraction (SVF) of adipose tissue 
and in liver and muscle tissues can affect glucose metabolism. For instance, it 
has been shown that the residual adipose tissue of AZIP-mouse, consisted of 
primary SVF, presents a hyperadipogenic niche (Berry and Rodeheffer, 
2013b; Birsoy et al., 2008a). Moreover, it has been shown that certain 
population of isolated wild-type preadipocytes showed varied adipogenic 
capacity when transplanted into AZIP or wild-type mice (Berry and 
Rodeheffer, 2013a), suggesting non-adipocyte autonomous factors in SVF 
that can alter the cellularity and functioning of whole adipose tissue, despite 
all the mature adipocytes are wild-type. Since AZIP-transgene is expressed 
under adipocyte specific aP2-promotor, it is also unclear whether the 
phenotype is a result of leaky expression. Previous study has demonstrated 
the promiscuity of aP2-promotor in other tissues and especially during 
development (Lee et al., 2013), therefore it is possible that early 
developmental events contribute to the observed metabolic phenotypes in 
adult animals. 
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The AZIP(FVB) blastocyst complementation experiment provided the 
preliminary validation of the method. However, we experienced difficulties 
when manipulating the AZIP(FVB) blastocysts, which developed poorly in 
vitro after isolation at morula stage. We suspected that FVB-background was 
not ideal for embryo manipulation and it was not compatible with B6-
backgroung of ES-cells (Schuster-Gossler et al., 2001). Additionally, B6 is the 
common strain employed in HFD study and it the best characterized in 
metabolism (West et al., 1992). Thus, to study effect of HFD on adipose tissue 
accumulation in chimeric animals, we generated a separate set of chimeric 
mice using AZIP(B6)-blastocyst and B6-Tyrc-YFP ES-cell. These chimeric 
animals carried inbred B6 genetic background in all cells, thus also avoided 
potential complication due to background variability.  
We analyzed 17 AZIP(B6)-chimeras and compared the results to 17 
AZIP(B6) transgenic mice and 19 WT(B6)-chimeras generated as littermates 
from blastocyst injection experiments. While AZIP(B6) transgenic mice 
showed lowered body weight at weaning (3 to 4 weeks old) compared to 
both chimeric groups, no difference was detected among the three groups in 
adult animals (FIGURE 5.6). At 12 weeks old, AZIP-chimeras showed 
10.0±0.6% body adiposity measured by MRI, which was indistinguishable 
from that of AZIP-uncomplemented animals at 8.9±0.3% but significantly 
lowered compared to WT-chimeras at 16.9±0.4% (p=10E-4; FIGURE 5.7A 
and B). The same comparisons were observed for adiposity measured at 24 
weeks old, where AZIP-chimeras showed 11.0±0.9%, AZIP showed 9.2±.4%, 
109 
and WT-chimeras showed 20.9±0.1%, n=15, 13, 18 respectively due to 
mortality (FIGURE 5.7C and D). Difference between AZIP-chimeras and WT-
chimeras remained significant with p=2x10E-4. Scattered plot of adiposity 
versus degree of chimerism showed that AZIP-chimeras are leaner than WT-
chimeras across the board (FIGRUE 5.7B and D). Consistently, at 12 weeks 
old, AZIP-chimeras have lowered serum leptin levels at 5.25±0.97ng/mL 
compared to that of WT-chimeras at 10.45±1.49ng/mL (p=6x10E-3). 
Nonetheless, AZIP-chimeras showed significant rescue of leptin deficiency 
phenotype of AZIP-uncomplemented mice, in which serum leptin levels were 































FIGURE 5.6 Body weight of animals from AZIP(B6) blastocyst 
complementation. AZIP(uncomp.) showed lowered body weight 
between 3 and 4 weeks (p=0.008 and 0.01 respectively), but no difference 
is detected among all groups in other age measured. n= 17 for 
AZIP(uncomp.) showed in black squares, n=17 for AZIP-chimera showed 
in blue squares, and n=19 for WT-chimera showed in white squares.  
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FIGURE 5.7 Body adiposity and serum leptin of AZIP(B6) animals. All 
animals presented are pups of blastocyst complementation. (A). Body adiposity 
at 12 weeks old measured by MRI, where AZIP(uncomp.), AZIP-chimera, and WT-
chimera have 8.9%, 10.0%, and 16.9% adiposity respectively. AZIP(uncomp.) 
and AZIP-chimera are indistinguishable while both are significantly lowered than 
WT-chimera (p=10E-4). (B). Adiposity at 12 weeks old versus chimerism in  
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leptin level does not correlate with chimerism. Two WT-chimeras with high 
leptin levels were excluded based on outlier tests. 
Next, we examined whether metabolic complications in 
lipodystrophic AZIP-transgenic mice can be rescued by complementing 
adipogenesis defect with ES-cells. Hyperinsulinemia at 12 weeks old due to 
adipose tissue defect in AZIP-transgenic mice was rescued in AZIP-chimeras, 
from 111±11ng/mL to 8±4ng/mL (p=5x10E-12). Insulin level in AZIP-
chimeras is slightly elevated compared to WT-chimeras at 1.84±0.24ng/mL, 
p=10E-2 (FIGURE 5.8A). Insulin level was inversely correlated with 
chimerism in AZIP-chimeras but not WT-chimeras (FIGURE 5.8B). Moverover, 
insulin level was also inversely correlated with body adiposity in AZIP-
chimeras but not WT-chimeras, suggesting that the incompletely rescued 
metabolic phenotype was secondary to adiposity defect (FIGRUE 5.8C). On 
the other hand, no significant difference in blood glucose at 12 weeks old was 
detected among groups, primarily because AZIP(B6) animals, as previous 
reported (Colombo et al., 2003; Haluzik et al., 2003), were not hyperglycemic 
to start with (FIGURE 5.8D). Liver steatosis prominent in AZIP(B6) mice, as 
measured by total liver weight (Colombo et al., 2002), was rescued by 
FIGURE 5.7 (cont.) AZIP-and WT-chimeras. AZIP-chimera show lower adiposity 
across all range of chimerism. (C). and (D). Body adiposity at 24 weeks old. (E). 
Serum leptin in three groups of animals. AZIP(uncomp.) has undetectable level of 
leptin. AZIP-chimera has 5.25 ng/mL leptin, which is lowered compared to that 
of WT-chimeras at 10.45 (p=6x10E-3). (F). Serum leptin versus chimerism in 
chimeric animals shows that AZIP-chimeras have lowered leptin across all range 
of chimerism.    
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FIGURE 5.8 Metabolic phenotype in AZIP(B6) animals. (A). Insulin levels at 
12 weeks old. AZIP(uncomp.) mice are hyperinsulinemic at 111 ng/mL, while 
insulin level is significantly lowered in AZIP-chimeras at 8 ng/mL (p=5x10E-12), 
which remain slightly elevated compared to WT-chimera at 1.8 ng/mL (p=10E-
2). (B). And (C). Insulin level is inversely correlated with chimerism and body 
adiposity. (D). Blood glucose in each group of animals at 12 weeks old. Despite 
having elevated insulin levels, AZIP-chimeras showed wild-type level of blood 
glucose. (F). And (G). Liver steatosis as measured by total liver weight. Liver 
weight is comparable in AZIP-and WT- chimeras across all range of chimerism.   
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complementation, where liver of AZIP-chimera weighed 1786±48mg (n=4) 
and liver of AZIP-uncomplemented mice weighted 6058±479mg (n=5), 
p=10E-4. Liver of WT-chimeras weighted 1505±125mg, with no 
distinguishable difference compared with AZIP-chimeras independent of 
chimerism (FIGURE 5.8E and F). 
The observations that AZIP-chimeras remained slightly lipodystrophic 
and leptin deficient suggested that partial adipose tissue defect was the 
primary cause of insulin resistance. This is consistent with observation in 
human patients where metabolic complication is in general correlated with 
extent of adipose tissue loss (Huang-Doran et al., 2010). In AZIP-chimeric 
model, since all mature adipocytes are derived from wild-type progenitors, 
this may reflect non-adipocyte autonomous factors that contributed to 
dysfunction of adipose tissue. For instance, insulin resistance in adipocytes 
can lead to defective adipogenesis and lipid accumulation, which can lead to 
lipotoxicity in other tissues despite only moderate lipodystrophy (Laustsen 
et al., 2002; Rosen and Spiegelman, 2000). Impaired glucose metabolism in 
adipose tissues, such as in case of early stage T2DM, is primary to 
development of insulin resistance in muscles and liver (Abel et al., 2001; 
Shepherd and Kahn, 1999). By this mechanism, it is postulated that AZIP-
chimeric mice became moderately insulin resistant despite having 
adipocytes restored. Whether AZIP-transgene, which is expressed in varying 
degree in other tissues of the chimeras, directly affects other tissues remains 
unclear. Although previous report suggested PPARg down-regulation in liver 
114 
of AZIP-transgenic model as a mechanism of liver insulin resistance 
(Gavrilova et al., 2003), it cannot be deduced from such case if it originated 
from a liver-autonomous defect. Alternatively, reduced plasma leptin itself 
can result in hyperinsulinemia, because leptin has been shown to negatively 
regulate insulin secretion as part of the adipoinsular axis (Kieffer and 
Habener, 2000; Kulkarni et al., 1997). 
Next, we place AZIP- and WT-chimeric animals on HFD treatment to 
assay whether limited adipocyte progenitors in AZIP-chimeric mice limits 
diet induced obesity. After 6 weeks of HFD starting from 6 weeks old, AZIP-
chimeras showed averaged 47.3% of weight gain (n=14), which is 
significantly lower than 78.8% weight gain of WT-chimeras (n=11; p=5x10E-
3). Comparing to WT-chimeras, AZIP-chimeras with low chimerism gained 
less weight (FIGURE 6.9A and B). A subset of these animals that were 
littermates were further studies on change in body adiposity and insulin 
levels after HFD. Body adiposity elevated by 5.7% in AZIP-chimeras (n=7), 
which is significantly lower than the elevation of 21.2% in WT-chimeras 
(n=10; p=8x10E-5). Similar to total body weight, low-chimerism correlated 
with less adipose tissue accumulation in AZIP-chimeras but not in their WT-
counterparts (FIGURE 6.9C and D). Insulin resistance developed more readily 
in AZIP-chimeras than WT-chimeras, where insulin levels were 
3.17±0.95ng/mL and 0.95±0.25ng/mL respectively (p=10E-2) while glucose 
levels were comparable (FIGURE 6.9E, F and G). Interestingly, serum leptin 
correlates with body adiposity measured after 6 weeks of HFD in both AZIP- 
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FIGURE 5.9 AZIP(B6)-chimeras are resistant to obesity but not metabolic 
complication of HFD. (A). Percent of total weight gain after 6 weeks of HFD 
(from 6 to 12 weeks old). AZIP-chimeras on average gained 47% weight while 
WT-chimeras gained significantly more, 79% (p=3x10E-3). (B). Analysis on 
percent weight gain versus chimerism shows that, at lower chimerism, WT-
chimeras gained more weight than AZIP-chimeras. n=14 for AZIP-chimera and 
n=11 for WT-chimera. (C). Analysis of a subset of littermate chimeras on body 
adiposity change after 6 w of HFD. AZIP-chimeras (6%) accumulated less fat 
mass compared with WT-chimeras (21%), p=8x10E-5. (D). Change in adiposity 
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and WT-chimeras (FIGURE 5.10). In summary, the result suggested that 
leptin production is a cell-autonomous property of adipocytes, adipose tissue 
expansion and metabolic complications as a result of adipose tissue defect 
are not adipocyte-autonomous. 
There are two possible explanations for the apparent resistance to 
HFD observed in AZIP-chimeric animals. Since adipose tissue expansion is 
accompanied by hypertrophy and hyperplasia (Arner and Spalding, 2010b), 
defects in either or both processes can lead to failure in adipose tissue 
accumulation. If AZIP-chimeric adipose tissue is insulin resistant as 
previously discussed and since insulin signaling is required for lipid 
accumulation in adipocytes (Yu et al., 2008), AZIP-chimeras will not become 
obese on HFD through hypertrophic adipose expansion. Alternatively, defect 
in hyperplasia can be explained by limited adipocyte progenitor imposed by 
ES-cell complementation. Since it has been shown that the pool of adipocyte 
is finite in adult animals (Pajvani et al., 2005; Wojtanik et al., 2009), it can be 
inferred that variation in ES-cell versus AZIP-cells makeup in this pool affects 
adipogenic capacity of the animal. This is consistent with the observation 
where higher degree of chimerism conferred to greater increase of body 
weight after HFD. Consistently, AZIP-chimeras developed greater insulin 
FIGURE 5.9 (cont.) versus chimerism shows that AZIP-chimeras with low 
chimerism is defective at accumulate fat mass. (E). Insulin levels of HFD-treated 
chimeras shows AZIP-chimeras are more susceptible to development of insulin 
resistance. (F). Blood glucose of HFD-treated chimeras shows no difference in 
glucose level in AZIP-and WT-chimera. For figure (C) to (F), n=7 for AZIP-
chimeras, and n=10 for WT-chimeras.    
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resistance compared with WT-chimeras under HFD, consistent with previous 
observation that limited expandability of adipose tissue is causative to 
metabolic complication (Huang-Doran et al., 2010; Virtue and Vidal-Puig, 
2008). However, low adiposity phenotype compared to WT-chimeras was 
observed under both chow and high-fat diet cross all range of chimerism, 
FIGURE 5.10 Serum leptin versus body adiposity of AZIP(B6)-
chimeras measured by MRI. (A). Animals are fed on chow diet. Both 
AZIP-and WT-chimeras have serum leptin level positively correlated with 
adiposity. n=17 for AZIP-chimera and n=19 for WT-chimeras. (B). Animals 
are fed on HFD. n=14 for AZIP-chimeras and n=11 for WT-chimeras.     
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suggesting that low contribution of ES-cell to the adipocyte per se cannot 
fully account of the observed phenotype. Additional factors such as the 
presence of AZIP-cells in the SVF can limit adipogenesis, including 
accumulation of lipid during terminal differentiation, must be considered. 
It has been a long debate whether hyperplasia contributes to obesity. 
Hyperplasia is strongly correlated with severity of obesity, especially in 
morbidly obese individuals (Hirsch and Batchelor, 1976). However, the data 
was collected cross-sectionally, and therefore gives no direct information on 
the longitudinal relationship between adiposity and adipocyte cellularity. 
Therefore it is impossible to conclude whether the average increase in 
adipocyte number seen in obese individuals is the result of adult adipocyte 
recruitment or rather a reflection of a population of people predisposed (by 
their pre-adulthood fat cell number) to obesity. At least in short-term studies, 
adult humans do not show any increase in adipocyte number following 
significant weight gain (Salans et al., 1971). Consistently, our data 
demonstrated that resistance to obesity as a result of predisposed limited 
adipocyte numbers, although complication from other tissues including the 
SVF cannot be ruled out. 
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TABLE 5.1 AZIP(FVB)-chimeric animals. 
120 
5.3 Application 
The presented blastocyst complementation assay provides a novel 
platform to establish the role of specific molecules to regulate adipose tissue 
mass in vivo. This is potentially a better alternative to the common employed 
loxP-CRE system for the blastocyst complementation requires fewer breeding 
and provides higher tissue specificity. 
The most widely used adipocyte-specific CRE-mouse model has been 
the aP2 promoter, which drives expression of fatty acid binding protein 4 
(FABP4). However, in vitro studies have shown that aP2 is induced late in 
adipogenesis (Bernlohr et al., 1985) and in vivo results have suggested that 
aP2 is not expressed in adipocyte precursors (Rodeheffer et al., 2008). In 
addition, the aP2-promoter expresses in other tissues during developments 
such as macrophages and brain (Lee et al., 2013). Alternatively, Adiponectin-
CRE provides higher adipocyte-specificity, but it is also only expressed in 
mature adipocytes (Jeffery et al., 2014). Lastly, PPARg-driven mouse model 
has been shown to label adipogenic stromal cells in vivo (Tang et al., 2008), 
yet its application is also limited stages in late adipogenesis. Most recently, a 
novel preadipocyte factor, Zfp423, was identified as adipogenic marker both 
in vitro and in vivo (Gupta et al., 2010; Gupta et al., 2012). Although Zfp423 is 
expressed prior to aforementioned adipocyte factors in adipogenesis, its 
specificity in vivo remained to be accessed. Indeed, as adipogenesis in vivo 
and accompanying cell markers are poorly known, no suitable genetic mouse 
model for studying preadipocytes have been constructed. With the AZIP-
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chimera model, adipocyte specific gene modifications can be achieved in one 
step by introducing gene targeted mutations into the donor ES cells (FIGURE 
5.11). As such, gene modification is achieved in early progenitor cells, which 
is very useful to study the genetics of adipose tissue development in vivo. 
However, the current AZIP-chimera model is limited in several 
regards. First, since AZIP-transgene is driven by aP2-promoter, tissue 
specificity remains concerning. Additionally, since any complementing effect, 
in theory, cannot be assayed before the expression of AZIP-transgene, defects 
in early adipocyte stages remain masked. Secondly, the moderate 
lipodystrophy observed in AZIP-chimeras complemented with wild-type ES 
cells is indicative of inherent developmental defects of cultured ES-cells. It 
FIGURE 5.11 AZIP-blastocyst complementation as a method to 
generate adipocyte specific knockout in one generation. Green and 
red color depicts ES-cells that are labeled with different marker. Blue 
triangle represents a homozygous knockout of a gene of interest, 
presumably generated by CRISPR mediated genome modification.  
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has been shown that cultured ES-cells accumulate epigenetic modifications 
that affect in vivo development (Eckardt et al., 2011). Even if a specific ES-cell 
clone has been proven pluripotent (defined as capable of producing live born 
through tetraploid complementation), it could be a result of developmental 
compensation and that it does not provide direct information on its 
developmental capacity under normal conditions. In addition, AZIP-
blastocyst is likely developmentally dominant over ES-cells. Although the 
mechanistic details are unclear, it has been shown that, through inter-species 
blastocyst complementation, the blastocyst host is instructive in determine 
overall animal size and organ morphology in interspecies chimeras (Solter, 
2010). As such, it is likely that the developmental potential of wild-type ES-
cells in terms of its adipogenic capacity is limited by AZIP-blastocyst. Two 
possible strategies can circumvent this limitation. First, aggregation chimeras 
using two embryos will address the concern of developmental discrepancy 
between live embryo and cultured cells. Second, reverse the combination of 
blastocyst and ES-cell by injecting AZIP-transgenic ES-cells into wild-type 
blastocysts. This provides additional advantage of lightening up the breeding 
load on AZIP-animals, which has compromised fertility.      
Despite having limitation in studying adipocyte development, we plan 
to apply blastocyst complementation method to characterize the in vivo 
functions of novel factors involved in leptin regulation. As described in 
Chapter 3, we mapped the cis-elements that regulate leptin expression in vivo 
using leptin-luciferase reporter mice. Combining biochemical assays and 
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genome-wide bioinformatics, we have identified several candidate trans-
factors that interact with these sequences. In Chapter 5, we have performed 
RNA-sequencing on leptin specific gene expression pattern, upon which we 
have identified different genes co-regulated with leptin. These data provided 
gene candidate that can be subject to generating ES-cell knockout using 
CRISPR technique (Wang et al., 2013a). The presented blastocyst 
complementation assay will be useful in generating adipocyte-specific 
knockout of these candidates in one generation and reveal their in vivo 
function in adipose tissue.  
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CHAPTER 6: CONCLUSION 
Since the discovery of leptin in 1994, a staggering amount of effort has 
advanced our understanding of leptin’s critical role in the regulation of 
energy homeostasis and glucose metabolism. Yet the molecular and cellular 
mechanisms regulating leptin production in adipose tissue have remained as 
a gap in knowledge. In the face of the growing prevalence of obesity, the 
molecular basis of adipose tissue expansion in response to diet-induced 
obesity is a pressing question for disease management. While leptin serves as 
the afferent signal of a feedback system for regulating energy homeostasis, 
common obesity are characterized by leptin resistance developed from 
chronic hyperleptinemia. Understanding the mechanism of increase leptin 
production in response to increase adiposity is therefore fundamental to 
study of pathogenesis of obesity. Since serum leptin correlates with body 
adiposity and correlates with mRNA levels in each adipocyte, it was 
hypothesized that leptin expression is regulated by an adipocyte cell-
autonomous mechanism that senses lipid content within adipocytes.  
Lack of a suitable cell culture model to study leptin regulation 
compounded with a lack of understanding of adipose tissue development in 
vivo had made the study of leptin regulation in vivo particularly challenging. 
We address this by developing a luciferase BAC-transgenic reporter mouse 
model that allows us to assay qualitative and quantitative leptin expression 
in vivo. In Chapter 3, using a series of reporter mice, we first narrowed down 
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a 40kb region from -22kb to +18kb that is sufficient for quantitative and 
qualitative leptin expression in vivo.  We further demonstrated that the 5’-
end of this construct alone is sufficient for leptin transcriptional regulation. 
Combination of sequence analysis and gel-shift assays identified a novel 
distal cis-element of the leptin gene at -16.5kb that is essential for leptin 
transcription. Since this cis-element contains a CCAAT-box sequence, a 
candidate approach was taken in a super-shift assay and identified an 
adipogenic factor, NF-Y, as the trans-element for this enhancer site. 
To study the function of NF-Y in adipose tissue in vivo, we generated 
lentiviral mediated knockdown of NF-Y in 3T3-L1 cells and generated 
adipocyte specific NF-Y knockout mice via crossing adiponectin-CRE to NF-YA 
fl/fl mice. These experiments, described in Chapter 4, consistently showed 
that NF-Y is required for adipogenesis, since NF-Y knockdown 3T3-L1 cells 
do not differentiate and NFY-KO mice showed progressive lipodystrophy. 
NFY-KO mice were insulin resistant and dyslipidemic, both of which can be 
ameliorated by leptin treatment. These results show that the metabolic 
complications in NFY-KO mice are secondary to adipose tissue loss cause by 
the deletion. Unfortunately, leptin expression is reduced in NFY-KO mice but 
likely as a result of lipodystrophy. To study the direct function of NF-Y in 
leptin transcriptional regulation in vivo, an inducible model such as the 
adiponectin-ER-CRE system can be considered. Alternatively, deletion or 
point mutation of the -16.5kb cis-element directly in the genome, which is 
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made accessible with CRISPR technique, may provide insight to the 
endogenous function of this regulatory sequence.    
While the leptin-luciferase transgenic model proved to be an excellent 
tool in identifying cis-elements within the leptin gene, there is no good 
unbiased method in identifying the corresponding trans-factors. We address 
this by performing RNA-sequencing experiments in adipose tissue with 
animals under varying ambient leptin. Leptin treatment, in both wild-type 
and ob/ob mice, produces unique metabolic effects that result in fat loss. As 
such, it is postulated that gene expression profiles vary with leptin 
expression levels and that by comparing among samples, one can identify 
molecular and cellular profiles that modulate leptin expression. Sequencing 
experiments were performed with untreated wild-type, ob/ob, wild-type 
leptin withdrawal (model of acute leptin deficiency), and ob/ob leptin 
replacement (model of leptin induced weight loss).  Coupled with other 
genomic methods such as the DNAse hypersensitivity assay and ChIP-seq 
assay, we aim to understand the transcriptional network modulated by leptin 
levels in white adipose tissue. This part of study is under progress. 
Lastly, we took the developmental approach to study leptin regulation 
in vivo. Adipose tissue is the most plastic organ in the body, of which the size 
is determined by coordinated processes between hypertrophy and 
hyperplasia. Regarding adipose tissue as an endocrine organ for leptin and 
other adipokines, it is intriguing how organ size control is achieved. We 
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performed an AZIP-blastocyst complementation experiment to study 
developmental control of adipose tissue and leptin regulation. The unique 
property of blastocyst complementation allows the distinction between 
adipocyte autonomous versus non-autonomous factors that contribute to 
determine body adiposity and regulate metabolic functions. Specifically, 
because the AZIP-blastocyst cannot develop into mature adipocytes, all 
mature adipocytes were progenies of wild-type ES cells in the chimeric 
animals. As such, we first showed that adipocyte progenitor number as 
represented by degree of chimerism does not affect adiposity in adult 
chimeras in chow diet. Nonetheless, at least in the case of B6 background, 
AZIP-chimeras are partially lipodystrophic with moderate insulin resistance. 
Moreover, AZIP-chimeras with low chimerism were unable to expand 
adipose tissue upon HFD challenge, suggesting that hyperplastic expansion is 
required to accommodate excess dietary fat. Adipose tissue expansion is 
critical to metabolic health, as excess lipid that cannot be stored in adipose 
tissue results in lipotoxicity and insulin resistance in other peripheral tissues. 
Overall, an incomplete rescue of AZIP-phenotype by ES-cell complementation 
showed that the broad spectrum of metabolic health is controlled by intricate 
mechanisms involving other cell types and tissues.  Nonetheless, under both 
chow and HFD conditions, serum leptin is correlated with body adiposity, 
suggesting adipocyte-autonomous regulation of leptin transcription. 
Altogether, this thesis presents the molecular basis as well as the 
cellular basis of leptin regulation by using different mouse models. Leptin-
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luciferase BAC transgenic mice can be applied to the study of acute leptin 
regulation by live luciferase imaging following pharmaceutical or genetic 
manipulations. The AZIP-blastocyst complementation model is useful in 
generating adipocyte specific knockout within one generation, avoiding time 
consuming crossing with the traditional genetic approach. Both models will 
be instrumental in further elucidating the molecular and cellular mechanisms 
regulating leptin gene expression in adipose tissue in vivo.    
129 
REFERENCES 
Abel, E.D., Peroni, O., Kim, J.K., Kim, Y.B., Boss, O., Hadro, E., Minnemann, T., 
Shulman, G.I., and Kahn, B.B. (2001). Adipose-selective targeting of the 
GLUT4 gene impairs insulin action in muscle and liver. Nature 409, 729-733. 
Ahima, R.S. (2006). Adipose tissue as an endocrine organ. Obesity 14, 242-
249. 
Ahima, R.S., Kelly, J., Elmquist, J.K., and Flier, J.S. (1999). Distinct physiologic 
and neuronal responses to decreased leptin and mild hyperleptinemia. 
Endocrinology 140, 4923-4931. 
Ahima, R.S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., 
and Flier, J.S. (1996). Role of leptin in the neuroendocrine response to fasting. 
Nature 382, 250-252. 
Allison, D.B., Fontaine, K.R., Manson, J.E., Stevens, J., and VanItallie, T.B. 
(1999a). Annual deaths attributable to obesity in the United States. Jama 282, 
1530-1538. 
Allison, D.B., and Pi-Sunyer, F.X. (1995). Obesity treatment: examining the 
premises. Endocrine practice : official journal of the American College of 
Endocrinology and the American Association of Clinical Endocrinologists 1, 
353-364. 
Allison, D.B., Zannolli, R., and Narayan, K.M. (1999b). The direct health care 
costs of obesity in the United States. American journal of public health 89, 
1194-1199. 
Arner, E., Westermark, P.O., Spalding, K.L., Britton, T., Ryden, M., Frisen, J., 
Bernard, S., and Arner, P. (2010). Adipocyte turnover: relevance to human 
adipose tissue morphology. Diabetes 59, 105-109. 
Arner, P., and Spalding, K.L. (2010a). Fat cell turnover in humans. 
Biochemical and biophysical research communications 396, 101-104. 
Arner, P., and Spalding, K.L. (2010b). Fat cell turnover in humans. 
Biochemical and biophysical research communications 396, 101-104. 
Asterholm, I.W., Halberg, N., and Scherer, P.E. (2007). Mouse Models of 
Lipodystrophy Key reagents for the understanding of the metabolic 
syndrome. Drug discovery today Disease models 4, 17-24. 
130 
Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, 
A., and Evans, R.M. (1999). PPAR gamma is required for placental, cardiac, 
and adipose tissue development. Molecular cell 4, 585-595. 
Barr, V.A., Malide, D., Zarnowski, M.J., Cushman, S.W., and Taylor, S.I. (1996). 
Insulin stimulates both the secretion and the production of leptin by white 
fat tissue. Mol Biol Cell 7, 2608-2608. 
Barroso, I., Gurnell, M., Crowley, V.E., Agostini, M., Schwabe, J.W., Soos, M.A., 
Maslen, G.L., Williams, T.D., Lewis, H., Schafer, A.J., et al. (1999). Dominant 
negative mutations in human PPARgamma associated with severe insulin 
resistance, diabetes mellitus and hypertension. Nature 402, 880-883. 
Barsh, G.S., Farooqi, I.S., and O'Rahilly, S. (2000). Genetics of body-weight 
regulation. Nature 404, 644-651. 
Bates, S.H., Stearns, W.H., Dundon, T.A., Schubert, M., Tso, A.W.K., Wang, Y.P., 
Banks, A.S., Lavery, H.J., Haq, A.K., Maratos-Flier, E., et al. (2003). STAT3 
signalling is required for leptin regulation of energy balance but not 
reproduction. Nature 421, 856-859. 
Ben-Menachem, E. (2007). Clinical guidelines on the identification, 
evaluation, and treatment of overweight and obesity in adults: The evidence 
report. Epilepsia 48, 42-45. 
Benatti, P., Basile, V., Merico, D., Fantoni, L.I., Tagliafico, E., and Imbriano, C. 
(2008). A balance between NF-Y and p53 governs the pro- and anti-apoptotic 
transcriptional response. Nucleic acids research 36, 1415-1428. 
Berglund, E.D., Vianna, C.R., Donato, J., Jr., Kim, M.H., Chuang, J.C., Lee, C.E., 
Lauzon, D.A., Lin, P., Brule, L.J., Scott, M.M., et al. (2012). Direct leptin action 
on POMC neurons regulates glucose homeostasis and hepatic insulin 
sensitivity in mice. The Journal of clinical investigation 122, 1000-1009. 
Bernardis, L.L., and Bellinger, L.L. (1993). The Lateral Hypothalamic Area 
Revisited - Neuroanatomy, Body-Weight Regulation, Neuroendocrinology 
and Metabolism. Neurosci Biobehav R 17, 141-193. 
Bernlohr, D.A., Bolanowski, M.A., Kelly, T.J., Jr., and Lane, M.D. (1985). 
Evidence for an increase in transcription of specific mRNAs during 
differentiation of 3T3-L1 preadipocytes. The Journal of biological chemistry 
260, 5563-5567. 
Berry, R., Jeffery, E., and Rodeheffer, M.S. (2014). Weighing in on Adipocyte 
Precursors. Cell metabolism 19, 8-20. 
131 
Berry, R., and Rodeheffer, M.S. (2013a). Characterization of the adipocyte 
cellular lineage in vivo. Nature cell biology 15, 302-308. 
Berry, R., and Rodeheffer, M.S. (2013b). Characterization of the adipocyte 
cellular lineage in vivo. Nature cell biology 15, 302-308. 
Bhattacharya, A., Deng, J.M., Zhang, Z., Behringer, R., de Crombrugghe, B., and 
Maity, S.N. (2003). The B Subunit of the CCAAT Box Binding Transcription 
Factor Complex (CBF/NF-Y) Is Essential for Early Mouse Development and 
Cell Proliferation. Cancer Research 63, 8167-8172. 
Billon, N., Iannarelli, P., Monteiro, M.C., Glavieux-Pardanaud, C., Richardson, 
W.D., Kessaris, N., Dani, C., and Dupin, E. (2007). The generation of adipocytes 
by the neural crest. Development 134, 2283-2292. 
Birsoy, K. (2009). Transcriptional Regulation Of Adipocyte Function. Student 
Theses and Dissertations. 
Birsoy, K., Berry, R., Wang, T., Ceyhan, O., Tavazoie, S., Friedman, J.M., and 
Rodeheffer, M.S. (2011). Analysis of gene networks in white adipose tissue 
development reveals a role for ETS2 in adipogenesis. Development 138, 
4709-4719. 
Birsoy, K., Chen, Z., and Friedman, J. (2008a). Transcriptional regulation of 
adipogenesis by KLF4. Cell metabolism 7, 339-347. 
Birsoy, K., Soukas, A., Torrens, J., Ceccarini, G., Montez, J., Maffei, M., Cohen, P., 
Fayzikhodjaeva, G., Viale, A., Socci, N.D., et al. (2008b). Cellular program 
controlling the recovery of adipose tissue mass: An in vivo imaging approach. 
Proceedings of the National Academy of Sciences of the United States of 
America 105, 12985-12990. 
Bjorbaek, C., Elmquist, J.K., Frantz, J.D., Shoelson, S.E., and Flier, J.S. (1998). 
Identification of SOCS-3 as a potential mediator of central leptin resistance. 
Molecular cell 1, 619-625. 
Bjorbak, C., Lavery, H.J., Bates, S.H., Olson, R.K., Davis, S.M., Flier, J.S., and 
Myers, M.G., Jr. (2000). SOCS3 mediates feedback inhibition of the leptin 
receptor via Tyr985. The Journal of biological chemistry 275, 40649-40657. 
Blundell, J.E., and Bellisle, F. (2013). Satiation, satiety and the control of food 
intake : theory and practice. 
Boden, G., Chen, X., Mozzoli, M., and Ryan, I. (1996). Effect of fasting on serum 
leptin in normal human subjects. The Journal of clinical endocrinology and 
metabolism 81, 3419-3423. 
132 
Bouchard, C., Tremblay, A., Despres, J.P., Nadeau, A., Lupien, P.J., Theriault, G., 
Dussault, J., Moorjani, S., Pinault, S., and Fournier, G. (1990). The response to 
long-term overfeeding in identical twins. The New England journal of 
medicine 322, 1477-1482. 
Bradley, R.L., and Cheatham, B. (1999). Regulation of ob gene expression and 
leptin secretion by insulin and dexamethasone in rat adipocytes. Diabetes 48, 
272-278. 
Brewer, C.J., and Balen, A.H. (2010). The adverse effects of obesity on 
conception and implantation. Reproduction 140, 347-364. 
Brown, M.S., and Goldstein, J.L. (1999). A proteolytic pathway that controls 
the cholesterol content of membranes, cells, and blood. Proceedings of the 
National Academy of Sciences of the United States of America 96, 11041-
11048. 
Bungartz, G., Land, H., Scadden, D.T., and Emerson, S.G. (2012). NF-Y is 
necessary for hematopoietic stem cell proliferation and survival. Blood 119, 
1380-1389. 
Calle, E.E., Thun, M.J., Petrelli, J.M., Rodriguez, C., and Heath, C.W., Jr. (1999). 
Body-mass index and mortality in a prospective cohort of U.S. adults. The 
New England journal of medicine 341, 1097-1105. 
Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P. (1995). 
Recombinant mouse OB protein: evidence for a peripheral signal linking 
adiposity and central neural networks. Science 269, 546-549. 
Cao, Z., Umek, R.M., and McKnight, S.L. (1991). Regulated expression of three 
C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes & 
development 5, 1538-1552. 
Ceribelli, M., Dolfini, D., Merico, D., Gatta, R., Vigano, A.M., Pavesi, G., and 
Mantovani, R. (2008). The histone-like NF-Y is a bifunctional transcription 
factor. Molecular and cellular biology 28, 2047-2058. 
Cervellati, C., Bonaccorsi, G., Cremonini, E., Romani, A., Castaldini, C., 
Ferrazzini, S., Giganti, M., Fila, E., Massari, L., and Bergamini, C.M. (2014). 
Waist circumference and dual-energy X-ray absorptiometry measures of 
overall and central obesity are similarly associated with systemic oxidative 
stress in women. Scandinavian journal of clinical and laboratory 
investigation 74, 102-107. 
Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. (1994). 
Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-
133 
predominant expression and induction early in adipocyte differentiation. 
Endocrinology 135, 798-800. 
Chen, H., Charlat, O., Tartaglia, L.A., Woolf, E.A., Weng, X., Ellis, S.J., Lakey, N.D., 
Culpepper, J., Moore, K.J., Breitbart, R.E., et al. (1996). Evidence that the 
diabetes gene encodes the leptin receptor: Identification of a mutation in the 
leptin receptor gene in db/db mice. Cell 84, 491-495. 
Chen, J., Lansford, R., Stewart, V., Young, F., and Alt, F.W. (1993). RAG-2-
deficient blastocyst complementation: an assay of gene function in 
lymphocyte development. Proceedings of the National Academy of Sciences 
of the United States of America 90, 4528-4532. 
Chen, X.L., Hartzell, D.L., McGraw, R.A., Hausman, G.J., and Dean, R.G. (1999). 
Analysis of a 762-bp proximal leptin promoter to drive and control 
regulation of transgene expression of growth hormone receptor in mice. 
Biochemical and biophysical research communications 262, 187-192. 
Choquet, H., and Meyre, D. (2011). Genetics of Obesity: What have we 
Learned? Curr Genomics 12, 169-179. 
Christy, R.J., Kaestner, K.H., Geiman, D.E., and Lane, M.D. (1991). 
CCAAT/enhancer binding protein gene promoter: binding of nuclear factors 
during differentiation of 3T3-L1 preadipocytes. Proceedings of the National 
Academy of Sciences of the United States of America 88, 2593-2597. 
Chua, S.C., Chung, W.K., WuPeng, X.S., Zhang, Y.Y., Liu, S.M., Tartaglia, L., and 
Leibel, R.L. (1996). Phenotypes of mouse diabetes and rat fatty due to 
mutations in the OB (leptin) receptor. Science 271, 994-996. 
Cinti, S., Cigolini, M., Bosello, O., and Bjorntorp, P. (1984). A morphological 
study of the adipocyte precursor. Journal of submicroscopic cytology 16, 243-
251. 
Clement, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., 
Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.M., et al. (1998). A mutation in 
the human leptin receptor gene causes obesity and pituitary dysfunction. 
Nature 392, 398-401. 
Cluskey, M., and Grobe, D. (2009). College Weight Gain and Behavior 
Transitions: Male and Female Differences. J Am Diet Assoc 109, 325-329. 
Coleman, D.L. (1973). Effects of Parabiosis of Obese with Diabetes and 
Normal Mice. Diabetologia 9, 294-298. 
Coleman, D.L. (1978). Obese and Diabetes - 2 Mutant-Genes Causing 
Diabetes-Obesity Syndromes in Mice. Diabetologia 14, 141-148. 
134 
Coleman, D.L., and Hummel, K.P. (1969). Effects of Parabiosis of Normal with 
Genetically Diabetic Mice. Am J Physiol 217, 1298-&. 
Coll, A.P., Farooqi, I.S., and O'Rahilly, S. (2007). The hormonal control of food 
intake. Cell 129, 251-262. 
Colombo, C., Cutson, J.J., Yamauchi, T., Vinson, C., Kadowaki, T., Gavrilova, O., 
and Reitman, M.L. (2002). Transplantation of adipose tissue lacking leptin is 
unable to reverse the metabolic abnormalities associated with lipoatrophy. 
Diabetes 51, 2727-2733. 
Colombo, C., Haluzik, M., Cutson, J.J., Dietz, K.R., Marcus-Samuels, B., Vinson, C., 
Gavrilova, O., and Reitman, M.L. (2003). Opposite effects of background 
genotype on muscle and liver insulin sensitivity of lipoatrophic mice. Journal 
of Biological Chemistry 278, 3992-3999. 
Comuzzie, A.G., Blangero, J., Mahaney, M.C., Haffner, S.M., Mitchell, B.D., Stern, 
M.P., and MacCluer, J.W. (1996). Genetic and environmental correlations 
among hormone levels and measures of body fat accumulation and 
topography. J Clin Endocr Metab 81, 597-600. 
Coners, H., Remschmidt, H., and Hebebrand, J. (1999). The relationship 
between premorbid body weight, weight loss, and weight at referral in 
adolescent patients with anorexia nervosa. Int J Eat Disorder 26, 171-178. 
Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., 
Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L., et al. (1996). 
Serum immunoreactive-leptin concentrations in normal-weight and obese 
humans. The New England journal of medicine 334, 292-295. 
Coppari, R., Ichinose, M., Lee, C.E., Pullen, A.E., Kenny, C.D., McGovern, R.A., 
Tang, V., Liu, S.M., Ludwig, T., Chua, S.C., Jr., et al. (2005). The hypothalamic 
arcuate nucleus: a key site for mediating leptin's effects on glucose 
homeostasis and locomotor activity. Cell metabolism 1, 63-72. 
Cote, P.D., Moukhles, H., Lindenbaum, M., and Carbonetto, S. (1999). 
Chimaeric mice deficient in dystroglycans develop muscular dystrophy and 
have disrupted myoneural synapses. Nature genetics 23, 338-342. 
Couillard, C., Mauriege, P., Imbeault, P., Prud'homme, D., Nadeau, A., Tremblay, 
A., Bouchard, C., and Despres, J.P. (2000). Hyperleptinemia is more closely 
associated with adipose cell hypertrophy than with adipose tissue 
hyperplasia. International journal of obesity and related metabolic disorders : 
journal of the International Association for the Study of Obesity 24, 782-788. 
Crossno, J.T., Jr., Majka, S.M., Grazia, T., Gill, R.G., and Klemm, D.J. (2006). 
Rosiglitazone promotes development of a novel adipocyte population from 
135 
bone marrow-derived circulating progenitor cells. The Journal of clinical 
investigation 116, 3220-3228. 
Darlington, G.J., Ross, S.E., and MacDougald, O.A. (1998). The role of C/EBP 
genes in adipocyte differentiation. The Journal of biological chemistry 273, 
30057-30060. 
David, V., Martin, A., Lafage-Proust, M.H., Malaval, L., Peyroche, S., Jones, D.B., 
Vico, L., and Guignandon, A. (2007). Mechanical loading down-regulates 
peroxisome proliferator-activated receptor gamma in bone marrow stromal 
cells and favors osteoblastogenesis at the expense of adipogenesis. 
Endocrinology 148, 2553-2562. 
de la Brousse, F.C., Shan, B., and Chen, J.L. (1996). Identification of the 
promoter of the mouse obese gene. Proceedings of the National Academy of 
Sciences of the United States of America 93, 4096-4101. 
Defronzo, R.A., Hendler, R., and Simonson, D. (1982). Insulin Resistance Is a 
Prominent Feature of Insulin-Dependent Diabetes. Diabetes 31, 795-801. 
DeVos, P., Lefebvre, A.M., Miller, S.G., GuerreMillo, M., Wong, K., Saladin, R., 
Hamann, L.G., Staels, B., Briggs, M.R., and Auwerx, J. (1996). 
Thiazolidinediones repress ob gene expression in rodents via activation of 
peroxisome proliferator-activated receptor gamma. Journal of Clinical 
Investigation 98, 1004-1009. 
Devos, P., Saladin, R., Auwerx, J., and Staels, B. (1995). Induction of Ob Gene-
Expression by Corticosteroids Is Accompanied by Body-Weight Loss and 
Reduced Food-Intake. Journal of Biological Chemistry 270, 15958-15961. 
Distel, R.J., Ro, H.S., Rosen, B.S., Groves, D.L., and Spiegelman, B.M. (1987). 
Nucleoprotein complexes that regulate gene expression in adipocyte 
differentiation: direct participation of c-fos. Cell 49, 835-844. 
Dolfini, D., Gatta, R., and Mantovani, R. (2012a). NF-Y and the transcriptional 
activation of CCAAT promoters. Critical reviews in biochemistry and 
molecular biology 47, 29-49. 
Dolfini, D., Minuzzo, M., Pavesi, G., and Mantovani, R. (2012b). The short 
isoform of NF-YA belongs to the embryonic stem cell transcription factor 
circuitry. Stem Cells 30, 2450-2459. 
Donati, G., Gatta, R., Dolfini, D., Fossati, A., Ceribelli, M., and Mantovani, R. 
(2008). An NF-Y-Dependent Switch of Positive and Negative Histone Methyl 
Marks on CCAAT Promoters. PloS one 3. 
136 
Dulloo, A.G., and Jacquet, J. (1998). Adaptive reduction in basal metabolic rate 
in response to food deprivation in humans: a role for feedback signals from 
fat stores. The American journal of clinical nutrition 68, 599-606. 
Dulloo, A.G., Jacquet, J., and Girardier, L. (1996). Autoregulation of body 
composition during weight recovery in human: The Minnesota Experiment 
revisited. Int J Obesity 20, 393-405. 
Dunbar, J.C., Hu, Y.G., and Lu, H.Q. (1997). Intracerebroventricular leptin 
increases lumbar and renal sympathetic nerve activity and blood pressure in 
normal rats. Diabetes 46, 2040-2043. 
Dykes, J., Brunner, E.J., Martikainen, P.T., and Wardle, J. (2004). 
Socioeconomic gradient in body size and obesity among women: the role of 
dietary restraint, disinhibition and hunger in the Whitehall II study. Int J 
Obesity 28, 262-268. 
Ebihara, K., Kusakabe, T., Hirata, M., Masuzaki, H., Miyanaga, F., Kobayashi, N., 
Tanaka, T., Chusho, H., Miyazawa, T., Hayashi, T., et al. (2007). Efficacy and 
safety of leptin-replacement therapy and possible mechanisms of leptin 
actions in patients with generalized lipodystrophy. The Journal of clinical 
endocrinology and metabolism 92, 532-541. 
Eckardt, S., McLaughlin, K.J., and Willenbring, H. (2011). Mouse chimeras as a 
system to investigate development, cell and tissue function, disease 
mechanisms and organ regeneration. Cell Cycle 10, 2091-2099. 
Eguchi, J., Wang, X., Yu, S., Kershaw, E.E., Chiu, P.C., Dushay, J., Estall, J.L., Klein, 
U., Maratos-Flier, E., and Rosen, E.D. (2011). Transcriptional control of 
adipose lipid handling by IRF4. Cell metabolism 13, 249-259. 
El-Haschimi, K., Pierroz, D.D., Hileman, S.M., Bjorbaek, C., and Flier, J.S. (2000). 
Two defects contribute to hypothalamic leptin resistance in mice with diet-
induced obesity. The Journal of clinical investigation 105, 1827-1832. 
El-Jack, A.K., Hamm, J.K., Pilch, P.F., and Farmer, S.R. (1999). Reconstitution of 
insulin-sensitive glucose transport in fibroblasts requires expression of both 
PPARgamma and C/EBPalpha. The Journal of biological chemistry 274, 7946-
7951. 
Elmquist, J.K., Elias, C.F., and Saper, C.B. (1999). From lesions to leptin: 
Hypothalamic control of food intake and body weight. Neuron 22, 221-232. 
Ernst, M.B., Wunderlich, C.M., Hess, S., Paehler, M., Mesaros, A., Koralov, S.B., 
Kleinridders, A., Husch, A., Munzberg, H., Hampel, B., et al. (2009). Enhanced 
Stat3 activation in POMC neurons provokes negative feedback inhibition of 
leptin and insulin signaling in obesity. J Neurosci 29, 11582-11593. 
137 
Espejel, S., Roll, G.R., McLaughlin, K.J., Lee, A.Y., Zhang, J.Y., Laird, D.J., Okita, K., 
Yamanaka, S., and Willenbring, H. (2010). Induced pluripotent stem cell-
derived hepatocytes have the functional and proliferative capabilities needed 
for liver regeneration in mice. Journal of Clinical Investigation 120, 3120-
3126. 
Faith, M.S., Butryn, M., Wadden, T.A., Fabricatore, A., Nguyen, A.M., and 
Heymsfield, S.B. (2011). Evidence for prospective associations among 
depression and obesity in population-based studies. Obesity reviews : an 
official journal of the International Association for the Study of Obesity 12, 
e438-453. 
Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A.M., Saladin, R., 
Najib, J., Laville, M., Fruchart, J.C., Deeb, S., et al. (1997). The organization, 
promoter analysis, and expression of the human PPARgamma gene. The 
Journal of biological chemistry 272, 18779-18789. 
Farina, A., Manni, I., Fontemaggi, G., Tiainen, M., Cenciarelli, C., Bellorini, M., 
Mantovani, R., Sacchi, A., and Piaggio, G. (1999). Down-regulation of cyclin B1 
gene transcription in terminally differentiated skeletal muscle cells is 
associated with loss of functional CCAAT-binding NF-Y complex. Oncogene 18, 
2818-2827. 
Farooqi, S., and O'Rahilly, S. (2006). Genetics of obesity in humans. Endocrine 
reviews 27, 710-718. 
Faust, I.M., Johnson, P.R., and Hirsch, J. (1977a). Adipose tissue regeneration 
following lipectomy. Science 197, 391-393. 
Faust, I.M., Johnson, P.R., and Hirsch, J. (1977b). Surgical removal of adipose 
tissue alters feeding behavior and the development of obesity in rats. Science 
197, 393-396. 
Faust, I.M., Johnson, P.R., Stern, J.S., and Hirsch, J. (1978). Diet-induced 
adipocyte number increase in adult rats: a new model of obesity. Am J 
Physiol 235, E279-286. 
Fei, H., Okano, H.J., Li, C., Lee, G.H., Zhao, C., Darnell, R., and Friedman, J.M. 
(1997). Anatomic localization of alternatively spliced leptin receptors (Ob-R) 
in mouse brain and other tissues. Proceedings of the National Academy of 
Sciences of the United States of America 94, 7001-7005. 
Fields, D.A., Goran, M.I., and McCrory, M.A. (2002). Body-composition 
assessment via air-displacement plethysmography in adults and children: a 
review. The American journal of clinical nutrition 75, 453-467. 
138 
Finkelstein, E.A., Trogdon, J.G., Cohen, J.W., and Dietz, W. (2009). Annual 
medical spending attributable to obesity: payer-and service-specific 
estimates. Health Aff (Millwood) 28, w822-831. 
Finucane, M.M., Stevens, G.A., Cowan, M.J., Danaei, G., Lin, J.K., Paciorek, C.J., 
Singh, G.M., Gutierrez, H.R., Lu, Y., Bahalim, A.N., et al. (2011). National, 
regional, and global trends in body-mass index since 1980: systematic 
analysis of health examination surveys and epidemiological studies with 960 
country-years and 9.1 million participants. Lancet 377, 557-567. 
Fleming, J.D., Pavesi, G., Benatti, P., Imbriano, C., Mantovani, R., and Struhl, K. 
(2013). NF-Y coassociates with FOS at promoters, enhancers, repetitive 
elements, and inactive chromatin regions, and is stereo-positioned with 
growth-controlling transcription factors. Genome research 23, 1195-1209. 
Frederich, R.C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B.B., and Flier, 
J.S. (1995). Leptin levels reflect body lipid content in mice: evidence for diet-
induced resistance to leptin action. Nature medicine 1, 1311-1314. 
Friedman-Einat, M., Camoin, L., Faltin, Z., Rosenblum, C.I., Kaliouta, V., Eshdat, 
Y., and Strosberg, A.D. (2003). Serum leptin activity in obese and lean 
patients. Regulatory peptides 111, 77-82. 
Friedman, J.M. (1997). The alphabet of weight control. Nature 385, 119-120. 
Friedman, J.M., and Halaas, J.L. (1998). Leptin and the regulation of body 
weight in mammals. Nature 395, 763-770. 
Fukumura, D., Ushiyama, A., Duda, D.G., Xu, L., Tam, J., Krishna, V., Chatterjee, 
K., Garkavtsev, I., and Jain, R.K. (2003). Paracrine regulation of angiogenesis 
and adipocyte differentiation during in vivo adipogenesis. Circ Res 93, e88-97. 
Gao, Q., Wolfgang, M.J., Neschen, S., Morino, K., Horvath, T.L., Shulman, G.I., 
and Fu, X.Y. (2004). Disruption of neural signal transducer and activator of 
transcription 3 causes obesity, diabetes, infertility, and thermal 
dysregulation. Proceedings of the National Academy of Sciences of the United 
States of America 101, 4661-4666. 
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R., 
Nicol, C.J., Vinson, C., Gonzalez, F.J., and Reitman, M.L. (2003). Liver 
peroxisome proliferator-activated receptor gamma contributes to hepatic 
steatosis, triglyceride clearance, and regulation of body fat mass. Journal of 
Biological Chemistry 278, 34268-34276. 
Gavrilova, O., Marcus-Samuels, B., Graham, D., Kim, J.K., Shulman, G.I., Castle, 
A.L., Vinson, C., Eckhaus, M., and Reitman, M.L. (2000). Surgical implantation 
139 
of adipose tissue reverses diabetes in lipoatrophic mice. Journal of Clinical 
Investigation 105, 271-278. 
German, J., Kim, F., Schwartz, G.J., Havel, P.J., Rhodes, C.J., Schwartz, M.W., and 
Morton, G.J. (2009). Hypothalamic leptin signaling regulates hepatic insulin 
sensitivity via a neurocircuit involving the vagus nerve. Endocrinology 150, 
4502-4511. 
German, J.P., Wisse, B.E., Thaler, J.P., Oh-I, S., Sarruf, D.A., Ogimoto, K., Kaiyala, 
K.J., Fischer, J.D., Matsen, M.E., Taborsky, G.J., et al. (2010). Leptin Deficiency 
Causes Insulin Resistance Induced by Uncontrolled Diabetes. Diabetes 59, 
1626-1634. 
Goeman, F., Manni, I., Artuso, S., Ramachandran, B., Toietta, G., Bossi, G., 
Rando, G., Cencioni, C., Germoni, S., Straino, S., et al. (2012). Molecular 
imaging of nuclear factor-Y transcriptional activity maps proliferation sites in 
live animals. Mol Biol Cell 23, 1467-1474. 
Gong, D.W., Bi, S., Pratley, R.E., and Weintraub, B.D. (1996). Genomic 
structure and promoter analysis of the human obese gene. Journal of 
Biological Chemistry 271, 3971-3974. 
Gong, S., Zheng, C., Doughty, M.L., Losos, K., Didkovsky, N., Schambra, U.B., 
Nowak, N.J., Joyner, A., Leblanc, G., Hatten, M.E., et al. (2003). A gene 
expression atlas of the central nervous system based on bacterial artificial 
chromosomes. Nature 425, 917-925. 
Green, H., and Kehinde, O. (1979). Formation of Normally Differentiated 
Subcutaneous Fat Pads by an Established Preadipose Cell-Line. Journal of 
cellular physiology 101, 169-171. 
Greenwood, M.R., Cleary, M.P., and Hirsch, J. (1979). Genetic obesity in man 
and rodents. Current concepts in nutrition 8, 143-170. 
Greenwood, M.R., and Hirsch, J. (1974). Postnatal development of adipocyte 
cellularity in the normal rat. J Lipid Res 15, 474-483. 
Gregor, M.F., and Hotamisligil, G.S. (2007). Thematic review series: Adipocyte 
Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J 
Lipid Res 48, 1905-1914. 
Grunfeld, C., Zhao, C., Fuller, J., Pollack, A., Moser, A., Friedman, J., and 
Feingold, K.R. (1996). Endotoxin and cytokines induce expression of leptin, 
the ob gene product, in hamsters. The Journal of clinical investigation 97, 
2152-2157. 
140 
Guh, D.P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C.L., and Anis, A.H. 
(2009). The incidence of co-morbidities related to obesity and overweight: a 
systematic review and meta-analysis. BMC public health 9, 88. 
Gunay-Aygun, M., Cassidy, S.B., and Nicholls, R.D. (1997). Prader-Willi and 
other syndromes associated with obesity and mental retardation. Behavior 
genetics 27, 307-324. 
Guo, K.Y., Halo, P., Leibel, R.L., and Zhang, Y. (2004). Effects of obesity on the 
relationship of leptin mRNA expression and adipocyte size in anatomically 
distinct fat depots in mice. American journal of physiology Regulatory, 
integrative and comparative physiology 287, R112-119. 
Gupta, R.K., Arany, Z., Seale, P., Mepani, R.J., Ye, L., Conroe, H.M., Roby, Y.A., 
Kulaga, H., Reed, R.R., and Spiegelman, B.M. (2010). Transcriptional control of 
preadipocyte determination by Zfp423. Nature 464, 619-U187. 
Gupta, R.K., Mepani, R.J., Kleiner, S., Lo, J.C., Khandekar, M.J., Cohen, P., 
Frontini, A., Bhowmick, D.C., Ye, L., Cinti, S., et al. (2012). Zfp423 Expression 
Identifies Committed Preadipocytes and Localizes to Adipose Endothelial and 
Perivascular Cells. Cell metabolism 15, 230-239. 
Gurtner, A., Fuschi, P., Magi, F., Colussi, C., Gaetano, C., Dobbelstein, M., Sacchi, 
A., and Piaggio, G. (2008). NF-Y dependent epigenetic modifications 
discriminate between proliferating and postmitotic tissue. PloS one 3, e2047. 
Gurtner, A., Manni, I., Fuschi, P., Mantovani, R., Guadagni, F., Sacchi, A., and 
Piaggio, G. (2003). Requirement for down-regulation of the CCAAT-binding 
activity of the NF-Y transcription factor during skeletal muscle differentiation. 
Mol Biol Cell 14, 2706-2715. 
Halaas, J.L., Boozer, C., Blair-West, J., Fidahusein, N., Denton, D.A., and 
Friedman, J.M. (1997). Physiological response to long-term peripheral and 
central leptin infusion in lean and obese mice. Proceedings of the National 
Academy of Sciences of the United States of America 94, 8878-8883. 
Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., 
Lallone, R.L., Burley, S.K., and Friedman, J.M. (1995). Weight-reducing effects 
of the plasma protein encoded by the obese gene. Science 269, 543-546. 
Haluzik, M., Colombo, C., Gavrilova, O., Chua, S., Wolf, N., Chen, M., Stannard, B., 
Le Roith, D., and Reitman, M. (2003). Genetic background (C57BL/6J versus 
FVB/N) strongly influences the severity of diabetes and insulin resistance in 
ob/ob mice. Diabetes 52, A328-A328. 
141 
Han, J., Lee, J.E., Jin, J., Lim, J.S., Oh, N., Kim, K., Chang, S.I., Shibuya, M., Kim, H., 
and Koh, G.Y. (2011). The spatiotemporal development of adipose tissue. 
Development 138, 5027-5037. 
Hannon, B.M., and Lohman, T.G. (1978). The energy cost of overweight in the 
United States. American journal of public health 68, 765-767. 
Haque, W.A., Shimomura, I., Matsuzawa, Y., and Garg, A. (2002). Serum 
adiponectin and leptin levels in patients with lipodystrophies. The Journal of 
clinical endocrinology and metabolism 87, 2395. 
Harris, R.B.S., Hervey, E., Hervey, G.R., and Tobin, G. (1987). Body-
Composition of Lean and Obese Zucker Rats in Parabiosis. Int J Obesity 11, 
275-283. 
Haynes, W.G., Morgan, D.A., Walsh, S.A., Mark, A.L., and Sivitz, W.I. (1997). 
Receptor-mediated regional sympathetic nerve activation by leptin. Journal 
of Clinical Investigation 100, 270-278. 
He, Y., Chen, H., Quon, M.J., and Reitman, M. (1995). The mouse obese gene. 
Genomic organization, promoter activity, and activation by 
CCAAT/enhancer-binding protein alpha. The Journal of biological chemistry 
270, 28887-28891. 
Hebebrand, J., Himmelmann, G.W., Herzog, W., HerpertzDahlmann, B.M., 
Steinhausen, H.C., Amstein, M., Seidel, R., Deter, H.C., Remschmidt, H., and 
Schafer, H. (1997). Prediction of low body weight at long-term follow-up in 
acute anorexia nervosa by low body weight at referral. Am J Psychiat 154, 
566-569. 
Hemmeryckx, B., Loeckx, D., Dresselaers, T., Himmelreich, U., Hoylaerts, M.F., 
and Lijnen, H.R. (2010). Age-associated adaptations in murine adipose 
tissues. Endocr J 57, 925-930. 
Hernandez, T.L., Kittelson, J.M., Law, C.K., Ketch, L.L., Stob, N.R., Lindstrom, 
R.C., Scherzinger, A., Stamm, E.R., and Eckel, R.H. (2011). Fat redistribution 
following suction lipectomy: defense of body fat and patterns of restoration. 
Obesity (Silver Spring) 19, 1388-1395. 
Hervey, G.R. (1959). The Effects of Lesions in the Hypothalamus in Parabiotic 
Rats. J Physiol-London 145, 336-&. 
Heymsfield, S.B., Greenberg, A.S., Fujioka, K., Dixon, R.M., Kushner, R., Hunt, T., 
Lubina, J.A., Patane, J., Self, B., Hunt, P., et al. (1999). Recombinant leptin for 
weight loss in obese and lean adults: a randomized, controlled, dose-
escalation trial. Jama 282, 1568-1575. 
142 
Hill, J.W., Williams, K.W., Ye, C.P., Luo, J., Balthasar, N., Coppari, R., Cowley, 
M.A., Cantley, L.C., Lowell, B.B., and Elmquist, J.K. (2008). Acute effects of 
leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons 
in mice. Journal of Clinical Investigation 118, 1796-1805. 
Himmshagen, J. (1979). Obesity May Be Due to a Malfunctioning of Brown Fat. 
Can Med Assoc J 121, 1361-1364. 
Hinney, A., Schmidt, A., Nottebom, K., Heibult, O., Becker, I., Ziegler, A., Gerber, 
G., Sina, M., Gorg, T., Mayer, H., et al. (1999). Several mutations in the 
melanocortin-4 receptor gene including a nonsense and a frameshift 
mutation associated with dominantly inherited obesity in humans. The 
Journal of clinical endocrinology and metabolism 84, 1483-1486. 
Hirsch, J., and Batchelor, B. (1976). Adipose-Tissue Cellularity in Human 
Obesity. Clin Endocrinol Meta 5, 299-311. 
Hirsch, J., and Han, P.W. (1969). Cellularity of rat adipose tissue: effects of 
growth, starvation, and obesity. J Lipid Res 10, 77-82. 
Hollenberg, A.N., Susulic, V.S., Madura, J.P., Zhang, B., Moller, D.E., Tontonoz, 
P., Sarraf, P., Spiegelman, B.M., and Lowell, B.B. (1997). Functional 
antagonism between CCAAT/enhancer binding protein-alpha and 
peroxisome proliferator-activated receptor-gamma on the leptin promoter. 
Journal of Biological Chemistry 272, 5283-5290. 
Horm, J., and Anderson, K. (1993). Who in America Is Trying to Lose Weight. 
Ann Intern Med 119, 672-676. 
Huang-Doran, I., Sleigh, A., Rochford, J.J., O'Rahilly, S., and Savage, D.B. (2010). 
Lipodystrophy: metabolic insights from a rare disorder. The Journal of 
endocrinology 207, 245-255. 
Hudak, C.S., Gulyaeva, O., Wang, Y.H., Park, S.M., Lee, L., Kang, C., and Sul, H.S. 
(2014). Pref-1 Marks Very Early Mesenchymal Precursors Required for 
Adipose Tissue Development and Expansion. Cell Rep 8, 678-687. 
Huo, L., Gamber, K., Greeley, S., Silva, J., Huntoon, N., Leng, X.H., and Bjorbaek, 
C. (2009). Leptin-Dependent Control of Glucose Balance and Locomotor 
Activity by POMC Neurons. Cell metabolism 9, 537-547. 
Hwa, J.J., Fawzi, A.B., Graziano, M.P., Ghibaudi, L., Williams, P., Van Heek, M., 
Davis, H., Rudinski, M., Sybertz, E., and Strader, C.D. (1997). Leptin increases 
energy expenditure and selectively promotes fat metabolism in ob/ob mice. 
Am J Physiol 272, R1204-1209. 
143 
Hwang, C.S., Loftus, T.M., Mandrup, S., and Lane, M.D. (1997). Adipocyte 
differentiation and leptin expression. Annual review of cell and 
developmental biology 13, 231-259. 
Hwang, C.S., Mandrup, S., MacDougald, O.A., Geiman, D.E., and Lane, M.D. 
(1996). Transcriptional activation of the mouse obese (ob) gene by 
CCAAT/enhancer binding protein alpha. Proceedings of the National 
Academy of Sciences of the United States of America 93, 873-877. 
Igel, M., Becker, W., Herberg, L., and Joost, H.G. (1997). Hyperleptinemia, 
leptin resistance, and polymorphic leptin receptor in the New Zealand obese 
mouse. Endocrinology 138, 4234-4239. 
Jackson, R.S., Creemers, J.W.M., Ohagi, S., RaffinSanson, M.L., Sanders, L., 
Montague, C.T., Hutton, J.C., and ORahilly, S. (1997). Obesity and impaired 
prohormone processing associated with mutations in the human 
prohormone convertase 1 gene. Nature genetics 16, 303-306. 
Janke, J., Engeli, S., Gorzelniak, K., Luft, F.C., and Sharma, A.M. (2002). Mature 
adipocytes inhibit in vitro differentiation of human preadipocytes via 
angiotensin type 1 receptors. Diabetes 51, 1699-1707. 
Javor, E.D., Cochran, E.K., Musso, C., Young, J.R., Depaoli, A.M., and Gorden, P. 
(2005). Long-term efficacy of leptin replacement in patients with generalized 
lipodystrophy. Diabetes 54, 1994-2002. 
Jeffery, E., Berry, R., Church, C.D., Yu, S., Shook, B.A., Horsley, V., Rosen, E.D., 
and Rodeheffer, M.S. (2014). Characterization of Cre recombinase models for 
the study of adipose tissue. Adipocyte 3, 206-211. 
Jequier, E. (2002). Leptin signaling, adiposity, and energy balance. Lipids and 
Insulin Resistance: The Role of Fatty Acid Metabolism and Fuel Partitioning 
967, 379-388. 
Jia, H., and Lubetkin, E.I. (2005). The impact of obesity on health-related 
quality-of-life in the general adult US population. J Public Health (Oxf) 27, 
156-164. 
Jo, J., Gavrilova, O., Pack, S., Jou, W., Mullen, S., Sumner, A.E., Cushman, S.W., 
and Periwal, V. (2009). Hypertrophy and/or Hyperplasia: Dynamics of 
Adipose Tissue Growth. PLoS computational biology 5, e1000324. 
Joe, A.W., Yi, L., Even, Y., Vogl, A.W., and Rossi, F.M. (2009). Depot-specific 
differences in adipogenic progenitor abundance and proliferative response to 
high-fat diet. Stem Cells 27, 2563-2570. 
144 
Jones, J.R., Barrick, C., Kim, K.A., Lindner, J., Blondeau, B., Fujimoto, Y., Shiota, 
M., Kesterson, R.A., Kahn, B.B., and Magnuson, M.A. (2005). Deletion of 
PPARgamma in adipose tissues of mice protects against high fat diet-induced 
obesity and insulin resistance. Proceedings of the National Academy of 
Sciences of the United States of America 102, 6207-6212. 
Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994). Insulin-Promoter-
Factor-1 Is Required for Pancreas Development in Mice. Nature 371, 606-609. 
Kamohara, S., Burcelin, R., Halaas, J.L., Friedman, J.M., and Charron, M.J. 
(1997). Acute stimulation of glucose metabolism in mice by leptin treatment. 
Nature 389, 374-377. 
Kassirer, J.P., and Angell, M. (1998). Losing weight - An ill-fated new year's 
resolution. New Engl J Med 338, 52-54. 
Katz, L.S., Geras-Raaka, E., and Gershengorn, M.C. (2014). Heritability of fat 
accumulation in white adipocytes. American journal of physiology 
Endocrinology and metabolism 307, E335-344. 
Keesey, R.E., and Hirvonen, M.D. (1997). Body weight set-points: 
determination and adjustment. The Journal of nutrition 127, 1875S-1883S. 
Keim, N.L., Stern, J.S., and Havel, P.J. (1998). Relation between circulating 
leptin concentrations and appetite during a prolonged, moderate energy 
deficit in women. American Journal of Clinical Nutrition 68, 794-801. 
Kennedy, G.C. (1953). The role of depot fat in the hypothalamic control of 
food intake in the rat. Proceedings of the Royal Society of London Series B, 
Biological sciences 140, 578-596. 
Keum, N., Greenwood, D.C., Lee, D.H., Kim, R., Aune, D., Ju, W., Hu, F.B., and 
Giovannucci, E.L. (2015). Adult weight gain and adiposity-related cancers: a 
dose-response meta-analysis of prospective observational studies. Journal of 
the National Cancer Institute 107. 
Khan, T., Muise, E.S., Iyengar, P., Wang, Z.V., Chandalia, M., Abate, N., Zhang, 
B.B., Bonaldo, P., Chua, S., and Scherer, P.E. (2009). Metabolic dysregulation 
and adipose tissue fibrosis: role of collagen VI. Molecular and cellular biology 
29, 1575-1591. 
Khatibzadeh, N., Gupta, S., Farrell, B., Brownell, W.E., and Anvari, B. (2012). 
Effects of cholesterol on nano-mechanical properties of the living cell plasma 
membrane. Soft Matter 8, 8350-8360. 
Kieffer, T.J., and Habener, J.F. (2000). The adipoinsular axis: effects of leptin 
on pancreatic beta-cells. Am J Physiol-Endoc M 278, E1-E14. 
145 
Kim, J.Y., De Wall, E.V., Laplante, M., Azzara, A., Trujillo, M.E., Hofmann, S.M., 
Schraw, T., Durand, J.L., Li, H., Li, G., et al. (2007). Obesity-associated 
improvements in metabolic profile through expansion of adipose tissue. 
Journal of Clinical Investigation 117, 2621-2637. 
King, D. (2011). The future challenge of obesity. Lancet 378, 743-744. 
Kirk, S.F.L., Penney, T.L., and McHugh, T.L.F. (2010). Characterizing the 
obesogenic environment: the state of the evidence with directions for future 
research. Obesity Reviews 11, 109-117. 
Klaassen, M., and Biebach, H. (1994). Energetics of Fattening and Starvation 
in the Long-Distance Migratory Garden Warbler, Sylvia Borin, during the 
Migratory Phase. J Comp Physiol B 164, 362-371. 
Klimentidis, Y.C., Beasley, T.M., Lin, H.Y., Murati, G., Glass, G.E., Guyton, M., 
Newton, W., Jorgensen, M., Heymsfield, S.B., Kemnitz, J., et al. (2011). Canaries 
in the coal mine: a cross-species analysis of the plurality of obesity epidemics. 
P Roy Soc B-Biol Sci 278, 1626-1632. 
Knebel, B., Kotzka, J., Lehr, S., Hartwig, S., Avci, H., Jacob, S., Nitzgen, U., 
Schiller, M., Marz, W., Hoffmann, M.M., et al. (2013). A mutation in the c-Fos 
gene associated with congenital generalized lipodystrophy. Orphanet J Rare 
Dis 8. 
Knight, Z.A., Hannan, K.S., Greenberg, M.L., and Friedman, J.M. (2010). 
Hyperleptinemia Is Required for the Development of Leptin Resistance. PloS 
one 5. 
Knittle, J.L., and Hirsch, J. (1968). Effect of early nutrition on the development 
of rat epididymal fat pads: cellularity and metabolism. The Journal of clinical 
investigation 47, 2091-2098. 
Koh, Y.J., Kang, S., Lee, H.J., Choi, T.S., Lee, H.S., Cho, C.H., and Koh, G.Y. (2007). 
Bone marrow-derived circulating progenitor cells fail to transdifferentiate 
into adipocytes in adult adipose tissues in mice. The Journal of clinical 
investigation 117, 3684-3695. 
Kopelman, P.G. (2000). Obesity as a medical problem. Nature 404, 635-643. 
Krude, H., Biebermann, H., Luck, W., Horn, R., Brabant, G., and Gruters, A. 
(1998). Severe early-onset obesity, adrenal insufficiency and red hair 
pigmentation caused by POMC mutations in humans. Nature genetics 19, 
155-157. 
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., 
Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999). PPAR gamma 
146 
mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. 
Molecular cell 4, 597-609. 
Kuczmarski, R.J., Flegal, K.M., Campbell, S.M., and Johnson, C.L. (1994). 
Increasing Prevalence of Overweight among Us Adults - the National-Health 
and Nutrition Examination Surveys, 1960 to 1991. Jama-J Am Med Assoc 272, 
205-211. 
Kulkarni, R.N., Wang, Z.L., Wang, R.M., Hurley, J.D., Smith, D.M., Ghatei, M.A., 
Withers, D.J., Gardiner, J.V., Bailey, C.J., and Bloom, S.R. (1997). Leptin rapidly 
suppresses insulin release from insulinoma cells, rat and human islets and, in 
vivo, in mice. Journal of Clinical Investigation 100, 2729-2736. 
Kunz, T.H., Wrazen, J.A., and Burnett, C.D. (1998). Changes in body mass and 
fat reserves in pre-hibernating little brown bats (Myotis lucifugus). 
Ecoscience 5, 8-17. 
Kusakabe, M., Yokoyama, M., Sakakura, T., Nomura, T., Hosick, H.L., and 
Nishizuka, Y. (1988). A Novel Methodology for Analysis of Cell Distribution in 
Chimeric Mouse Organs Using a-Strain Specific Antibody. Journal of Cell 
Biology 107, 257-265. 
Laustsen, P.G., Michael, M.D., Crute, B.E., Cohen, S.E., Ueki, K., Kulkarni, R.N., 
Keller, S.R., Lienhard, G.E., and Kahn, C.R. (2002). Lipoatrophic diabetes in 
Irs1(-/-)/Irs3(-/-) double knockout mice. Genes & development 16, 3213-
3222. 
Le Lay, S., Krief, S., Farnier, C., Lefrere, I., Le Liepvre, X., Bazin, R., Ferre, P., 
and Dugail, I. (2001). Cholesterol, a cell size-dependent signal that regulates 
glucose metabolism and gene expression in adipocytes. Journal of Biological 
Chemistry 276, 16904-16910. 
Lee, G.H., Proenca, R., Montez, J.M., Carroll, K.M., Darvishzadeh, J.G., Lee, J.I., 
and Friedman, J.M. (1996). Abnormal splicing of the leptin receptor in 
diabetic mice. Nature 379, 632-635. 
Lee, K.Y., Russell, S.J., Ussar, S., Boucher, J., Vernochet, C., Mori, M.A., Smyth, G., 
Rourk, M., Cederquist, C., Rosen, E.D., et al. (2013). Lessons on Conditional 
Gene Targeting in Mouse Adipose Tissue. Diabetes 62, 864-874. 
Lee, S.L., Wang, W.W., Lanzillo, J.J., and Fanburg, B.L. (1994). Serotonin 
produces both hyperplasia and hypertrophy of bovine pulmonary artery 
smooth muscle cells in culture. Am J Physiol 266, L46-52. 
Lee, Y.H., Petkova, A.P., Mottillo, E.P., and Granneman, J.G. (2012). In vivo 
identification of bipotential adipocyte progenitors recruited by beta3-
adrenoceptor activation and high-fat feeding. Cell metabolism 15, 480-491. 
147 
Lefterova, M.I., Zhang, Y., Steger, D.J., Schupp, M., Schug, J., Cristancho, A., Feng, 
D., Zhuo, D., Stoeckert, C.J., Jr., Liu, X.S., et al. (2008). PPARgamma and C/EBP 
factors orchestrate adipocyte biology via adjacent binding on a genome-wide 
scale. Genes & development 22, 2941-2952. 
Lemonnier, D. (1972). Effect of age, sex, and sites on the cellularity of the 
adipose tissue in mice and rats rendered obese by a high-fat diet. The Journal 
of clinical investigation 51, 2907-2915. 
Leonhardt, W., Hanefeld, M., Schneider, H., and Haller, H. (1972). Human 
adipocyte volumes: maximum size, and correlation to weight index in 
maturity onset-diabetes. Diabetologia 8, 287-291. 
Levin, N., Nelson, C., Gurney, A., Vandlen, R., and de Sauvage, F. (1996). 
Decreased food intake does not completely account for adiposity reduction 
after ob protein infusion. Proceedings of the National Academy of Sciences of 
the United States of America 93, 1726-1730. 
Li, Z., Ceccarini, G., Eisenstein, M., Tan, K., and Friedman, J.M. (2013). 
Phenotypic effects of an induced mutation of the ObRa isoform of the leptin 
receptor. Molecular metabolism 2, 364-375. 
Liegeois, N.J., Horner, J.W., and DePinho, R.A. (1996). Lens complementation 
system for the genetic analysis of growth, differentiation, and apoptosis in 
vivo. Proceedings of the National Academy of Sciences of the United States of 
America 93, 1303-1307. 
Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., 
Vedantam, S., Buchkovich, M.L., Yang, J., et al. (2015). Genetic studies of body 
mass index yield new insights for obesity biology. Nature 518, 197-206. 
Lonn, M., Mehlig, K., Bengtsson, C., and Lissner, L. (2010). Adipocyte size 
predicts incidence of type 2 diabetes in women. Faseb J 24, 326-331. 
Lonnqvist, F., Nordfors, L., Jansson, M., Thorne, A., Schalling, M., and Arner, P. 
(1997). Leptin secretion from adipose tissue in women - Relationship to 
plasma levels and gene expression. Journal of Clinical Investigation 99, 2398-
2404. 
Lord, G.M., Matarese, G., Howard, J.K., Baker, R.J., Bloom, S.R., and Lechler, R.I. 
(1998). Leptin modulates the T-cell immune response and reverses 
starvation-induced immunosuppression. Nature 394, 897-901. 
Low, H.P., Greco, B., Tanahashi, Y., Gallant, J., Jones, S.N., Billings-Gagliardi, S., 
Recht, L.D., and Schwartz, W.J. (2009). Embryonic stem cell rescue of tremor 
and ataxia in myelin-deficient shiverer mice. J Neurol Sci 276, 133-137. 
148 
Luckman, S.M., Rosenzweig, I., and Dickson, S.L. (1999). Activation of arcuate 
nucleus neurons by systemic administration of leptin and growth hormone-
releasing peptide-6 in normal and fasted rats. Neuroendocrinology 70, 93-
100. 
Luke, A., and Schoeller, D.A. (1992). Basal metabolic rate, fat-free mass, and 
body cell mass during energy restriction. Metabolism: clinical and 
experimental 41, 450-456. 
Luo, R., Lu, J.F., Hu, Q., and Maity, S.N. (2008). CBF/NF-Y controls 
endoplasmic reticulum stress induced transcription through recruitment of 
both ATF6(N) and TBP. Journal of cellular biochemistry 104, 1708-1723. 
Ly, L.L., Yoshida, H., and Yamaguchi, M. (2013). Nuclear transcription factor Y 
and its roles in cellular processes related to human disease. American journal 
of cancer research 3, 339-346. 
Macdougald, O.A., Hwang, C.S., Fan, H.Y., and Lane, M.D. (1995). Regulated 
Expression of the Obese Gene-Product (Leptin) in White Adipose-Tissue and 
3t3-L1 Adipocytes. Proceedings of the National Academy of Sciences of the 
United States of America 92, 9034-9037. 
Maes, H.H., Neale, M.C., and Eaves, L.J. (1997). Genetic and environmental 
factors in relative body weight and human adiposity. Behavior genetics 27, 
325-351. 
Maffei, M., Fei, H., Lee, G.H., Dani, C., Leroy, P., Zhang, Y., Proenca, R., Negrel, R., 
Ailhaud, G., and Friedman, J.M. (1995a). Increased expression in adipocytes 
of ob RNA in mice with lesions of the hypothalamus and with mutations at 
the db locus. Proceedings of the National Academy of Sciences of the United 
States of America 92, 6957-6960. 
Maffei, M., Halaas, J., Ravussin, E., Pratley, R.E., Lee, G.H., Zhang, Y., Fei, H., Kim, 
S., Lallone, R., Ranganathan, S., et al. (1995b). Leptin levels in human and 
rodent: measurement of plasma leptin and ob RNA in obese and weight-
reduced subjects. Nature medicine 1, 1155-1161. 
Mandrup, S., Loftus, T.M., MacDougald, O.A., Kuhajda, F.P., and Lane, M.D. 
(1997). Obese gene expression at in vivo levels by fat pads derived from sc 
implanted 3T3-F442A preadipocytes. Proceedings of the National Academy 
of Sciences of the United States of America 94, 4300-4305. 
Mantovani, R. (1999). The molecular biology of the CCAAT-binding factor NF-
Y. Gene 239, 15-27. 
Mantzoros, C.S., Qu, D., Frederich, R.C., Susulic, V.S., Lowell, B.B., Maratos-Flier, 
E., and Flier, J.S. (1996). Activation of beta(3) adrenergic receptors 
149 
suppresses leptin expression and mediates a leptin-independent inhibition of 
food intake in mice. Diabetes 45, 909-914. 
Marikovsky, M., Rosenblum, C.I., Faltin, Z., and Friedman-Einat, M. (2002). 
Appearance of leptin in wound fluid as a response to injury. Wound repair 
and regeneration : official publication of the Wound Healing Society [and] the 
European Tissue Repair Society 10, 302-307. 
Marques, B.G., Hausman, D.B., and Martin, R.J. (1998). Association of fat cell 
size and paracrine growth factors in development of hyperplastic obesity. Am 
J Physiol 275, R1898-1908. 
Martin, S.L. (2008). Mammalian hibernation: a naturally reversible model for 
insulin resistance in man? Diabetes Vasc Dis Re 5, 76-81. 
Mason, M.M., He, Y., Chen, H., Quon, M.J., and Reitman, M. (1998). Regulation 
of leptin promoter function by Sp1, C/EBP, and a novel factor. Endocrinology 
139, 1013-1022. 
Mercer, J.G., Hoggard, N., Williams, L.M., Lawrence, C.B., Hannah, L.T., and 
Trayhurn, P. (1996). Localization of leptin receptor mRNA and the long form 
splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by 
in situ hybridization. FEBS letters 387, 113-116. 
Miller, S.G., De Vos, P., Guerre-Millo, M., Wong, K., Hermann, T., Staels, B., 
Briggs, M.R., and Auwerx, J. (1996). The adipocyte specific transcription 
factor C/EBPalpha modulates human ob gene expression. Proceedings of the 
National Academy of Sciences of the United States of America 93, 5507-5511. 
Moitra, J., Mason, M.M., Olive, M., Krylov, D., Gavrilova, O., Marcus-Samuels, B., 
Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., et al. (1998). Life without 
white fat: a transgenic mouse. Genes & development 12, 3168-3181. 
Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J., 
Sewter, C.P., Digby, J.E., Mohammed, S.N., Hurst, J.A., et al. (1997a). Congenital 
leptin deficiency is associated with severe early-onset obesity in humans. 
Nature 387, 903-908. 
Montague, C.T., Prins, J.B., Sanders, L., Digby, J.E., and O'Rahilly, S. (1997b). 
Depot- and sex-specific differences in human leptin mRNA expression: 
implications for the control of regional fat distribution. Diabetes 46, 342-347. 
Montague, C.T., Prins, J.B., Sanders, L., Zhang, J., Sewter, C.P., Digby, J., Byrne, 
C.D., and O'Rahilly, S. (1998). Depot-related gene expression in human 
subcutaneous and omental adipocytes. Diabetes 47, 1384-1391. 
150 
Montez, J.M., Soukas, A., Asilmaz, E., Fayzikhodjaeva, G., Fantuzzi, G., and 
Friedman, J.M. (2005). Acute leptin deficiency, leptin resistance, and the 
physiologic response to leptin withdrawal. Proceedings of the National 
Academy of Sciences of the United States of America 102, 2537-2542. 
Moore, F., and Kerlinger, P. (1987). Stopover and Fat Deposition by North-
American Wood-Warblers (Parulinae) Following Spring Migration over the 
Gulf of Mexico. Oecologia 74, 47-54. 
Moreno-Aliaga, M.J., Stanhope, K.L., Kras, K.M., Martinez, J.A., and Havel, P.J. 
(2000). Regulation of leptin secretion, ob gene expression, and the 
transcriptional activity of the leptin promoter by insulin-stimulated glucose 
metabolism in cultured rat adipocytes and 3T3-L1 cells. Obes Res 8, 63s-63s. 
Motyl, K.J., and Rosen, C.J. (2012). Understanding leptin-dependent 
regulation of skeletal homeostasis. Biochimie 94, 2089-2096. 
Nabokina, S.M., Valle, J.E., and Said, H.M. (2013). Characterization of the 
human mitochondrial thiamine pyrophosphate transporter SLC25A19 
minimal promoter: a role for NF-Y in regulating basal transcription. Gene 528, 
248-255. 
Naggert, J.K., Fricker, L.D., Varlamov, O., Nishina, P.M., Rouille, Y., Steiner, D.F., 
Carroll, R.J., Paigen, B.J., and Leiter, E.H. (1995). Hyperproinsulinaemia in 
obese fat/fat mice associated with a carboxypeptidase E mutation which 
reduces enzyme activity. Nature genetics 10, 135-142. 
Nagy, A. (2003). Manipulating the mouse embryo : a laboratory manual, 3rd 
edn (Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press). 
Nardini, M., Gnesutta, N., Donati, G., Gatta, R., Forni, C., Fossati, A., Vonrhein, C., 
Moras, D., Romier, C., Bolognesi, M., et al. (2013). Sequence-specific 
transcription factor NF-Y displays histone-like DNA binding and H2B-like 
ubiquitination. Cell 152, 132-143. 
Neel, J.V. (1962). Diabetes Mellitus - a Thrifty Genotype Rendered 
Detrimental by Progress. Am J Hum Genet 14, 353-&. 
Niswender, K.D., Morton, G.J., Stearns, W.H., Rhodes, C.J., Myers, M.G., and 
Schwartz, M.W. (2001). Intracellular signalling - Key enzyme in leptin-
induced anorexia. Nature 413, 794-795. 
Nohturfft, A., Yabe, D., Goldstein, J.L., Brown, M.S., and Espenshade, P.J. (2000). 
Regulated step in cholesterol feedback localized to budding of SCAP from ER 
membranes. Cell 102, 315-323. 
151 
O'Keefe, J.H., and Abuannadi, M. (2010). Dietary strategies for the prevention 
& treatment of metabolic syndrome. Missouri medicine 107, 406-409. 
Ogden, C.L., Carroll, M.D., Kit, B.K., and Flegal, K.M. (2014). Prevalence of 
childhood and adult obesity in the United States, 2011-2012. Jama 311, 806-
814. 
Oldfield, A.J., Yang, P., Conway, A.E., Cinghu, S., Freudenberg, J.M., Yellaboina, 
S., and Jothi, R. (2014). Histone-fold domain protein NF-Y promotes 
chromatin accessibility for cell type-specific master transcription factors. 
Molecular cell 55, 708-722. 
Oliver, L.N., and Hayes, M.V. (2005). Neighbourhood socio-economic status 
and the prevalence of overweight Canadian children and youth. Canadian 
journal of public health = Revue canadienne de sante publique 96, 415-420. 
Ong, C.T., and Corces, V.G. (2011). Enhancer function: new insights into the 
regulation of tissue-specific gene expression. Nature Reviews Genetics 12, 
283-293. 
Oza-Frank, R., and Cunningham, S.A. (2010). The weight of US residence 
among immigrants: a systematic review. Obesity Reviews 11, 271-280. 
Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.H., Iwakoshi, N.N., Ozdelen, E., Tuncman, 
G., Gorgun, C., Glimcher, L.H., and Hotamisligil, G.S. (2004). Endoplasmic 
reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 
457-461. 
Pajvani, U.B., Trujillo, M.E., Combs, T.P., Iyengar, P., Jelicks, L., Roth, K.A., Kitsis, 
R.N., and Scherer, P.E. (2005). Fat apoptosis through targeted activation of 
caspase 8: a new mouse model of inducible and reversible lipoatrophy. 
Nature medicine 11, 797-803. 
Park, S.K., Oh, S.Y., Lee, M.Y., Yoon, S., Kim, K.S., and Kim, J.W. (2004). 
CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin 
gene expression in adipose tissue. Diabetes 53, 2757-2766. 
Pasarica, M., Sereda, O.R., Redman, L.M., Albarado, D.C., Hymel, D.T., Roan, L.E., 
Rood, J.C., Burk, D.H., and Smith, S.R. (2009). Reduced Adipose Tissue 
Oxygenation in Human Obesity Evidence for Rarefaction, Macrophage 
Chemotaxis, and Inflammation Without an Angiogenic Response. Diabetes 58, 
718-725. 
Patel, A.V., Hildebrand, J.S., and Gapstur, S.M. (2014). Body mass index and 
all-cause mortality in a large prospective cohort of white and black U.S. 
Adults. PloS one 9, e109153. 
152 
Payne, P.R., and Dugdale, A.E. (1977). A model for the prediction of energy 
balance and body weight. Annals of human biology 4, 525-535. 
Paz-Filho, G., Wong, M.L., and Licinio, J. (2011). Ten years of leptin 
replacement therapy. Obesity reviews : an official journal of the International 
Association for the Study of Obesity 12, e315-323. 
Pearce, J., Blakely, T., Witten, K., and Bartie, P. (2007). Neighborhood 
deprivation and access to fast-food retailing: a national study. American 
journal of preventive medicine 32, 375-382. 
Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, T., 
and Collins, F. (1995). Effects of the obese gene product on body weight 
regulation in ob/ob mice. Science 269, 540-543. 
Peng, Y.W., and Jahroudi, N. (2002). The NFY transcription factor functions as 
a repressor and activator of the von Willebrand factor promoter. Blood 99, 
2408-2417. 
Peterfy, M., Phan, J., Xu, P., and Reue, K. (2001). Lipodystrophy in the fld 
mouse results from mutation of a new gene encoding a nuclear protein, lipin. 
Nature genetics 27, 121-124. 
Poissonnet, C.M., Burdi, A.R., and Bookstein, F.L. (1983). Growth and 
development of human adipose tissue during early gestation. Early human 
development 8, 1-11. 
Poissonnet, C.M., Burdi, A.R., and Garn, S.M. (1984). The chronology of 
adipose tissue appearance and distribution in the human fetus. Early human 
development 10, 1-11. 
Polak, P., Cybulski, N., Feige, J.N., Auwerx, J., Ruegg, M.A., and Hall, M.N. 
(2008). Adipose-specific knockout of raptor results in lean mice with 
enhanced mitochondrial respiration. Cell metabolism 8, 399-410. 
Poskitt, E.M.E. (2009). Countries in transition: underweight to obesity non-
stop? Ann Trop Paediatr 29, 1-11. 
Prada, P.O., Quaresma, P.G., Caricilli, A.M., Santos, A.C., Guadagnini, D., Morari, 
J., Weissmann, L., Ropelle, E.R., Carvalheira, J.B., Velloso, L.A., et al. (2013). 
Tub has a key role in insulin and leptin signaling and action in vivo in 
hypothalamic nuclei. Diabetes 62, 137-148. 
Price, R.A., and Gottesman, I.I. (1991). Body-Fat in Identical-Twins Reared 
Apart - Roles for Genes and Environment. Behavior genetics 21, 1-7. 
153 
Prieur, X., Le May, C., Magre, J., and Cariou, B. (2014). Congenital 
lipodystrophies and dyslipidemias. Current atherosclerosis reports 16, 437. 
Rajala, M.W., and Scherer, P.E. (2003). Minireview: The adipocyte - At the 
crossroads of energy homeostasis, inflammation, and atherosclerosis. 
Endocrinology 144, 3765-3773. 
Rangwala, S.M., and Lazar, M.A. (2000). Transcriptional control of 
adipogenesis. Annual Review of Nutrition 20, 535-559. 
Ravussin, E., Pratley, R.E., Maffei, M., Wang, H., Friedman, J.M., Bennett, P.H., 
and Bogardus, C. (1997). Relatively low plasma leptin concentrations 
precede weight gain in Pima Indians. Nature medicine 3, 238-240. 
Reed, B.D., Charos, A.E., Szekely, A.M., Weissman, S.M., and Snyder, M. (2008). 
Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals 
novel functional roles and combinatorial regulation of distinct classes of 
genes. PLoS genetics 4, e1000133. 
Reue, K., and Dwyer, J.R. (2009). Lipin proteins and metabolic homeostasis. J 
Lipid Res 50 Suppl, S109-114. 
Reue, K., and Phan, J. (2006). Metabolic consequences of lipodystrophy in 
mouse models. Curr Opin Clin Nutr 9, 436-441. 
Reyne, Y., Nougues, J., and Vezinhet, A. (1983). Adipose tissue regeneration in 
6-month-old and adult rabbits following lipectomy. Proc Soc Exp Biol Med 
174, 258-264. 
Robert, S.A., and Reither, E.N. (2004). A multilevel analysis of race, 
community disadvantage, and body mass index among adults in the US. Soc 
Sci Med 59, 2421-2434. 
Rodeheffer, M.S., Birsoy, K., and Friedman, J.M. (2008). Identification of white 
adipocyte progenitor cells in vivo. Cell 135, 240-249. 
Rolls, B.J., Roe, L.S., and Meengs, J.S. (2007). The effect of large portion sizes 
on energy intake is sustained for 11 days. Obesity (Silver Spring) 15, 1535-
1543. 
Romero-Corral, A., Somers, V.K., Sierra-Johnson, J., Thomas, R.J., Collazo-
Clavell, M.L., Korinek, J., Allison, T.G., Batsis, J.A., Sert-Kuniyoshi, F.H., and 
Lopez-Jimenez, F. (2008). Accuracy of body mass index in diagnosing obesity 
in the adult general population. Int J Obes (Lond) 32, 959-966. 
Rosen, E.D., and MacDougald, O.A. (2006). Adipocyte differentiation from the 
inside out. Nature reviews Molecular cell biology 7, 885-896. 
154 
Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., 
Spiegelman, B.M., and Mortensen, R.M. (1999). PPAR gamma is required for 
the differentiation of adipose tissue in vivo and in vitro. Molecular cell 4, 611-
617. 
Rosen, E.D., and Spiegelman, B.M. (2000). Molecular regulation of 
adipogenesis. Annual review of cell and developmental biology 16, 145-171. 
Rosen, E.D., Walkey, C.J., Puigserver, P., and Spiegelman, B.M. (2000). 
Transcriptional regulation of adipogenesis. Genes & development 14, 1293-
1307. 
Rosenbaum, M., Murphy, E.M., Heymsfield, S.B., Matthews, D.E., and Leibel, 
R.L. (2002). Low dose leptin administration reverses effects of sustained 
weight-reduction on energy expenditure and circulating concentrations of 
thyroid hormones. The Journal of clinical endocrinology and metabolism 87, 
2391-2394. 
Rosenbaum, M., Nicolson, M., Hirsch, J., Heymsfield, S.B., Gallagher, D., Chu, F., 
and Leibel, R.L. (1996). Effects of gender, body composition, and menopause 
on plasma concentrations of leptin. The Journal of clinical endocrinology and 
metabolism 81, 3424-3427. 
Rosenblum, C.I., Tota, M., Cully, D., Smith, T., Collum, R., Qureshi, S., Hess, J.F., 
Phillips, M.S., Hey, P.J., Vongs, A., et al. (1996). Functional STAT 1 and 3 
signaling by the leptin receptor (OB-R); reduced expression of the rat fatty 
leptin receptor in transfected cells. Endocrinology 137, 5178-5181. 
Rosenblum, C.I., Vongs, A., Tota, M.R., Varnerin, J.P., Frazier, E., Cully, D.F., 
Morsy, M.A., and Van der Ploeg, L.H. (1998). A rapid, quantitative functional 
assay for measuring leptin. Molecular and cellular endocrinology 143, 117-
123. 
Rothwell, N.J., and Stock, M.J. (1979). Role for Brown Adipose-Tissue in Diet-
Induced Thermogenesis. Nature 281, 31-35. 
Rovere, C., Viale, A., Nahon, J., and Kitabgi, P. (1996). Impaired processing of 
brain proneurotensin and promelanin-concentrating hormone in obese 
fat/fat mice. Endocrinology 137, 2954-2958. 
Rupnick, M.A., Panigrahy, D., Zhang, C.Y., Dallabrida, S.M., Lowell, B.B., Langer, 
R., and Folkman, M.J. (2002). Adipose tissue mass can be regulated through 
the vasculature. Proceedings of the National Academy of Sciences of the 
United States of America 99, 10730-10735. 
155 
Salans, L.B., Cushman, S.W., and Weismann, R.E. (1973). Studies of human 
adipose tissue. Adipose cell size and number in nonobese and obese patients. 
The Journal of clinical investigation 52, 929-941. 
Salans, L.B., Horton, E.S., and Sims, E.A. (1971). Experimental obesity in man: 
cellular character of the adipose tissue. The Journal of clinical investigation 
50, 1005-1011. 
Sarraf, P., Frederich, R.C., Turner, E.M., Ma, G., Jaskowiak, N.T., Rivet, D.J., 3rd, 
Flier, J.S., Lowell, B.B., Fraker, D.L., and Alexander, H.R. (1997). Multiple 
cytokines and acute inflammation raise mouse leptin levels: potential role in 
inflammatory anorexia. The Journal of experimental medicine 185, 171-175. 
Savage, D.B. (2009). Mouse models of inherited lipodystrophy. Dis Model 
Mech 2, 554-562. 
Schmidt, H.H.J., Genschel, J., Baier, P., Schmidt, M., Ockenga, J., Tietge, U.J.F., 
Propsting, M., Buttner, C., Manns, M.P., Lochs, H., et al. (2001). Dyslipemia in 
familial partial lipodystrophy caused by an R482W mutation in the LMNA 
gene. J Clin Endocr Metab 86, 2289-2295. 
Scholz, G.H., Englaro, P., Thiele, I., Scholz, M., Klusmann, T., Kellner, K., 
Rascher, W., and Blum, W.F. (1996). Dissociation of serum leptin 
concentration and body fat content during long term dietary intervention in 
obese individuals. Hormone and metabolic research = Hormon- und 
Stoffwechselforschung = Hormones et metabolisme 28, 718-723. 
Schott, M., Scherbaum, W.A., and Bornstein, S.R. (2004). Acquired and 
inherited lipodystrophies. The New England journal of medicine 351, 103-
104; author reply 103-104. 
Schuster-Gossler, K., Lee, A.W., Lerner, C.P., Parker, H.J., Dyer, V.W., Scott, V.E., 
Gossler, A., and Conover, J.C. (2001). Use of coisogenic host blastocysts for 
efficient establishment of germline chimeras with C57BL/6J ES cell lines. 
BioTechniques 31, 1022-1024, 1026. 
Sen, B., Xie, Z.H., Case, N., Ma, M.Y., Rubin, C., and Rubin, J. (2008). Mechanical 
Strain Inhibits Adipogenesis in Mesenchymal Stem Cells by Stimulating a 
Durable beta-Catenin Signal. Endocrinology 149, 6065-6075. 
Sera, Y., LaRue, A.C., Moussa, O., Mehrotra, M., Duncan, J.D., Williams, C.R., 
Nishimoto, E., Schulte, B.A., Watson, P.M., Watson, D.K., et al. (2009). 
Hematopoietic stem cell origin of adipocytes. Exp Hematol 37, 1108-1120, 
1120 e1101-1104. 
156 
Shan, T., Liu, W., and Kuang, S. (2013). Fatty acid binding protein 4 
expression marks a population of adipocyte progenitors in white and brown 
adipose tissues. Faseb J 27, 277-287. 
Shepherd, P.R., and Kahn, B.B. (1999). Mechanisms of disease - Glucose 
transporters and insulin action - Implications for insulin resistance and 
diabetes mellitus. New Engl J Med 341, 248-257. 
Shimabukuro, M., Koyama, K., Chen, G.X., Wang, M.Y., Trieu, F., Lee, Y., 
Newgard, C.B., and Unger, R.H. (1997). Direct antidiabetic effect of leptin 
through triglyceride depletion of tissues. Proceedings of the National 
Academy of Sciences of the United States of America 94, 4637-4641. 
Sivitz, W.I., Walsh, S.A., Morgan, D.A., Thomas, M.J., and Haynes, W.G. (1997). 
Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138, 
3395-3401. 
Slieker, L.J., Sloop, K.W., and Surface, P.L. (1998). Differentiation method-
dependent expression of leptin in adipocyte cell lines. Biochemical and 
biophysical research communications 251, 225-229. 
Slieker, L.J., Sloop, K.W., Surface, P.L., Kriauciunas, A., LaQuier, F., Manetta, J., 
Bue-Valleskey, J., and Stephens, T.W. (1996). Regulation of expression of ob 
mRNA and protein by glucocorticoids and cAMP. The Journal of biological 
chemistry 271, 5301-5304. 
Sobal, J., Hanson, K.L., and Frongillo, E.A. (2009). Gender, Ethnicity, Marital 
Status, and Body Weight in the United States. Obesity 17, 2223-2231. 
Solter, D. (2010). Viable Rat-Mouse Chimeras: Where Do We Go from Here? 
Cell 142, 676-678. 
Soukas, A., Cohen, P., Socci, N.D., and Friedman, J.M. (2000). Leptin-specific 
patterns of gene expression in white adipose tissue. Genes & development 14, 
963-980. 
Soukas, A., Socci, N.D., Saatkamp, B.D., Novelli, S., and Friedman, J.M. (2001). 
Distinct transcriptional profiles of adipogenesis in vivo and in vitro. The 
Journal of biological chemistry 276, 34167-34174. 
Spalding, K.L., Arner, E., Westermark, P.O., Bernard, S., Buchholz, B.A., 
Bergmann, O., Blomqvist, L., Hoffstedt, J., Naslund, E., Britton, T., et al. (2008). 
Dynamics of fat cell turnover in humans. Nature 453, 783-787. 
Speakman, J.R. (2008). Thrifty genes for obesity, an attractive but flawed idea, 
and an alternative perspective: the 'drifty gene' hypothesis. Int J Obesity 32, 
1611-1617. 
157 
Speakman, J.R. (2013). Evolutionary Perspectives on the Obesity Epidemic: 
Adaptive, Maladaptive, and Neutral Viewpoints. Annu Rev Nutr 33, 289-317. 
Speakman, J.R., Levitsky, D.A., Allison, D.B., Bray, M.S., de Castro, J.M., Clegg, 
D.J., Clapham, J.C., Dulloo, A.G., Gruer, L., Haw, S., et al. (2011). Set points, 
settling points and some alternative models: theoretical options to 
understand how genes and environments combine to regulate body adiposity. 
Dis Model Mech 4, 733-745. 
Spiegelman, B.M., Choy, L., Hotamisligil, G.S., Graves, R.A., and Tontonoz, P. 
(1993). Regulation of adipocyte gene expression in differentiation and 
syndromes of obesity/diabetes. The Journal of biological chemistry 268, 
6823-6826. 
Stanger, B.Z., Tanaka, A.J., and Melton, D.A. (2007). Organ size is limited by 
the number of embryonic progenitor cells in the pancreas but not the liver. 
Nature 445, 886-891. 
Ste Marie, L., Miura, G.I., Marsh, D.J., Yagaloff, K., and Palmiter, R.D. (2000). A 
metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. 
Proceedings of the National Academy of Sciences of the United States of 
America 97, 12339-12344. 
Stiles, J.W., Francendese, A.A., and Masoro, E.J. (1975). Influence of age on 
size and number of fat cells in the epididymal depot. Am J Physiol 229, 1561-
1568. 
Strobel, A., Issad, T., Camoin, L., Ozata, M., and Strosberg, A.D. (1998). A leptin 
missense mutation associated with hypogonadism and morbid obesity. 
Nature genetics 18, 213-215. 
Stunkard, A.J., Harris, J.R., Pedersen, N.L., and Mcclearn, G.E. (1990). The 
Body-Mass Index of Twins Who Have Been Reared Apart. New Engl J Med 
322, 1483-1487. 
Sun, K., Halberg, N., Khan, M., Magalang, U.J., and Scherer, P.E. (2013). 
Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose 
tissue dysfunction. Molecular and cellular biology 33, 904-917. 
Sun, K., Kusminski, C.M., and Scherer, P.E. (2011). Adipose tissue remodeling 
and obesity. Journal of Clinical Investigation 121, 2094-2101. 
Surwit, R.S., Edwards, C.L., Murthy, S., and Petro, A.E. (2000). Transient 
effects of long-term leptin supplementation in the prevention of diet-induced 
obesity in mice. Diabetes 49, 1203-1208. 
158 
Swallen, K.C., Reither, E.N., Haas, S.A., and Meier, A.M. (2005). Overweight, 
obesity, and health-related quality of life among adolescents: the National 
Longitudinal Study of Adolescent Health. Pediatrics 115, 340-347. 
Tanabe, Y., Koga, M., Saito, M., Matsunaga, Y., and Nakayama, K. (2004). 
Inhibition of adipocyte differentiation by mechanical stretching through 
ERK-mediated downregulation of PPAR gamma(2). Journal of cell science 117, 
3605-3614. 
Tanaka, T., Hidaka, S., Masuzaki, H., Yasue, S., Minokoshi, Y., Ebihara, K., 
Chusho, H., Ogawa, Y., Toyoda, T., Sato, K., et al. (2005). Skeletal muscle AMP-
activated protein kinase phosphorylation parallels metabolic phenotype in 
leptin transgenic mice under dietary modification. Diabetes 54, 2365-2374. 
Tang, W., Zeve, D., Suh, J.M., Bosnakovski, D., Kyba, M., Hammer, R.E., Tallquist, 
M.D., and Graff, J.M. (2008). White fat progenitor cells reside in the adipose 
vasculature. Science 322, 583-586. 
Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., 
Richards, G.J., Campfield, L.A., Clark, F.T., Deeds, J., et al. (1995). Identification 
and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-1271. 
Taylor, S.M., and Jones, P.A. (1979). Multiple new phenotypes induced in 
10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17, 771-779. 
Tchoukalova, Y.D., Fitch, M., Rogers, P.M., Covington, J.D., Henagan, T.M., Ye, J., 
Hellerstein, M.K., and Ravussin, E. (2012). In vivo adipogenesis in rats 
measured by cell kinetics in adipocytes and plastic-adherent stroma-vascular 
cells in response to high-fat diet and thiazolidinedione. Diabetes 61, 137-144. 
Thornton, L.E., Crawford, D.A., and Ball, K. (2011). Who is eating where? 
Findings from the SocioEconomic Status and Activity in Women (SESAW) 
study. Public health nutrition 14, 523-531. 
Tiwari, V.K., Stadler, M.B., Wirbelauer, C., Paro, R., Schubeler, D., and Beisel, C. 
(2012). A chromatin-modifying function of JNK during stem cell 
differentiation. Nature genetics 44, 94-100. 
Tohnai, G., Adachi, H., Katsuno, M., Doi, H., Matsumoto, S., Kondo, N., Miyazaki, 
Y., Iida, M., Nakatsuji, H., Qiang, Q., et al. (2014). Paeoniflorin eliminates a 
mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular 
atrophy. Human molecular genetics 23, 3552-3565. 
Tran, K.V., Gealekman, O., Frontini, A., Zingaretti, M.C., Morroni, M., Giordano, 
A., Smorlesi, A., Perugini, J., De Matteis, R., Sbarbati, A., et al. (2012). The 
vascular endothelium of the adipose tissue gives rise to both white and 
brown fat cells. Cell metabolism 15, 222-229. 
159 
Tran, T.T., and Kahn, C.R. (2010). Transplantation of adipose tissue and stem 
cells: role in metabolism and disease. Nature reviews Endocrinology 6, 195-
213. 
Unger, R.H. (2003). Lipid overload and overflow: metabolic trauma and the 
metabolic syndrome. Trends in endocrinology and metabolism: TEM 14, 398-
403. 
Vaisse, C., Clement, K., Guy-Grand, B., and Froguel, P. (1998). A frameshift 
mutation in human MC4R is associated with a dominant form of obesity. 
Nature genetics 20, 113-114. 
Vaisse, C., Halaas, J.L., Horvath, C.M., Darnell, J.E., Jr., Stoffel, M., and Friedman, 
J.M. (1996). Leptin activation of Stat3 in the hypothalamus of wild-type and 
ob/ob mice but not db/db mice. Nature genetics 14, 95-97. 
Van Heek, M., Compton, D.S., France, C.F., Tedesco, R.P., Fawzi, A.B., Graziano, 
M.P., Sybertz, E.J., Strader, C.D., and Davis, H.R., Jr. (1997). Diet-induced obese 
mice develop peripheral, but not central, resistance to leptin. The Journal of 
clinical investigation 99, 385-390. 
Varlamov, O., Chu, M., Cornea, A., Sampath, H., and Roberts, C.T., Jr. (2015). 
Cell-autonomous heterogeneity of nutrient uptake in white adipose tissue of 
rhesus macaques. Endocrinology 156, 80-89. 
Virtue, S., and Vidal-Puig, A. (2008). It's not how fat you are, it's what you do 
with it that counts. PLoS biology 6, e237. 
Vogels, N., and Westerterp-Plantenga, M.S. (2005). Categorical strategies 
based on subject characteristics of dietary restraint and physical activity, for 
weight maintenance. Int J Obesity 29, 849-857. 
Wabitsch, M., Jensen, P.B., Blum, W.F., Christoffersen, C.T., Englaro, P., Heinze, 
E., Rascher, W., Teller, W., Tornqvist, H., and Hauner, H. (1996). Insulin and 
cortisol promote leptin production in cultured human fat cells. Diabetes 45, 
1435-1438. 
Wakabayashi, I. (2013). Necessity of both waist circumference and waist-to-
height ratio for better evaluation of central obesity. Metabolic syndrome and 
related disorders 11, 189-194. 
Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., and 
Jaenisch, R. (2013a). One-step generation of mice carrying mutations in 
multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-
918. 
160 
Wang, Q.A., Tao, C., Gupta, R.K., and Scherer, P.E. (2013b). Tracking 
adipogenesis during white adipose tissue development, expansion and 
regeneration. Nature medicine 19, 1338-1344. 
Wang, Z.V., Deng, Y., Wang, Q.A., Sun, K., and Scherer, P.E. (2010). 
Identification and characterization of a promoter cassette conferring 
adipocyte-specific gene expression. Endocrinology 151, 2933-2939. 
Ward, A., Pollock, M.L., Jackson, A.S., Ayres, J.J., and Pape, G. (1978). A 
comparison of body fat determined by underwater weighing and volume 
displacement. Am J Physiol 234, E94-96. 
Wassermann, F. (2010). The development of adipose tissue. In 
Comprehensive Physiology (John Wiley & Sons, Inc.). 
West, D.B., Boozer, C.N., Moody, D.L., and Atkinson, R.L. (1992). Dietary 
obesity in nine inbred mouse strains. Am J Physiol 262, R1025-1032. 
WesterterpPlantenga, M.S., Pasman, W.J., Yedema, M.J.W., and 
WijckmansDuijsens, N.E.G. (1996). Energy intake adaptation of food intake to 
extreme energy densities of food by obese and non-obese women. European 
journal of clinical nutrition 50, 401-407. 
Weyer, C., Foley, J.E., Bogardus, C., Tataranni, P.A., and Pratley, R.E. (2000). 
Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, 
predicts type II diabetes independent of insulin resistance. Diabetologia 43, 
1498-1506. 
White, M.F. (2006). Regulating insulin signaling and beta-cell function 
through IRS proteins. Can J Physiol Pharm 84, 725-737. 
Whitlock, G., Lewington, S., Sherliker, P., Clarke, R., Emberson, J., Halsey, J., 
Qizilbash, N., Collins, R., and Peto, R. (2009). Body-mass index and cause-
specific mortality in 900 000 adults: collaborative analyses of 57 prospective 
studies. Lancet 373, 1083-1096. 
WHO (2015). Obesity and overweight. 
Willett, W.C., Dietz, W.H., and Colditz, G.A. (1999). Guidelines for healthy 
weight. New Engl J Med 341, 427-434. 
Wojtanik, K.M., Edgemon, K., Viswanadha, S., Lindsey, B., Haluzik, M., Chen, 
W.P., Poy, G., Reitman, M., and Londos, C. (2009). The role of LMNA in adipose: 
a novel mouse model of lipodystrophy based on the Dunnigan-type familial 
partial lipodystrophy mutation. J Lipid Res 50, 1068-1079. 
161 
Woods, S.C., and Ramsay, D.S. (2007). Homeostasis: Beyond Curt Richter. 
Appetite 49, 388-398. 
Wrann, C.D., Eguchi, J., Bozec, A., Xu, Z., Mikkelsen, T., Gimble, J., Nave, H., 
Wagner, E.F., Ong, S.E., and Rosen, E.D. (2012). FOSL2 promotes leptin gene 
expression in human and mouse adipocytes. The Journal of clinical 
investigation 122, 1010-1021. 
Wu, Z., Bucher, N.L., and Farmer, S.R. (1996). Induction of peroxisome 
proliferator-activated receptor gamma during the conversion of 3T3 
fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and 
glucocorticoids. Molecular and cellular biology 16, 4128-4136. 
Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmant, G., Troy, A.E., McKeon, C., 
Darlington, G.J., and Spiegelman, B.M. (1999). Cross-regulation of C/EBP 
alpha and PPAR gamma controls the transcriptional pathway of adipogenesis 
and insulin sensitivity. Molecular cell 3, 151-158. 
Yamanaka, T., Tosaki, A., Kurosawa, M., Matsumoto, G., Koike, M., Uchiyama, 
Y., Maity, S.N., Shimogori, T., Hattori, N., and Nukina, N. (2014). NF-Y 
inactivation causes atypical neurodegeneration characterized by ubiquitin 
and p62 accumulation and endoplasmic reticulum disorganization. Nature 
communications 5, 3354. 
Yang, M.U., Presta, E., and Bjorntorp, P. (1990). Refeeding after fasting in rats: 
effects of duration of starvation and refeeding on food efficiency in diet-
induced obesity. The American journal of clinical nutrition 51, 970-978. 
Yang, V.W. (1998). Eukaryotic transcription factors: identification, 
characterization and functions. The Journal of nutrition 128, 2045-2051. 
Yeh, W.C., Cao, Z., Classon, M., and McKnight, S.L. (1995). Cascade regulation 
of terminal adipocyte differentiation by three members of the C/EBP family 
of leucine zipper proteins. Genes & development 9, 168-181. 
Yeo, G.S., Farooqi, I.S., Aminian, S., Halsall, D.J., Stanhope, R.G., and O'Rahilly, S. 
(1998). A frameshift mutation in MC4R associated with dominantly inherited 
human obesity. Nature genetics 20, 111-112. 
Ykijarvinen, H., and Koivisto, V.A. (1986). Natural Course of Insulin 
Resistance in Type-I Diabetes. New Engl J Med 315, 224-230. 
Yu, X., Park, B.H., Wang, M.Y., Wang, Z.V., and Unger, R.H. (2008). Making 
insulin-deficient type 1 diabetic rodents thrive without insulin. Proceedings 
of the National Academy of Sciences of the United States of America 105, 
14070-14075. 
162 
Zebisch, K., Voigt, V., Wabitsch, M., and Brandsch, M. (2012). Protocol for 
effective differentiation of 3T3-L1 cells to adipocytes. Analytical 
Biochemistry 425, 88-90. 
Zhang, H.T., Zhang, D., Zha, Z.G., and Hu, C.D. (2014). Transcriptional 
activation of PRMT5 by NF-Y is required for cell growth and negatively 
regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochimica et 
biophysica acta 1839, 1330-1340. 
Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., Zhong, W., Xiao, Y., Floyd, D., Liang, J., 
Li, E., et al. (2004). Selective disruption of PPARgamma 2 impairs the 
development of adipose tissue and insulin sensitivity. Proceedings of the 
National Academy of Sciences of the United States of America 101, 10703-
10708. 
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. 
(1994). Positional cloning of the mouse obese gene and its human homologue. 
Nature 372, 425-432. 
Zhu, J., Zhang, Y., Joe, G.J., Pompetti, R., and Emerson, S.G. (2005). NF-Ya 
activates multiple hematopoietic stem cell (HSC) regulatory genes and 
promotes HSC self-renewal. Proceedings of the National Academy of Sciences 
of the United States of America 102, 11728-11733. 
Zhu, X.G., Wang, Y.C., Pi, W.H., Liu, H., Wickrema, A., and Tuan, D. (2012). NF-Y 
Recruits Both Transcription Activator and Repressor to Modulate Tissue- and 
Developmental Stage-Specific Expression of Human gamma-Globin Gene. 
PloS one 7. 
Zhu, Y., Qi, C., Korenberg, J.R., Chen, X.N., Noya, D., Rao, M.S., and Reddy, J.K. 
(1995). Structural organization of mouse peroxisome proliferator-activated 
receptor gamma (mPPAR gamma) gene: alternative promoter use and 
different splicing yield two mPPAR gamma isoforms. Proceedings of the 
National Academy of Sciences of the United States of America 92, 7921-7925. 
